aidx;assay_category;assay_cell_type;assay_chembl_id;assay_classifications;assay_organism;assay_parameters;assay_strain;assay_subcellular_fraction;assay_tax_id;assay_test_type;assay_tissue;assay_type;assay_type_description;bao_format;bao_label;cell_chembl_id;confidence_description;confidence_score;description;document_chembl_id;relationship_description;relationship_type;src_assay_id;src_id;target_chembl_id;tissue_chembl_id;variant_sequence
CLD0;;NIH3T3;CHEMBL615497;[];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307716;Target assigned is non-molecular;1;In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells;CHEMBL1130863;Non-molecular target assigned;N;;1;CHEMBL614822;;
CLD0;;ADJ/PC6;CHEMBL620509;[];Mus musculus;[];;;10090.0;;Plasma;F;Functional;BAO_0000219;cell-based format;CHEMBL3307899;Target assigned is non-molecular;1;Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor;CHEMBL1121753;Non-molecular target assigned;N;;1;CHEMBL614265;CHEMBL3559721;
CLD0;;ADJ/PC6;CHEMBL620511;[];Mus musculus;[];;;10090.0;;Plasma;A;ADME;BAO_0000219;cell-based format;CHEMBL3307899;Target assigned is non-molecular;1;Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group;CHEMBL1121753;Non-molecular target assigned;N;;1;CHEMBL614265;CHEMBL3559721;
CLD0;;;CHEMBL628290;[];;[];;;;;;P;Physicochemical;BAO_0000100;small-molecule physicochemical format;;Default value - Target unknown or has yet to be assigned;0;Calculated membrane partition coefficient (Kmemb);CHEMBL1149124;Default value - Target has yet to be curated;U;;1;CHEMBL2362975;;
CLD0;;;CHEMBL633649;[];;[];;;;;;A;ADME;BAO_0000019;assay format;;Default value - Target unknown or has yet to be assigned;0;Delta logD (logD6.5 - logD7.4);CHEMBL1133765;Default value - Target has yet to be curated;U;;1;CHEMBL612558;;
CLD0;;;CHEMBL635477;[];;[];;;;;;P;Physicochemical;BAO_0000100;small-molecule physicochemical format;;Default value - Target unknown or has yet to be assigned;0;Partition coefficient (logD7.4);CHEMBL1124835;Default value - Target has yet to be curated;U;;1;CHEMBL2362975;;
CLD0;;;CHEMBL635885;[];;[];;;;;;A;ADME;BAO_0000019;assay format;;Default value - Target unknown or has yet to be assigned;0;The half life at a pH 1.2;CHEMBL1127411;Default value - Target has yet to be curated;U;;1;CHEMBL612558;;
CLD0;;;CHEMBL632735;[];;[];;;;;;A;ADME;BAO_0000019;assay format;;Default value - Target unknown or has yet to be assigned;0;The half life at a physiological pH;CHEMBL1127411;Default value - Target has yet to be curated;U;;1;CHEMBL612558;;
CLD0;;;CHEMBL634283;[];;[];;;;;;P;Physicochemical;BAO_0000100;small-molecule physicochemical format;;Default value - Target unknown or has yet to be assigned;0;Partition coefficient (logD6.5);CHEMBL1133765;Default value - Target has yet to be curated;U;;1;CHEMBL2362975;;
CLD0;;;CHEMBL874960;[];;[];;;;;;P;Physicochemical;BAO_0000100;small-molecule physicochemical format;;Default value - Target unknown or has yet to be assigned;0;Ionization constant (pKa);CHEMBL1133765;Default value - Target has yet to be curated;U;;1;CHEMBL2362975;;
CLD0;;;CHEMBL633098;[];Homo sapiens;[];;;9606.0;In vivo;;A;ADME;BAO_0000218;organism-based format;;Default value - Target unknown or has yet to be assigned;0;Oral bioavailability in human;CHEMBL1133765;Default value - Target has yet to be curated;U;;1;CHEMBL612558;;
CLD0;;B16;CHEMBL648663;[{'assay_class_id': 91, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Melanoma Oncology Models', 'l3': 'Experimental Melanoma', 'source': 'phenotype'}, {'assay_class_id': 92, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Melanoma Oncology Models', 'l3': 'General Melanoma', 'source': 'phenotype'}, {'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '100.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '100.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308454;Target assigned is non-molecular;1;Compound was evaluated for the antineoplastic activity on B16 Melanoma cells at the optimal dose of 100 mg/kg through intraperitoneal route on days 1,5,9;CHEMBL1122849;Non-molecular target assigned;N;;1;CHEMBL381;;
CLD0;;B16;CHEMBL648665;[{'assay_class_id': 91, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Melanoma Oncology Models', 'l3': 'Experimental Melanoma', 'source': 'phenotype'}, {'assay_class_id': 92, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Melanoma Oncology Models', 'l3': 'General Melanoma', 'source': 'phenotype'}, {'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '120.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '120.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308454;Target assigned is non-molecular;1;Compound was evaluated for the antineoplastic activity on B16 Melanoma cells at the optimal dose of 120 mg/kg through intraperitoneal route on days 1,5,9;CHEMBL1122849;Non-molecular target assigned;N;;1;CHEMBL381;;
CLD0;;B16;CHEMBL648409;[{'assay_class_id': 91, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Melanoma Oncology Models', 'l3': 'Experimental Melanoma', 'source': 'phenotype'}, {'assay_class_id': 92, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Melanoma Oncology Models', 'l3': 'General Melanoma', 'source': 'phenotype'}, {'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '70.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '70.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308454;Target assigned is non-molecular;1;Compound was evaluated for the antineoplastic activity on B16 Melanoma cells at the optimal dose of 70 mg/kg through intraperitoneal route on days 1,5,9;CHEMBL1122849;Non-molecular target assigned;N;;1;CHEMBL381;;
CLD0;;B16-F10;CHEMBL651051;[{'assay_class_id': 91, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Melanoma Oncology Models', 'l3': 'Experimental Melanoma', 'source': 'phenotype'}, {'assay_class_id': 92, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Melanoma Oncology Models', 'l3': 'General Melanoma', 'source': 'phenotype'}, {'assay_class_id': 93, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Metastatic Oncology Models', 'l3': 'Metastatic Activity', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '50.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '50.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307762;Target assigned is non-molecular;1;Effect on metastases of B16F10.9 melanoma cells (intraperitoneally implanted) in B6C3F1/OLAC/HSD mice was observed after administration of 50 mg/kg dose;CHEMBL1125374;Non-molecular target assigned;N;;1;CHEMBL381;;
CLD0;;B16-F10;CHEMBL875426;[{'assay_class_id': 91, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Melanoma Oncology Models', 'l3': 'Experimental Melanoma', 'source': 'phenotype'}, {'assay_class_id': 92, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Melanoma Oncology Models', 'l3': 'General Melanoma', 'source': 'phenotype'}, {'assay_class_id': 93, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Metastatic Oncology Models', 'l3': 'Metastatic Activity', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '50.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '50.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307762;Target assigned is non-molecular;1;Effect on metastases of B16F10.9 melanoma cells (intraperitoneally implanted) in B6C3F1/OLAC/HSD mice was observed after administration of 50 mg/kg dose;CHEMBL1125374;Non-molecular target assigned;N;;1;CHEMBL381;;
CLD0;;NIH3T3;CHEMBL651595;[];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307716;Target assigned is non-molecular;1;In vitro cytotoxicity against BALB/c 3T3 cells;CHEMBL1128257;Non-molecular target assigned;N;;1;CHEMBL614822;;
CLD0;;;CHEMBL651603;[];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000019;assay format;;Target assigned is non-molecular;1;In vitro cytotoxicity in BALB/c3T3 mouse embryo fibroblasts.;CHEMBL1125916;Non-molecular target assigned;N;;1;CHEMBL3879801;;
CLD0;;Colon 26;CHEMBL655141;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '125.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '125.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307623;Target assigned is non-molecular;1;Antitumor activity against C26 implants through intraperitoneal route along with the optimal dose of 125 mg/kg through intraperitoneal injection on 1,4 days;CHEMBL1122849;Non-molecular target assigned;N;;1;CHEMBL614466;;
CLD0;;Colon 26;CHEMBL655228;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '125.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '125.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Subcutaneous', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Subcutaneous', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307623;Target assigned is non-molecular;1;Antitumor activity against C26 implants through subcutaneous route along with the optimal dose of 125 mg/kg through intraperitoneal injection on 1,4 days;CHEMBL1122849;Non-molecular target assigned;N;;1;CHEMBL614466;;
CLD0;;CHRC5 cell line;CHEMBL658551;[];Cricetulus griseus;[];;;10029.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307930;Target assigned is non-molecular;1;Effect on collateral sensitivity of CHRC5 cells to local anesthetics/steroids.;CHEMBL1124835;Non-molecular target assigned;N;;1;CHEMBL614457;;
CLD0;;L1210;CHEMBL700817;[];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3308391;Target assigned is non-molecular;1;Concentration required to reduce the viability of L1210 cells by 50% after 1-h incubation at 37 degrees C;CHEMBL1125866;Non-molecular target assigned;N;;1;CHEMBL386;;
CLD0;;L1210;CHEMBL700909;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 88, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'L1210 Experimental Leukemia', 'source': 'Hock_2016'}, {'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308391;Target assigned is non-molecular;1;In vivo antitumor activity against intraperitoneal murine cyclophosphamide resistant L1210 Leukemia cells at 170 umol/kg;CHEMBL1125770;Non-molecular target assigned;N;;1;CHEMBL386;;
CLD0;;L1210;CHEMBL700910;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 88, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'L1210 Experimental Leukemia', 'source': 'Hock_2016'}, {'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308391;Target assigned is non-molecular;1;In vivo antitumor activity against intraperitoneal murine cyclophosphamide resistant L1210 Leukemia cells at 510 umol/kg;CHEMBL1125770;Non-molecular target assigned;N;;1;CHEMBL386;;
CLD0;;L1210;CHEMBL700913;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 88, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'L1210 Experimental Leukemia', 'source': 'Hock_2016'}, {'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308391;Target assigned is non-molecular;1;"In vivo antitumor activity against intraperitoneal murine cyclophosphamide resistant L1210 Leukemia cells at 680 umol/kg; Toxic";CHEMBL1125770;Non-molecular target assigned;N;;1;CHEMBL386;;
CLD0;;L1210;CHEMBL700914;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 88, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'L1210 Experimental Leukemia', 'source': 'Hock_2016'}, {'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308391;Target assigned is non-molecular;1;In vivo antitumor activity against intraperitoneal murine cyclophosphamide resistant L1210 Leukemia cells at 340 umol/kg;CHEMBL1125770;Non-molecular target assigned;N;;1;CHEMBL386;;
CLD0;;L1210;CHEMBL700915;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 88, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'L1210 Experimental Leukemia', 'source': 'Hock_2016'}, {'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308391;Target assigned is non-molecular;1;In vivo antitumor activity against intraperitoneal murine wild type L1210 Leukemia cells at 170 umol/kg;CHEMBL1125770;Non-molecular target assigned;N;;1;CHEMBL386;;
CLD0;;L1210;CHEMBL700916;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 88, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'L1210 Experimental Leukemia', 'source': 'Hock_2016'}, {'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308391;Target assigned is non-molecular;1;In vivo antitumor activity against intraperitoneal murine wild type L1210 Leukemia cells at 340 umol/kg;CHEMBL1125770;Non-molecular target assigned;N;;1;CHEMBL386;;
CLD0;;L1210;CHEMBL700917;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 88, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'L1210 Experimental Leukemia', 'source': 'Hock_2016'}, {'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308391;Target assigned is non-molecular;1;In vivo antitumor activity against intraperitoneal murine wild type L1210 Leukemia cells at 510 umol/kg;CHEMBL1125770;Non-molecular target assigned;N;;1;CHEMBL386;;
CLD0;;L1210;CHEMBL701072;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 88, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'L1210 Experimental Leukemia', 'source': 'Hock_2016'}, {'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308391;Target assigned is non-molecular;1;In vivo antitumor activity against intraperitoneal murine wild type L1210 Leukemia cells at 680 umol/kg;CHEMBL1125770;Non-molecular target assigned;N;;1;CHEMBL386;;
CLD0;;L1210;CHEMBL706087;[];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3308391;Target assigned is non-molecular;1;"Compound was tested in vitro for its inhibition against replication of L1210 neoplastic cells; Inactive";CHEMBL1121561;Non-molecular target assigned;N;;1;CHEMBL386;;
CLD0;;;CHEMBL717564;[{'assay_class_id': 114, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'Spontaneous Autoimmune Diseases In Animals', 'source': 'Vogel_2008'}, {'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus sp.;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '300.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '300.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;10095.0;;;T;Toxicity;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Drug related lethality is percent animals in treated groups dying prior to first tumor related death in untreated groups measured in BDF1 mice after ip administration at 300 mg/kg dose days 3 after tumor challenge;CHEMBL1125643;Non-molecular target assigned;N;;1;CHEMBL613490;;
CLD0;;;CHEMBL708204;[{'assay_class_id': 114, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'Spontaneous Autoimmune Diseases In Animals', 'source': 'Vogel_2008'}, {'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus sp.;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '400.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '400.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;10095.0;;;T;Toxicity;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Drug related lethality is percent animals in treated groups dying prior to first tumor related death in untreated groups measured in BDF1 mice after ip administration at 400 mg/kg dose days 3 after tumor challenge;CHEMBL1125643;Non-molecular target assigned;N;;1;CHEMBL613490;;
CLD0;;;CHEMBL878472;[{'assay_class_id': 93, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Metastatic Oncology Models', 'l3': 'Metastatic Activity', 'source': 'phenotype'}, {'assay_class_id': 114, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'Spontaneous Autoimmune Diseases In Animals', 'source': 'Vogel_2008'}, {'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus sp.;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '300.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '300.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;10095.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;In vivo activity was measured against 3LL metastasis in BDF1 mice after ip administration at 300 mg/kg dose, dosing on days 3 after tumor challenge;CHEMBL1125643;Non-molecular target assigned;N;;1;CHEMBL613490;;
CLD0;;;CHEMBL716274;[{'assay_class_id': 93, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Metastatic Oncology Models', 'l3': 'Metastatic Activity', 'source': 'phenotype'}, {'assay_class_id': 114, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'Spontaneous Autoimmune Diseases In Animals', 'source': 'Vogel_2008'}, {'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus sp.;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '400.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '400.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;10095.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;In vivo activity was measured against 3LL metastasis in BDF1 mice after ip administration at 400 mg/kg dose, dosing on days 3 after tumor challenge;CHEMBL1125643;Non-molecular target assigned;N;;1;CHEMBL613490;;
CLD0;;;CHEMBL717766;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 89, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'P388 Experimental Leukemia', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Average weight change on day 5 in mice infected by P-388 leukemia when treated with a dose of 125 mg/Kg of compound;CHEMBL1124137;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL717770;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 89, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'P388 Experimental Leukemia', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Average weight change on day 5 in mice infected by P-388 leukemia when treated with a dose of 250 mg/Kg of compound;CHEMBL1124137;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;L1210;CHEMBL721668;[];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '100.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '100.0'}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308391;Target assigned is non-molecular;1;"Percent increase in life span of mice bearing L1210 ascites cells compared to control; Administered alone and concurrently with the preceding compounds onday 1 at a dose of 100 mg/kg (in vivo)";CHEMBL1121408;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;L1210;CHEMBL721787;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 88, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'L1210 Experimental Leukemia', 'source': 'Hock_2016'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308391;Target assigned is non-molecular;1;"Percentage increased life span against L1210 leukemia cells in mice;(1.08 mmol/kg dosage)";CHEMBL1128257;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL722937;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Compound was administered to non-tumor bearing female CDF1 mice in,Mean corpuscular hemoglobin concentration (MCHC);CHEMBL1133719;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL721923;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Antitumor activity was tested in mice and percent increase of life span at a dose of 125 ug/kg was reported;CHEMBL1133719;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL721653;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 88, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'L1210 Experimental Leukemia', 'source': 'Hock_2016'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Increase in life span of mice bearing L1210 leukemia after administration of 25 mg compound;CHEMBL1136807;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;L1210;CHEMBL721383;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 114, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'Spontaneous Autoimmune Diseases In Animals', 'source': 'Vogel_2008'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '100.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '100.0'}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308391;Target assigned is non-molecular;1;Increased life span against L1210 lymphoid leukemia cells in male BDF1 mice at a dose of 100 mg/kg;CHEMBL1123176;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;L1210;CHEMBL721384;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 114, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'Spontaneous Autoimmune Diseases In Animals', 'source': 'Vogel_2008'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308391;Target assigned is non-molecular;1;Increased life span against L1210 lymphoid leukemia cells in male BDF1 mice at a dose of 100x1 mg/kg;CHEMBL1123176;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;L1210;CHEMBL721387;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 114, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'Spontaneous Autoimmune Diseases In Animals', 'source': 'Vogel_2008'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '200.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '200.0'}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308391;Target assigned is non-molecular;1;Increased life span against L1210 lymphoid leukemia cells in male BDF1 mice at a dose of 200 mg/kg;CHEMBL1123176;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL721400;[];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '100.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '100.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;"Maximum life span of mice after 100 mg/kg ip administration; Increases range 75-100";CHEMBL1121862;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL725396;[];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '200.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '200.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;"Maximum life span of mice after 200 mg/kg ip administration; Increases range 150-200";CHEMBL1121862;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL721972;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;"In vivo activity against transplanted Mam-16/C/ Taxol tumors of mice; Not active";CHEMBL1134487;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL728038;[];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '25.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '25.0'}];;;10090.0;;Spleen;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Percent reduction in spleen weight in mice as compared to infected untreated controls at 25 mg/kg;CHEMBL1122410;Non-molecular target assigned;N;;1;CHEMBL375;CHEMBL3559722;
CLD0;;;CHEMBL726143;[];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '25.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '25.0'}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Compound was tested for the ability to suppress humoral immune response in mice treated for days 0,+1,and +2 at dose of 25 mg/kg (control = 7.1);CHEMBL1121811;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL723592;[{'assay_class_id': 82, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Carcinoma Oncology Models', 'l3': 'Carcinoma', 'source': 'phenotype'}, {'assay_class_id': 84, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Carcinoma Oncology Models', 'l3': 'Lewis Lung Carcinoma', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '120.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '120.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intravenous', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intravenous', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Effect of compound on life span of mice inoculated intravenously with lewis lung carcinoma at the dose of 120 mg/kg in experiment 2;CHEMBL1121997;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL723593;[{'assay_class_id': 82, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Carcinoma Oncology Models', 'l3': 'Carcinoma', 'source': 'phenotype'}, {'assay_class_id': 84, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Carcinoma Oncology Models', 'l3': 'Lewis Lung Carcinoma', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '150.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '150.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intravenous', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intravenous', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Effect of compound on life span of mice inoculated intravenously with lewis lung carcinoma at the dose of 150 mg/kg in experiment 3;CHEMBL1121997;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL724972;[{'assay_class_id': 82, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Carcinoma Oncology Models', 'l3': 'Carcinoma', 'source': 'phenotype'}, {'assay_class_id': 84, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Carcinoma Oncology Models', 'l3': 'Lewis Lung Carcinoma', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '300.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '300.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intravenous', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intravenous', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Effect of compound on life span of mice inoculated intravenously with lewis lung carcinoma at the dose of 300 mg/kg in experiment 3;CHEMBL1121997;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL722131;[{'assay_class_id': 82, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Carcinoma Oncology Models', 'l3': 'Carcinoma', 'source': 'phenotype'}, {'assay_class_id': 84, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Carcinoma Oncology Models', 'l3': 'Lewis Lung Carcinoma', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '37.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '37.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intravenous', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intravenous', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Effect of compound on life span of mice inoculated intravenously with lewis lung carcinoma at the dose of 37 mg/kg in experiment 3;CHEMBL1121997;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL722139;[{'assay_class_id': 82, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Carcinoma Oncology Models', 'l3': 'Carcinoma', 'source': 'phenotype'}, {'assay_class_id': 84, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Carcinoma Oncology Models', 'l3': 'Lewis Lung Carcinoma', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '75.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '75.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intravenous', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intravenous', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Effect of compound on life span of mice inoculated intravenously with lewis lung carcinoma at the dose of 75 mg/kg in experiment 3;CHEMBL1121997;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL722143;[{'assay_class_id': 82, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Carcinoma Oncology Models', 'l3': 'Carcinoma', 'source': 'phenotype'}, {'assay_class_id': 84, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Carcinoma Oncology Models', 'l3': 'Lewis Lung Carcinoma', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '90.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '90.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intravenous', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intravenous', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Effect of compound on life span of mice inoculated intravenously with lewis lung carcinoma at the dose of 90 mg/kg in experiment 2;CHEMBL1121997;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL723422;[];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Hematological effects in female CDF1 mice at the dose of 30 mg, in red blood cells cells;CHEMBL1133719;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL730491;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 89, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'P388 Experimental Leukemia', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Median survival time (MST) of treated mice infected by P-388 leukemia, as percent of the MST of untreated controls when treated with a dose of 125 mg/Kg of compound;CHEMBL1124137;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL730495;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 89, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'P388 Experimental Leukemia', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Median survival time (MST) of treated mice infected by P-388 leukemia, as percent of the MST of untreated controls when treated with a dose of 250 mg/Kg of compound;CHEMBL1124137;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;Lewis lung carcinoma cell line;CHEMBL726159;[{'assay_class_id': 82, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Carcinoma Oncology Models', 'l3': 'Carcinoma', 'source': 'phenotype'}, {'assay_class_id': 84, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Carcinoma Oncology Models', 'l3': 'Lewis Lung Carcinoma', 'source': 'phenotype'}, {'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '20.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '20.0'}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307859;Target assigned is non-molecular;1;Compound was ested for antitumor activity against Lewis lung carcinoma cells implanted in male C57BL mice at a dose of 20 mg/kg;CHEMBL1123176;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL727527;[];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '1.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '1.0'}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;"Number of survivors on day 60 at a dose of 100 x 1 mg/kg; 0/7";CHEMBL1123176;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL727528;[];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '100.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '100.0'}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;"Number of survivors on day 60 at a dose of 100 mg/kg; 0/6";CHEMBL1123176;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL727529;[];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '100.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '100.0'}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;"Number of survivors on day 60 at a dose of 100 mg/kg; 0/7";CHEMBL1123176;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL727530;[];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '100.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '100.0'}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;"Number of survivors on day 60 at a dose of 100 mg/kg; 4/7";CHEMBL1123176;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL880124;[];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '200.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '200.0'}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;"Number of survivors on day 60 at a dose of 200 mg/kg; 4/7";CHEMBL1123176;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL728916;[];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Number of survivors on the toxicity day (day = 15) at a dose of 100x1 mg/kg;CHEMBL1123176;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL722592;[{'assay_class_id': 82, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Carcinoma Oncology Models', 'l3': 'Carcinoma', 'source': 'phenotype'}, {'assay_class_id': 84, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Carcinoma Oncology Models', 'l3': 'Lewis Lung Carcinoma', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '120.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '120.0'}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Number of survivors out of 10 mice after 60 days infected with lewis lung carcinoma at the dose of 120 mg/kg in experiment 2;CHEMBL1121997;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL722593;[{'assay_class_id': 82, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Carcinoma Oncology Models', 'l3': 'Carcinoma', 'source': 'phenotype'}, {'assay_class_id': 84, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Carcinoma Oncology Models', 'l3': 'Lewis Lung Carcinoma', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '150.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '150.0'}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Number of survivors out of 10 mice after 60 days infected with lewis lung carcinoma at the dose of 150 mg/kg in experiment 3;CHEMBL1121997;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL722602;[{'assay_class_id': 82, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Carcinoma Oncology Models', 'l3': 'Carcinoma', 'source': 'phenotype'}, {'assay_class_id': 84, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Carcinoma Oncology Models', 'l3': 'Lewis Lung Carcinoma', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '300.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '300.0'}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Number of survivors out of 10 mice after 60 days infected with lewis lung carcinoma at the dose of 300 mg/kg in experiment 3;CHEMBL1121997;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL728803;[{'assay_class_id': 82, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Carcinoma Oncology Models', 'l3': 'Carcinoma', 'source': 'phenotype'}, {'assay_class_id': 84, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Carcinoma Oncology Models', 'l3': 'Lewis Lung Carcinoma', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '37.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '37.0'}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Number of survivors out of 10 mice after 60 days infected with lewis lung carcinoma at the dose of 37 mg/kg in experiment 3;CHEMBL1121997;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL728960;[{'assay_class_id': 82, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Carcinoma Oncology Models', 'l3': 'Carcinoma', 'source': 'phenotype'}, {'assay_class_id': 84, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Carcinoma Oncology Models', 'l3': 'Lewis Lung Carcinoma', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '75.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '75.0'}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Number of survivors out of 10 mice after 60 days infected with lewis lung carcinoma at the dose of 75 mg/kg in experiment 3;CHEMBL1121997;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL728964;[{'assay_class_id': 82, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Carcinoma Oncology Models', 'l3': 'Carcinoma', 'source': 'phenotype'}, {'assay_class_id': 84, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Carcinoma Oncology Models', 'l3': 'Lewis Lung Carcinoma', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '90.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '90.0'}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Number of survivors out of 10 mice after 60 days infected with lewis lung carcinoma at the dose of 90 mg/kg in experiment 2;CHEMBL1121997;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL724097;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Tumor free mice out of 8 surviving to day 60 or beyond was determined;CHEMBL1122849;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;Lewis lung carcinoma cell line;CHEMBL726930;[{'assay_class_id': 82, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Carcinoma Oncology Models', 'l3': 'Carcinoma', 'source': 'phenotype'}, {'assay_class_id': 84, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Carcinoma Oncology Models', 'l3': 'Lewis Lung Carcinoma', 'source': 'phenotype'}, {'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307859;Target assigned is non-molecular;1;The compound was tested for the anticancer activity against Lewis lung carcinoma cells implanted in male BALB/c mice at a dose of 100x1 mg/kg;CHEMBL1123176;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;Lewis lung carcinoma cell line;CHEMBL726931;[{'assay_class_id': 82, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Carcinoma Oncology Models', 'l3': 'Carcinoma', 'source': 'phenotype'}, {'assay_class_id': 84, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Carcinoma Oncology Models', 'l3': 'Lewis Lung Carcinoma', 'source': 'phenotype'}, {'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307859;Target assigned is non-molecular;1;The compound was tested for the anticancer activity against Lewis lung carcinoma cells implanted in male C57BL mice at a dose of 100x1 mg/kg;CHEMBL1123176;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL725498;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 88, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'L1210 Experimental Leukemia', 'source': 'Hock_2016'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Number of mice bearing L1210 leukemia that survived after 30 days, after administration of 25 mg compound;CHEMBL1136807;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL729562;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;In vivo antitumor activity measured in mice against the Colon26/A murine solid tumors.;CHEMBL1131098;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL729565;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;In vivo antitumor activity measured in mice against the Mam16/C murine solid tumors.;CHEMBL1131098;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL729566;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;In vivo antitumor activity measured in mice against the Panc 02 murine solid tumors.;CHEMBL1131098;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL726366;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 88, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'L1210 Experimental Leukemia', 'source': 'Hock_2016'}, {'assay_class_id': 114, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'Spontaneous Autoimmune Diseases In Animals', 'source': 'Vogel_2008'}, {'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '188.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '188.0'}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;"Antitumor activity in BDF1 male mice bearing L1210 Leukemia, at a dose of 188 mg/kg; survivors for 30 days was reported";CHEMBL1133719;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL726367;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 88, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'L1210 Experimental Leukemia', 'source': 'Hock_2016'}, {'assay_class_id': 114, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'Spontaneous Autoimmune Diseases In Animals', 'source': 'Vogel_2008'}, {'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '250.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '250.0'}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;"Antitumor activity in BDF1 male mice bearing L1210 Leukemia, at a dose of 250 mg/kg; survivors for 30 days was reported";CHEMBL1133719;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL730349;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 88, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'L1210 Experimental Leukemia', 'source': 'Hock_2016'}, {'assay_class_id': 114, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'Spontaneous Autoimmune Diseases In Animals', 'source': 'Vogel_2008'}, {'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '125.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '125.0'}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;"Antitumor activity in BDF1 male mice bearing L1210 Leukemia, at a dose of 125 mg/kg; survivors for 30 days was reported";CHEMBL1133719;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL726342;[];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Hematological effects in female CDF1 mice at the dose of 30 mg, in platelet cells;CHEMBL1133719;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL726234;[];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Hematological effects in female CDF1 mice at the dose of 30 mg, in white blood cells;CHEMBL1133719;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL728599;[];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '120.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '120.0'}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Average body weight in grams on day 5 minus average body weight on day 1 at the dose of 120 mg/kg in experiment 2;CHEMBL1121997;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL728600;[];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '150.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '150.0'}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Average body weight in grams on day 5 minus average body weight on day 1 at the dose of 150 mg/kg in experiment 3;CHEMBL1121997;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL729383;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;In vivo activity against iv transplanted AML Leukemia 1498 tumors of mice;CHEMBL1134487;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL734242;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;In vivo activity against iv transplanted Leukemia L1210 tumors of mice;CHEMBL1134487;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL734243;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;In vivo activity against transplanted Mam-16/C tumors of mice;CHEMBL1134487;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL734245;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;In vivo activity against transplanted Mam-16/C/Adr tumors of mice;CHEMBL1134487;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL879666;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;In vivo activity against transplanted Mam-17 tumors of mice;CHEMBL1134487;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL734247;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;In vivo activity against transplanted Mam-17/Adr tumors of mice;CHEMBL1134487;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL859316;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;In vivo activity against transplanted Mel-B16 tumors of mice;CHEMBL1134487;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL734248;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;In vivo activity against transplanted Panc-02 tumors of mice;CHEMBL1134487;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL734249;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;In vivo activity against transplanted Panc-03 tumors of mice;CHEMBL1134487;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL734250;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;In vivo activity against transplanted Squam lung-LC12 tumors of mice;CHEMBL1134487;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL734251;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;In vivo activity against transplanted colon-26 tumors of mice;CHEMBL1134487;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL734252;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;In vivo activity against transplanted colon-38 tumors of mice;CHEMBL1134487;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL734253;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;In vivo activity against transplanted colon-51 tumors of mice;CHEMBL1134487;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL728440;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 88, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'L1210 Experimental Leukemia', 'source': 'Hock_2016'}, {'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '30.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '30.0'}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Antitumor activity in mice bearing L1210 Leukemia, at a dose of 30 mg/kg at 50 days;CHEMBL1133719;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL730721;[];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '300.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '300.0'}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Average body weight in grams on day 5 minus average body weight on day 1 at the dose of 300 mg/kg in experiment 3;CHEMBL1121997;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL730722;[];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '37.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '37.0'}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Average body weight in grams on day 5 minus average body weight on day 1 at the dose of 37 mg/kg in experiment 3;CHEMBL1121997;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL730730;[];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '75.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '75.0'}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Average body weight in grams on day 5 minus average body weight on day 1 at the dose of 75 mg/kg in experiment 3;CHEMBL1121997;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL730733;[];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '90.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '90.0'}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Average body weight in grams on day 5 minus average body weight on day 1 at the dose of 90 mg/kg in experiment 2;CHEMBL1121997;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL734017;[];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '100.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '100.0'}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;"Percent animals surviving 50 days from day 1; Administered alone and concurrently with the preceding compounds onday 1 at a dose of 100 mg/kg (in vivo)";CHEMBL1121408;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL733134;[];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Body weight change between days 0 and the day when the animal weight was the lowest;CHEMBL1133719;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL729839;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 88, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'L1210 Experimental Leukemia', 'source': 'Hock_2016'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Weight change in mice bearing L1210 leukemia after administration of 25 mg compound;CHEMBL1136807;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL733630;[{'assay_class_id': 94, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'Acute Graft Versus Host Disease GVHD in Rats', 'source': 'Vogel_2008'}, {'assay_class_id': 104, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'General Immunosuppressive Activity', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '200.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '200.0'}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;"Tested in vivo for immunosuppressive activity in mouse using graft vs. Host rejection technique (GVHR); % suppression at a dose of 200 mg/kg";CHEMBL1130359;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL733998;[{'assay_class_id': 94, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'Acute Graft Versus Host Disease GVHD in Rats', 'source': 'Vogel_2008'}, {'assay_class_id': 104, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'General Immunosuppressive Activity', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '200.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '200.0'}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;"Tested in vivo for immunosuppressive activity in mouse using graft vs. Host rejection technique (GVHR); body weight at a dose of 200 mg/kg";CHEMBL1130359;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL737223;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 88, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'L1210 Experimental Leukemia', 'source': 'Hock_2016'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '120.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '120.0'}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Percentage increase in life span of L1210 leukemia implanted mice at a dose of 120 mg/kg;CHEMBL1123954;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL737225;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 88, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'L1210 Experimental Leukemia', 'source': 'Hock_2016'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '150.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '150.0'}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Percentage increase in life span of L1210 leukemia implanted mice at a dose of 150 mg/kg;CHEMBL1123954;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL734739;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 88, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'L1210 Experimental Leukemia', 'source': 'Hock_2016'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '200.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '200.0'}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Percentage increase in life span of L1210 leukemia implanted mice at a dose of 200 mg/kg;CHEMBL1123954;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL734742;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 88, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'L1210 Experimental Leukemia', 'source': 'Hock_2016'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '300.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '300.0'}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Percentage increase in life span of L1210 leukemia implanted mice at a dose of 300 mg/kg;CHEMBL1123954;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL734743;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 88, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'L1210 Experimental Leukemia', 'source': 'Hock_2016'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '400.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '400.0'}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Percentage increase in life span of L1210 leukemia implanted mice at a dose of 400 mg/kg;CHEMBL1123954;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL734405;[];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Effective dose that causes 50% increase in life span of mice;CHEMBL1123954;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL738289;[];Mus musculus;[];;;10090.0;;;T;Toxicity;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Lethal dose was evaluated after single intraperitoneal injection in mice;CHEMBL1127411;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL741650;[];Mus musculus;[];;;10090.0;;;T;Toxicity;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Lethal dose to kill 50% of the mice after single ip injection to healthy female CD2F1 mice;CHEMBL1123954;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL880063;[{'assay_class_id': 100, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'Delayed Type Hypersensitivity', 'source': 'Vogel_2008'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '50.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '50.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Oral', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Oral', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Evaluated for the delayed type hypersensitivity (DTH) response to methylated BSA (mBSA) in sensitive mice after peroral administration of 50 mg/kg;CHEMBL1124858;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL740757;[];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '120.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '120.0'}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;"Number of mice that survived on day 60 at a dose of 120 mg/kg; 1/12";CHEMBL1123954;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL740759;[];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '150.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '150.0'}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;"Number of mice that survived on day 60 at a dose of 150 mg/kg; 1/19";CHEMBL1123954;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL737842;[];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '200.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '200.0'}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;"Number of mice that survived on day 60 at a dose of 200 mg/kg; 8/12";CHEMBL1123954;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL737846;[];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '300.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '300.0'}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;"Number of mice that survived on day 60 at a dose of 300 mg/kg; 16/18";CHEMBL1123954;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL739604;[];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '400.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '400.0'}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;"Number of mice that survived on day 60 at a dose of 400 mg/kg; 7/18";CHEMBL1123954;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL741463;[{'assay_class_id': 94, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'Acute Graft Versus Host Disease GVHD in Rats', 'source': 'Vogel_2008'}, {'assay_class_id': 104, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'General Immunosuppressive Activity', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '200.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '200.0'}];;;10090.0;;Spleen;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;"Tested in vivo for immunosuppressive activity in mouse using graft vs. Host rejection technique (GVHR); spleen index at a dose of 200 mg/kg";CHEMBL1130359;Non-molecular target assigned;N;;1;CHEMBL375;CHEMBL3559722;
CLD0;;;CHEMBL743346;[{'assay_class_id': 94, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'Acute Graft Versus Host Disease GVHD in Rats', 'source': 'Vogel_2008'}, {'assay_class_id': 104, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'General Immunosuppressive Activity', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '200.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '200.0'}];;;10090.0;;Spleen;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;"Tested in vivo for immunosuppressive activity in mouse using graft vs. Host rejection technique (GVHR); spleen weight normalized to D8 body weight at a dose of 200 mg/kg";CHEMBL1130359;Non-molecular target assigned;N;;1;CHEMBL375;CHEMBL3559722;
CLD0;;;CHEMBL742461;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '10.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '10.0'}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Immunological activity in mice as the percentage of suppression of the cellular response to EI4 tumor cells at 10 mg/kg;CHEMBL1121658;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL877178;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '10.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '10.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Oral', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Oral', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Compound was evaluated for immunological activity in mice as the percentage of suppression of the humoral response to EI4 tumor cells at 10 mg/kg, po;CHEMBL1121658;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL745966;[{'assay_class_id': 94, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'Acute Graft Versus Host Disease GVHD in Rats', 'source': 'Vogel_2008'}, {'assay_class_id': 104, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'General Immunosuppressive Activity', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '200.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '200.0'}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;"Tested in vivo for immunosuppressive activity in mouse using graft vs. Host rejection technique (GVHR); weight change at a dose of 200 mg/kg";CHEMBL1130359;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL793922;[{'assay_class_id': 108, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'Passive Cutaneous Anaphylaxis', 'source': 'Vogel_2008'}];Rattus norvegicus;[];;;10116.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;"Evaluated for effect against passive cutaneous anaphylaxis in rats immunized with DNP-As and B. pertussis; PCA (log2)";CHEMBL1121993;Non-molecular target assigned;N;;1;CHEMBL376;;
CLD0;;;CHEMBL795510;[];Rattus norvegicus;[];;;10116.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;"Evaluated for effect against passive hemagglutinination in rats immunized with DNP-As and B. pertussis; PHA(log2)";CHEMBL1121993;Non-molecular target assigned;N;;1;CHEMBL376;;
CLD0;;;CHEMBL797498;[{'assay_class_id': 96, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'Adjuvant Arthritis in Rats', 'source': 'Hock_2016'}, {'assay_class_id': 296, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'MUSCULO-SKELETAL SYSTEM', 'l2': 'Anti-Inflammatory Activity', 'l3': 'General Anti-Inflammatory Models', 'source': 'phenotype'}];Rattus norvegicus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '25.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '25.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Oral', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Oral', 'type': 'ROUTE', 'units': None, 'value': None}];;;10116.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Antiinflammatory activity against D-adjuvant arthritis in injected rat paw at the dose of 25 mg/kg by oral administration;CHEMBL1125290;Non-molecular target assigned;N;;1;CHEMBL376;;
CLD0;;;CHEMBL797575;[{'assay_class_id': 96, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'Adjuvant Arthritis in Rats', 'source': 'Hock_2016'}, {'assay_class_id': 296, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'MUSCULO-SKELETAL SYSTEM', 'l2': 'Anti-Inflammatory Activity', 'l3': 'General Anti-Inflammatory Models', 'source': 'phenotype'}];Rattus norvegicus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '25.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '25.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Oral', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Oral', 'type': 'ROUTE', 'units': None, 'value': None}];;;10116.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Antiinflammatory activity against D-adjuvant arthritis in uninjected rat paw at the dose of 25 mg/kg by oral administration;CHEMBL1125290;Non-molecular target assigned;N;;1;CHEMBL376;;
CLD0;;;CHEMBL802252;[];Rattus norvegicus;[];;Microsomes;10116.0;;Liver;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;"Alkylating activity determined by incubating with rat hepatic microsomes and time dependent release of alkylating species with no pretreatment; Activity expressed as uM of mechlorethamine equiv/g of liver/h";CHEMBL1125916;Non-molecular target assigned;N;;1;CHEMBL376;CHEMBL3559723;
CLD0;;;CHEMBL802253;[];Rattus norvegicus;[];;Microsomes;10116.0;;Liver;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;"Alkylating activity determined by incubating with rat hepatic microsomes and time dependent release of alkylating species with phenobarbital pretreatment; Activity expressed as uM of mechlorethamine equiv/g of liver/h";CHEMBL1125916;Non-molecular target assigned;N;;1;CHEMBL376;CHEMBL3559723;
CLD0;;;CHEMBL802254;[];Rattus norvegicus;[];;;10116.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Percent decrease in the microsomal activation determined with no pretreatment;CHEMBL1125916;Non-molecular target assigned;N;;1;CHEMBL376;;
CLD0;;;CHEMBL802256;[];Rattus norvegicus;[];;;10116.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Percent decrease in the microsomal activation determined with pretreatment with phenobarbital.;CHEMBL1125916;Non-molecular target assigned;N;;1;CHEMBL376;;
CLD0;;;CHEMBL804491;[];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Ability of compound (220 mg/kg, single dose) to inhibit growth of Sc colon 38 tumor cells in mice;CHEMBL1124442;Non-molecular target assigned;N;;1;CHEMBL3879801;;
CLD0;;;CHEMBL843490;[{'assay_class_id': 96, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'Adjuvant Arthritis in Rats', 'source': 'Hock_2016'}, {'assay_class_id': 296, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'MUSCULO-SKELETAL SYSTEM', 'l2': 'Anti-Inflammatory Activity', 'l3': 'General Anti-Inflammatory Models', 'source': 'phenotype'}];Rattus norvegicus;[];;;10116.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Antiinflammatory activity dosed orally against D-adjuvant arthritis in rat.;CHEMBL1125290;Non-molecular target assigned;N;;1;CHEMBL376;;
CLD0;;;CHEMBL846893;[{'assay_class_id': 296, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'MUSCULO-SKELETAL SYSTEM', 'l2': 'Anti-Inflammatory Activity', 'l3': 'General Anti-Inflammatory Models', 'source': 'phenotype'}, {'assay_class_id': 301, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'MUSCULO-SKELETAL SYSTEM', 'l2': 'Anti-Inflammatory Activity', 'l3': 'Paw Edema Test', 'source': 'Hock_2016'}];Rattus norvegicus;[];;;10116.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Antiinflammatory activity dosed orally against carrageenan induced rat paw edema(CPE);CHEMBL1125290;Non-molecular target assigned;N;;1;CHEMBL376;;
CLD0;;;CHEMBL850451;[];;[];;;;;;A;ADME;BAO_0000019;assay format;;Default value - Target unknown or has yet to be assigned;0;Therapeutic index as the ratio of LD50 to ED50 of the compound;CHEMBL1121753;Default value - Target has yet to be curated;U;;1;CHEMBL612558;;
CLD0;;;CHEMBL838188;[{'assay_class_id': 104, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'General Immunosuppressive Activity', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Effect (10 mg/kg/day*7 days, i.v.) on cyclophosphamide (CY, i.p.) treated mice (immunosuppressed animal model) assessed by CD4+/CD8+ ratio in peripheral blood mononuclear cells;CHEMBL1141138;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;CCRF S-180;CHEMBL868090;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '30.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '30.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307278;Target assigned is non-molecular;1;Antitumor activity against S180 cells implanted in mouse at 30 mg/kg, ip;CHEMBL1138959;Non-molecular target assigned;N;;1;CHEMBL614027;;
CLD0;;H22;CHEMBL868091;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '30.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '30.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307751;Target assigned is non-molecular;1;Antitumor activity against H22 cells implanted in mouse at 30 mg/kg, ip;CHEMBL1138959;Non-molecular target assigned;N;;1;CHEMBL614998;;
CLD0;;;CHEMBL868096;[];Mus musculus;[];;;10090.0;;;T;Toxicity;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Toxicity in ip dosed mouse;CHEMBL1138959;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;CCRF S-180;CHEMBL904664;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '50.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '50.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307278;Target assigned is non-molecular;1;Antitumor activity against S180 cells inoculated in ICR mouse assessed as tumor weight at 50 mg/kg, ip after 8 days;CHEMBL1142889;Non-molecular target assigned;N;;1;CHEMBL614027;;
CLD0;;CCRF S-180;CHEMBL904666;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '50.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '50.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307278;Target assigned is non-molecular;1;Antitumor activity against S180 cells inoculated in ICR mouse assessed as inhibition at 50 mg/kg, ip after 8 days relative to control;CHEMBL1142889;Non-molecular target assigned;N;;1;CHEMBL614027;;
CLD0;;Lewis lung carcinoma cell line;CHEMBL903031;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '100.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '100.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;Lung;F;Functional;BAO_0000218;organism-based format;CHEMBL3307859;Target assigned is non-molecular;1;Antitumor activity against LLC cells inoculated in C57BL/6J mouse assessed as lung weight at 100 mg/kg, ip administered alternatively for 12 days;CHEMBL1138358;Non-molecular target assigned;N;;1;CHEMBL614088;CHEMBL3638235;
CLD0;;H22;CHEMBL903542;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}, {'assay_class_id': 119, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Xenograft Oncology Models', 'l3': 'Xenograft Models of Anti-Tumor Assays', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '30.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '30.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intravenous', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intravenous', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307751;Target assigned is non-molecular;1;Antitumor activity in H22 cells xenografted ICR mouse assessed as tumor weight at 30 mg/kg, iv after 4 days;CHEMBL1139134;Non-molecular target assigned;N;;1;CHEMBL614998;;
CLD0;;H22;CHEMBL903543;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}, {'assay_class_id': 119, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Xenograft Oncology Models', 'l3': 'Xenograft Models of Anti-Tumor Assays', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '30.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '30.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intravenous', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intravenous', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307751;Target assigned is non-molecular;1;Antitumor activity in H22 cells xenografted ICR mouse assessed as tumor growth inhibition at 30 mg/kg, iv after 4 days;CHEMBL1139134;Non-molecular target assigned;N;;1;CHEMBL614998;;
CLD0;;;CHEMBL926687;[];Homo sapiens;[];;;9606.0;In vivo;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Oral bioavailability in human;CHEMBL1141299;Non-molecular target assigned;N;;1;CHEMBL372;;
CLD0;;CCRF S-180;CHEMBL947964;[];Mus musculus;[{'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307278;Target assigned is non-molecular;1;Effect on body weight in mouse bearing S180 cells at 30 mg/kg/day, ip after 10 days;CHEMBL1142371;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;CCRF S-180;CHEMBL947966;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}, {'assay_class_id': 119, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Xenograft Oncology Models', 'l3': 'Xenograft Models of Anti-Tumor Assays', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307278;Target assigned is non-molecular;1;Antitumor activity in mouse xenografted with S180 cells assessed as inhibition of tumor growth at 30 mg/kg/day, ip after 10 days;CHEMBL1142371;Non-molecular target assigned;N;;1;CHEMBL614027;;
CLD0;;H22;CHEMBL946963;[];Mus musculus;[{'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307751;Target assigned is non-molecular;1;Effect on body weight in mouse bearing H22 cells at 30 mg/kg/day, ip after 10 days;CHEMBL1142371;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;H22;CHEMBL948107;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}, {'assay_class_id': 119, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Xenograft Oncology Models', 'l3': 'Xenograft Models of Anti-Tumor Assays', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307751;Target assigned is non-molecular;1;Antitumor activity in mouse xenografted with H22 cells assessed as inhibition of tumor growth at 30 mg/kg/day, ip after 10 days;CHEMBL1142371;Non-molecular target assigned;N;;1;CHEMBL614998;;
CLD0;;MX1;CHEMBL1007927;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}, {'assay_class_id': 119, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Xenograft Oncology Models', 'l3': 'Xenograft Models of Anti-Tumor Assays', 'source': 'phenotype'}];Homo sapiens;[{'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;9606.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308046;Target assigned is non-molecular;1;Antitumor activity against human MX1 cells xenografted in SCID mouse assessed as tumor volume at 12.5 mg/kg/day, ip after 34 days;CHEMBL1139389;Non-molecular target assigned;N;;1;CHEMBL613704;;
CLD0;;MX1;CHEMBL1007928;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}, {'assay_class_id': 119, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Xenograft Oncology Models', 'l3': 'Xenograft Models of Anti-Tumor Assays', 'source': 'phenotype'}];Homo sapiens;[{'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;9606.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308046;Target assigned is non-molecular;1;Antitumor activity against human MX1 cells xenografted in SCID mouse assessed as growth inhibition at 12.5 mg/kg/day, ip after 34 days relative to control;CHEMBL1139389;Non-molecular target assigned;N;;1;CHEMBL613704;;
CLD0;;MX1;CHEMBL1007929;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}, {'assay_class_id': 119, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Xenograft Oncology Models', 'l3': 'Xenograft Models of Anti-Tumor Assays', 'source': 'phenotype'}];Homo sapiens;[{'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;9606.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308046;Target assigned is non-molecular;1;Antitumor activity against human MX1 cells xenografted in SCID mouse assessed as tumor volume at 12.5 mg/kg/day, ip after 48 days;CHEMBL1139389;Non-molecular target assigned;N;;1;CHEMBL613704;;
CLD0;;H22;CHEMBL976473;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}, {'assay_class_id': 119, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Xenograft Oncology Models', 'l3': 'Xenograft Models of Anti-Tumor Assays', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intravenous', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intravenous', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307751;Target assigned is non-molecular;1;Antitumor activity in mouse H22 cell xenografted mouse at 20 mg/kg/day, iv after 4 days;CHEMBL1155921;Non-molecular target assigned;N;;1;CHEMBL614998;;
CLD0;;HEK293;CHEMBL993349;[];Homo sapiens;[];;;9606.0;;;B;Binding;BAO_0000219;cell-based format;CHEMBL3307715;Direct single protein target assigned;9;Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy;CHEMBL1140113;Direct protein target assigned;D;;1;CHEMBL5685;;
CLD0;;U-87MG ATCC;CHEMBL954890;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}, {'assay_class_id': 119, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Xenograft Oncology Models', 'l3': 'Xenograft Models of Anti-Tumor Assays', 'source': 'phenotype'}];Homo sapiens;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '80.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '80.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intravenous', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intravenous', 'type': 'ROUTE', 'units': None, 'value': None}];;;9606.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307575;Target assigned is non-molecular;1;Antitumor activity in human U87 MG cells xenografted mouse at 80 mg/kg, iv administered in Q2D x 5 schedule;CHEMBL1150326;Non-molecular target assigned;N;;1;CHEMBL614247;;
CLD0;;U-87MG ATCC;CHEMBL954892;[];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '80.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '80.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intravenous', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intravenous', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;T;Toxicity;BAO_0000218;organism-based format;CHEMBL3307575;Target assigned is non-molecular;1;Toxicity against human U87 MG cells xenografted mouse assessed as body weight loss at 80 mg/kg, iv administered in Q2D x 5 schedule;CHEMBL1150326;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL958103;[];Escherichia coli;[];DH5alpha;;562.0;;;B;Binding;BAO_0000019;assay format;;Default value - Target unknown or has yet to be assigned;0;Effect on DNA cleavage in ampicillin resistant Escherichia coli DH5alpha transformed pBluescript 2 KS+ DNA assessed as number of colonies at 10 mM after 15 hrs by transformation assay;CHEMBL1150296;Default value - Target has yet to be curated;U;;1;CHEMBL612545;;
CLD0;;;CHEMBL958105;[];Escherichia coli;[];;;562.0;;;B;Binding;BAO_0000019;assay format;;Default value - Target unknown or has yet to be assigned;0;Induction of Escherichia coli pBluescript 2 KS+ DNA cleavage at 10 mM by gel electrophoresis;CHEMBL1150296;Default value - Target has yet to be curated;U;;1;CHEMBL612545;;
CLD0;;;CHEMBL965578;[];Mus musculus;[];;;10090.0;;;B;Binding;BAO_0000019;assay format;;Direct single protein target assigned;9;Inhibition of mouse brain MAOA;CHEMBL1152129;Direct protein target assigned;D;;1;CHEMBL3681;;
CLD0;;;CHEMBL965579;[];Mus musculus;[];;;10090.0;;;B;Binding;BAO_0000019;assay format;;Direct single protein target assigned;9;Inhibition of mouse liver MAOB;CHEMBL1152129;Direct protein target assigned;D;;1;CHEMBL3050;;
CLD0;;;CHEMBL965580;[];Mus musculus;[];;;10090.0;;;B;Binding;BAO_0000019;assay format;;Direct single protein target assigned;9;Inhibition of mouse brain MAOB;CHEMBL1152129;Direct protein target assigned;D;;1;CHEMBL3050;;
CLD0;;;CHEMBL965582;[];Bos taurus;[];;;9913.0;;;B;Binding;BAO_0000019;assay format;;Direct single protein target assigned;9;Inhibition of bovine brain MAOA;CHEMBL1152129;Direct protein target assigned;D;;1;CHEMBL3254;;
CLD0;;;CHEMBL965584;[];Bos taurus;[];;;9913.0;;;B;Binding;BAO_0000019;assay format;;Direct single protein target assigned;9;Inhibition of bovine brain MAOB;CHEMBL1152129;Direct protein target assigned;D;;1;CHEMBL2756;;
CLD0;;;CHEMBL1035433;[];Homo sapiens;[];;;9606.0;In vivo;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Total body clearance in human;CHEMBL1151930;Non-molecular target assigned;N;;1;CHEMBL372;;
CLD0;;;CHEMBL1035434;[];Homo sapiens;[];;;9606.0;In vivo;Kidney;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Renal clearance in human;CHEMBL1151930;Non-molecular target assigned;N;;1;CHEMBL372;CHEMBL3638241;
CLD0;;;CHEMBL1043580;[];Homo sapiens;[];;;9606.0;;Plasma;A;ADME;BAO_0000366;cell-free format;;Target assigned is non-molecular;1;Fraction unbound in human plasma;CHEMBL1156824;Non-molecular target assigned;N;;1;CHEMBL613652;CHEMBL3559721;
CLD0;;;CHEMBL1043581;[];Homo sapiens;[];;;9606.0;In vivo;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Total clearance in human;CHEMBL1156824;Non-molecular target assigned;N;;1;CHEMBL372;;
CLD0;;;CHEMBL1043582;[];Homo sapiens;[];;;9606.0;In vivo;Liver;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Hepatic clearance in human;CHEMBL1156824;Non-molecular target assigned;N;;1;CHEMBL372;CHEMBL3559723;
CLD0;;;CHEMBL1043583;[];Homo sapiens;[];;;9606.0;In vivo;Kidney;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Renal clearance in human;CHEMBL1156824;Non-molecular target assigned;N;;1;CHEMBL372;CHEMBL3638241;
CLD0;;;CHEMBL1043584;[];Homo sapiens;[];;;9606.0;In vivo;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Oral bioavailability in human;CHEMBL1156824;Non-molecular target assigned;N;;1;CHEMBL372;;
CLD0;;;CHEMBL1043585;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Fraction absorbed in human;CHEMBL1156824;Non-molecular target assigned;N;;1;CHEMBL372;;
CLD0;;;CHEMBL1043586;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Fraction escaping gut-wall elimination in human;CHEMBL1156824;Non-molecular target assigned;N;;1;CHEMBL372;;
CLD0;;;CHEMBL1043587;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Fraction escaping hepatic elimination in human;CHEMBL1156824;Non-molecular target assigned;N;;1;CHEMBL372;;
CLD0;;;CHEMBL1043588;[];Homo sapiens;[];;;9606.0;In vivo;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Volume of distribution at steady state in human;CHEMBL1156824;Non-molecular target assigned;N;;1;CHEMBL372;;
CLD0;;;CHEMBL1108963;[];;[];;;;;;P;Physicochemical;BAO_0000100;small-molecule physicochemical format;;Default value - Target unknown or has yet to be assigned;0;Octanol-water partition coefficient, log P of the compound;CHEMBL1157036;Default value - Target has yet to be curated;U;;1;CHEMBL2362975;;
CLD0;;CCRF S-180;CHEMBL1104816;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}, {'assay_class_id': 119, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Xenograft Oncology Models', 'l3': 'Xenograft Models of Anti-Tumor Assays', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '100.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '100.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intragastric', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intragastric', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307278;Target assigned is non-molecular;1;Antitumor activity against mouse S180 cells xenografted in ICR mouse assessed as reduction of tumor weight at 100 mg/kg, ig administered 2 days after tumor inoculation qd for 7 days;CHEMBL1157124;Non-molecular target assigned;N;;1;CHEMBL614027;;
CLD0;;CCRF S-180;CHEMBL1104818;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}, {'assay_class_id': 119, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Xenograft Oncology Models', 'l3': 'Xenograft Models of Anti-Tumor Assays', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '100.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '100.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intragastric', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intragastric', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307278;Target assigned is non-molecular;1;Antitumor activity against mouse S180 cells xenografted in ICR mouse assessed as inhibition of tumor weight at 100 mg/kg, ig administered 2 days after tumor inoculation qd for 7 days relative to control;CHEMBL1157124;Non-molecular target assigned;N;;1;CHEMBL614027;;
CLD0;;;CHEMBL1266185;[];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000019;assay format;;Default value - Target unknown or has yet to be assigned;0;Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay;CHEMBL1255231;Default value - Target has yet to be curated;U;;1;CHEMBL612545;;
CLD0;;HEp-2;CHEMBL1274285;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307694;Target assigned is non-molecular;1;Cytotoxicity against human Hep2 cells by MTT assay;CHEMBL1268823;Non-molecular target assigned;N;;1;CHEMBL614735;;
CLD0;;HL-60;CHEMBL1274286;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307654;Target assigned is non-molecular;1;Cytotoxicity against human HL60 cells by MTT assay;CHEMBL1268823;Non-molecular target assigned;N;;1;CHEMBL383;;
CLD0;;HEK-293T;CHEMBL1274287;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3706569;Target assigned is non-molecular;1;Cytotoxicity against human HEK293T cells by MTT assay;CHEMBL1268823;Non-molecular target assigned;N;;1;CHEMBL3706568;;
CLD0;;CCRF S-180;CHEMBL1273719;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}, {'assay_class_id': 119, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Xenograft Oncology Models', 'l3': 'Xenograft Models of Anti-Tumor Assays', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '100.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '100.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307278;Target assigned is non-molecular;1;Anticancer activity against mouse S180 cells xenografted in ICR mouse assessed as tumor weight inhibition at 100 mg/kg, ip relative to control;CHEMBL1268940;Non-molecular target assigned;N;;1;CHEMBL614027;;
CLD0;;;CHEMBL1283848;[];Pasteurella multocida;[];AL435;;747.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Antibacterial activity against Pasteurella multocida AL435 after 24 hrs by broth dilution method;CHEMBL1275542;Non-molecular target assigned;N;;1;CHEMBL614409;;
CLD0;;;CHEMBL1283849;[];Pasteurella multocida;[];pm0527;;747.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Antibacterial activity against TolC deficient Pasteurella multocida pm0527 after 24 hrs by broth dilution method;CHEMBL1275542;Non-molecular target assigned;N;;1;CHEMBL614409;;
CLD0;;;CHEMBL1283850;[];Pasteurella multocida;[];pm0527;;747.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Antibacterial activity against Pasteurella multocida pm0527 after 24 hrs by broth dilution method;CHEMBL1275542;Non-molecular target assigned;N;;1;CHEMBL614409;;
CLD0;;;CHEMBL1283851;[];Pasteurella multocida;[];;;747.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Ratio of MIC for Pasteurella multocida AL435 to MIC for TolC deficient Pasteurella multocida pm0527;CHEMBL1275542;Non-molecular target assigned;N;;1;CHEMBL614409;;
CLD0;;;CHEMBL1283852;[];Pasteurella multocida;[];pm1980;;747.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Antibacterial activity against TolC deficient Pasteurella multocida pm1980 after 24 hrs by broth dilution method;CHEMBL1275542;Non-molecular target assigned;N;;1;CHEMBL614409;;
CLD0;;;CHEMBL1283853;[];Pasteurella multocida;[];pm1980;;747.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Antibacterial activity against Pasteurella multocida pm1980 after 24 hrs by broth dilution method;CHEMBL1275542;Non-molecular target assigned;N;;1;CHEMBL614409;;
CLD0;;;CHEMBL1283854;[];Pasteurella multocida;[];;;747.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Ratio of MIC for Pasteurella multocida AL435 to MIC for TolC deficient Pasteurella multocida pm1980;CHEMBL1275542;Non-molecular target assigned;N;;1;CHEMBL614409;;
CLD0;;;CHEMBL1285392;[];Candida albicans;[];;;5476.0;;;B;Binding;BAO_0000019;assay format;;Default value - Target unknown or has yet to be assigned;0;Binding affinity to Candida albicans CaCdr1p expressed in yeast AD1-8u;CHEMBL1275276;Default value - Target has yet to be curated;U;;1;CHEMBL612545;;
CLD0;;;CHEMBL1285393;[];Saccharomyces cerevisiae;[];AD1-8u;;4932.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Antifungal activity against yeast AD1-8u expressing Candida albicans CaMdr1p by agar disk diffusion assay;CHEMBL1275276;Non-molecular target assigned;N;;1;CHEMBL361;;
CLD0;;;CHEMBL1285394;[];Candida albicans;[];;;5476.0;;;B;Binding;BAO_0000019;assay format;;Default value - Target unknown or has yet to be assigned;0;Binding affinity to Candida albicans CaMdr1p expressed in yeast AD1-8u;CHEMBL1275276;Default value - Target has yet to be curated;U;;1;CHEMBL612545;;
CLD0;;;CHEMBL1285395;[];Saccharomyces cerevisiae;[];AD1-8u;;4932.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Antifungal activity against yeast AD1-8u expressing Candida albicans CaCdr1p by agar disk diffusion assay;CHEMBL1275276;Non-molecular target assigned;N;;1;CHEMBL361;;
CLD0;confirmatory;;CHEMBL1614240;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000019;assay format;;Direct single protein target assigned;9;PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase). (Class of assay: confirmatory) ;CHEMBL1201862;Direct protein target assigned;D;887;7;CHEMBL2903;;
CLD0;confirmatory;;CHEMBL1613808;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000019;assay format;;Direct single protein target assigned;9;PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay. (Class of assay: confirmatory) ;CHEMBL1201862;Direct protein target assigned;D;995;7;CHEMBL4040;;
CLD0;confirmatory;;CHEMBL1613914;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000019;assay format;;Direct single protein target assigned;9;PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Human Jumonji Domain Containing 2E (JMJD2E). (Class of assay: confirmatory) ;CHEMBL1201862;Direct protein target assigned;D;2147;7;CHEMBL1293226;;
CLD0;confirmatory;;CHEMBL1614052;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000019;assay format;;Direct single protein target assigned;9;PUBCHEM_BIOASSAY: qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction. (Class of assay: confirmatory) ;CHEMBL1201862;Direct protein target assigned;D;1461;7;CHEMBL5162;;
CLD0;confirmatory;;CHEMBL1614211;[];;[];;;;;;F;Functional;BAO_0000019;assay format;;Homologous single protein target assigned;8;PubChem BioAssay. qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1).   (Class of assay: confirmatory) ;CHEMBL1201862;Homologous protein target assigned;H;2517;7;CHEMBL5619;;
CLD0;;;CHEMBL1614670;[];Homo sapiens;[];;;9606.0;In vivo;;A;ADME;BAO_0000218;organism-based format;;Default value - Target unknown or has yet to be assigned;0;Volume of distribution at steady state in human after iv administration;CHEMBL1614632;Default value - Target has yet to be curated;U;;1;CHEMBL612558;;
CLD0;;;CHEMBL1614671;[];Homo sapiens;[];;;9606.0;In vivo;;A;ADME;BAO_0000218;organism-based format;;Default value - Target unknown or has yet to be assigned;0;Clearance in human after iv administration;CHEMBL1614632;Default value - Target has yet to be curated;U;;1;CHEMBL612558;;
CLD0;;;CHEMBL1614672;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Fraction unbound in human after iv administration;CHEMBL1614632;Non-molecular target assigned;N;;1;CHEMBL3879801;;
CLD0;;;CHEMBL1614673;[];Homo sapiens;[];;;9606.0;In vivo;;A;ADME;BAO_0000218;organism-based format;;Default value - Target unknown or has yet to be assigned;0;Mean residence time in human after iv administration;CHEMBL1614632;Default value - Target has yet to be curated;U;;1;CHEMBL612558;;
CLD0;;;CHEMBL1614674;[];Homo sapiens;[];;;9606.0;In vivo;;A;ADME;BAO_0000218;organism-based format;;Default value - Target unknown or has yet to be assigned;0;Half life in human after iv administration;CHEMBL1614632;Default value - Target has yet to be curated;U;;1;CHEMBL612558;;
CLD0;;;CHEMBL1614675;[];Rattus norvegicus;[];;;10116.0;In vivo;;A;ADME;BAO_0000218;organism-based format;;Default value - Target unknown or has yet to be assigned;0;Clearance in rat after iv administration;CHEMBL1614629;Default value - Target has yet to be curated;U;;1;CHEMBL612558;;
CLD0;;;CHEMBL1614676;[];Rattus norvegicus;[];;;10116.0;In vivo;;A;ADME;BAO_0000218;organism-based format;;Default value - Target unknown or has yet to be assigned;0;Volume of distribution at steady state in rat after iv administration;CHEMBL1614629;Default value - Target has yet to be curated;U;;1;CHEMBL612558;;
CLD0;;;CHEMBL1614677;[];Canis lupus familiaris;[];;;9615.0;In vivo;;A;ADME;BAO_0000218;organism-based format;;Default value - Target unknown or has yet to be assigned;0;Clearance in dog after iv administration;CHEMBL1614629;Default value - Target has yet to be curated;U;;1;CHEMBL612558;;
CLD0;;;CHEMBL1614678;[];Canis lupus familiaris;[];;;9615.0;In vivo;;A;ADME;BAO_0000218;organism-based format;;Default value - Target unknown or has yet to be assigned;0;Volume of distribution at steady state in dog after iv administration;CHEMBL1614629;Default value - Target has yet to be curated;U;;1;CHEMBL612558;;
CLD0;;;CHEMBL1614679;[];Macaca;[];;;9539.0;In vivo;;A;ADME;BAO_0000218;organism-based format;;Default value - Target unknown or has yet to be assigned;0;Clearance in monkey after iv administration;CHEMBL1614629;Default value - Target has yet to be curated;U;;1;CHEMBL612558;;
CLD0;;;CHEMBL1614680;[];Macaca;[];;;9539.0;In vivo;;A;ADME;BAO_0000218;organism-based format;;Default value - Target unknown or has yet to be assigned;0;Volume of distribution at steady state in monkey after iv administration;CHEMBL1614629;Default value - Target has yet to be curated;U;;1;CHEMBL612558;;
CLD0;;;CHEMBL1614681;[];Homo sapiens;[];;;9606.0;In vivo;;A;ADME;BAO_0000218;organism-based format;;Default value - Target unknown or has yet to be assigned;0;Clearance in human after iv administration;CHEMBL1614629;Default value - Target has yet to be curated;U;;1;CHEMBL612558;;
CLD0;;;CHEMBL1614682;[];Homo sapiens;[];;;9606.0;In vivo;;A;ADME;BAO_0000218;organism-based format;;Default value - Target unknown or has yet to be assigned;0;Volume of distribution at steady state in human after iv administration;CHEMBL1614629;Default value - Target has yet to be curated;U;;1;CHEMBL612558;;
CLD0;;;CHEMBL1633749;[{'assay_class_id': 104, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'General Immunosuppressive Activity', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '100.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '100.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];BALB/c;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Immunosuppressive activity against MAV-1 infected BALB/c mouse assessed as viral-induced mortality rate at 100 mg/kg, ip treated 8 days before infection for 2 weeks;CHEMBL1629543;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL1633750;[{'assay_class_id': 104, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'General Immunosuppressive Activity', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '100.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '100.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];BALB/c;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Immunosuppressive activity against MAV-1 infected BALB/c mouse assessed as viral-induced mortality rate at 100 mg/kg, ip treated 8 days before infection for 3 weeks;CHEMBL1629543;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL1633751;[{'assay_class_id': 104, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'General Immunosuppressive Activity', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '100.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '100.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];BALB/c;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Immunosuppressive activity against MAV-1 infected BALB/c mouse assessed as viral-induced mortality rate at 100 mg/kg, ip treated 8 days before infection for 4 weeks;CHEMBL1629543;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL1633752;[{'assay_class_id': 104, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'General Immunosuppressive Activity', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '100.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '100.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];BALB/c;;10090.0;;;T;Toxicity;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Toxicity in MAV-1 infected nonimmunosuppressed BALB/c mouse assessed as effect on survival at 100 mg/kg, ip treated 8 days before infection for 2 to 4 weeks;CHEMBL1629543;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL1633753;[];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '100.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '100.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];BALB/c;;10090.0;;;T;Toxicity;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Toxicity in BALB/c mouse assessed as effect on survival rate at 100 mg/kg, ip after 2 to 4 weeks;CHEMBL1629543;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL1633754;[{'assay_class_id': 104, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'General Immunosuppressive Activity', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '100.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '100.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];BALB/c;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Immunosuppressive activity against MAV-1 infected BALB/c mouse assessed as leukopenia in lymph node at 100 mg/kg, ip treated 8 days before infection measured 3 days post infection by flow cytometry;CHEMBL1629543;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL1633755;[{'assay_class_id': 104, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'General Immunosuppressive Activity', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '100.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '100.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];BALB/c;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Immunosuppressive activity against MAV-1 infected BALB/c mouse assessed as increase in neutrophils at 100 mg/kg, ip treated 8 days before infection for 2 weeks measured 14 days post infection by flow cytometry;CHEMBL1629543;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;B;CHEMBL1633756;[{'assay_class_id': 104, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'General Immunosuppressive Activity', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '100.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '100.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];BALB/c;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Immunosuppressive activity against MAV-1 infected BALB/c mouse assessed as B cells suppression at 100 mg/kg, ip treated 8 days before infection for 4 weeks measured 14 days post infection by flow cytometry;CHEMBL1629543;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL1633757;[{'assay_class_id': 104, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'General Immunosuppressive Activity', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '100.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '100.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];BALB/c;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Immunosuppressive activity against MAV-1 infected BALB/c mouse assessed as effect on leukocyte proliferation by T-cell stimulus alphaCD3 at 100 mg/kg, ip treated 8 days before infection by flow cytometry;CHEMBL1629543;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL1634556;[{'assay_class_id': 104, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'General Immunosuppressive Activity', 'source': 'phenotype'}, {'assay_class_id': 296, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'MUSCULO-SKELETAL SYSTEM', 'l2': 'Anti-Inflammatory Activity', 'l3': 'General Anti-Inflammatory Models', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '100.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '100.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];BALB/c;;10090.0;;Liver;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Immunosuppressive activity against MAV-1 infected BALB/c mouse assessed as effect on parenchymal inflammation in liver at 100 mg/kg, ip treated 8 days before infection for 2 weeks by flow cytometry;CHEMBL1629543;Non-molecular target assigned;N;;1;CHEMBL375;CHEMBL3559723;
CLD0;;;CHEMBL1634557;[];Murine adenovirus 1;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '100.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '100.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;10530.0;;Liver;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Antiviral activity against MAV-1 infected in immunocompromized BALB/c mouse assessed as effect on viral DNA load in liver at 100 mg/kg, ip treated 8 days before infection for 3 weeks by RT-PCR;CHEMBL1629543;Non-molecular target assigned;N;;1;CHEMBL3879801;CHEMBL3559723;
CLD0;;;CHEMBL1634558;[];Murine adenovirus 1;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '100.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '100.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;10530.0;;Liver;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Antiviral activity against MAV-1 infected in immunocompromized BALB/c mouse assessed as effect on viral DNA load in liver at 100 mg/kg, ip treated 8 days before infection for 4 weeks by RT-PCR;CHEMBL1629543;Non-molecular target assigned;N;;1;CHEMBL3879801;CHEMBL3559723;
CLD0;;;CHEMBL1634559;[];Murine adenovirus 1;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '100.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '100.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;10530.0;;Liver;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Antiviral activity against MAV-1 infected in immunocompromized BALB/c mouse assessed as decrease in viral DNA load in liver at 100 mg/kg, ip treated 8 days before infection measured after 28 days post infection by RT-PCR;CHEMBL1629543;Non-molecular target assigned;N;;1;CHEMBL3879801;CHEMBL3559723;
CLD0;;;CHEMBL1634560;[{'assay_class_id': 104, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'General Immunosuppressive Activity', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '100.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '100.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];BALB/c;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Immunosuppressive activity against MAV-1 infected BALB/c mouse assessed as enhancement of cidofovir-induced antiviral activity at 100 mg/kg, ip cyclophosphamide treated 8 days before infection for 2 to 4 weeks;CHEMBL1629543;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL1634561;[{'assay_class_id': 104, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'General Immunosuppressive Activity', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '100.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '100.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];BALB/c;;10090.0;;Liver;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Immunosuppressive activity against MAV-1 infected BALB/c mouse assessed as effect on cidofovir-induced effect on viral DNA load in liver at 100 mg/kg, ip treated 8 days before infection for 2 to 3 weeks measured after 62 days postinfection by RT-PCR;CHEMBL1629543;Non-molecular target assigned;N;;1;CHEMBL375;CHEMBL3559723;
CLD0;;;CHEMBL1634562;[{'assay_class_id': 104, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'General Immunosuppressive Activity', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '100.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '100.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];BALB/c;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Immunosuppressive activity against MAV-1 infected BALB/c mouse assessed as inhibition of production of protective antibodies at 100 mg/kg, ip treated 8 days before infection for 3 weeks measured after 62 days postinfection;CHEMBL1629543;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL1634563;[{'assay_class_id': 104, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'General Immunosuppressive Activity', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '100.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '100.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];BALB/c;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Immunosuppressive activity against MAV-1 infected BALB/c mouse assessed as inhibition of production of protective antibodies at 100 mg/kg, ip treated 8 days before infection for 2 weeks measured after 62 days postinfection;CHEMBL1629543;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;;CHEMBL1634564;[{'assay_class_id': 104, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'General Immunosuppressive Activity', 'source': 'phenotype'}, {'assay_class_id': 296, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'MUSCULO-SKELETAL SYSTEM', 'l2': 'Anti-Inflammatory Activity', 'l3': 'General Anti-Inflammatory Models', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '100.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '100.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];BALB/c;;10090.0;;Liver;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Immunosuppressive activity against MAV-1 infected BALB/c mouse assessed as effect portal inflammation in liver at 100 mg/kg, ip treated 8 days before infection for 2 weeks by flow cytometry;CHEMBL1629543;Non-molecular target assigned;N;;1;CHEMBL375;CHEMBL3559723;
CLD0;;T-cell;CHEMBL1634565;[{'assay_class_id': 104, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'General Immunosuppressive Activity', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '100.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '100.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];BALB/c;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307588;Target assigned is non-molecular;1;Immunosuppressive activity against MAV-1 infected BALB/c mouse assessed as T cells suppression at 100 mg/kg, ip treated 8 days before infection for 4 weeks measured 14 days post infection by flow cytometry;CHEMBL1629543;Non-molecular target assigned;N;;1;CHEMBL375;;
CLD0;;U-87MG ATCC;CHEMBL1646603;[];Homo sapiens;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '80.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '80.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intravenous', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intravenous', 'type': 'ROUTE', 'units': None, 'value': None}];;;9606.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307575;Target assigned is non-molecular;1;Anticancer activity against human U87MG cells xenografted in athymic mouse assessed as tumor suppression at 80 mg/kg, iv Q2D for 6 days;CHEMBL1641520;Non-molecular target assigned;N;;1;CHEMBL3879801;;
CLD0;;;CHEMBL1697722;[];;[];;;;;;A;ADME;BAO_0000019;assay format;;Target assigned is non-molecular;1;Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset;CHEMBL1697692;Non-molecular target assigned;N;;1;CHEMBL1697861;;
CLD0;;;CHEMBL1697730;[];Homo sapiens;[];;;9606.0;;Liver;A;ADME;BAO_0000221;tissue-based format;;Target assigned is non-molecular;1;Human drug-induced liver injury (DILI) modelling dataset from Ekins et al;CHEMBL1697723;Non-molecular target assigned;N;;1;CHEMBL1697861;CHEMBL3559723;
CLD0;;;CHEMBL1697778;[];Homo sapiens;[];;;9606.0;;Liver;A;ADME;BAO_0000221;tissue-based format;;Target assigned is non-molecular;1;Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans;CHEMBL1697731;Non-molecular target assigned;N;;1;CHEMBL1697861;CHEMBL3559723;
CLD0;;;CHEMBL1697779;[];Rodentia;[];;;9989.0;;Liver;A;ADME;BAO_0000221;tissue-based format;;Target assigned is non-molecular;1;Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents;CHEMBL1697731;Non-molecular target assigned;N;;1;CHEMBL1697861;CHEMBL3559723;
CLD0;;;CHEMBL1697780;[];;[];;;;;Liver;A;ADME;BAO_0000221;tissue-based format;;Target assigned is non-molecular;1;Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents;CHEMBL1697731;Non-molecular target assigned;N;;1;CHEMBL1697861;CHEMBL3559723;
CLD0;;;CHEMBL1697797;[];Homo sapiens;[];;;9606.0;;Liver;A;ADME;BAO_0000221;tissue-based format;;Target assigned is non-molecular;1;FDA HLAED, liver enzyme composite activity;CHEMBL1697781;Non-molecular target assigned;N;;1;CHEMBL1697861;CHEMBL3559723;
CLD0;;;CHEMBL1697798;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000019;assay format;;Target assigned is non-molecular;1;FDA HLAED, alkaline phosphatase increase;CHEMBL1697781;Non-molecular target assigned;N;;1;CHEMBL1697861;;
CLD0;;;CHEMBL1697799;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000019;assay format;;Target assigned is non-molecular;1;FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase;CHEMBL1697781;Non-molecular target assigned;N;;1;CHEMBL1697861;;
CLD0;;;CHEMBL1697800;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000019;assay format;;Target assigned is non-molecular;1;FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase;CHEMBL1697781;Non-molecular target assigned;N;;1;CHEMBL1697861;;
CLD0;;;CHEMBL1697801;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000019;assay format;;Target assigned is non-molecular;1;FDA HLAED, lactate dehydrogenase (LDH) increase;CHEMBL1697781;Non-molecular target assigned;N;;1;CHEMBL1697861;;
CLD0;;;CHEMBL1697802;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000019;assay format;;Target assigned is non-molecular;1;FDA HLAED, gamma-glutamyl transferase (GGT) increase;CHEMBL1697781;Non-molecular target assigned;N;;1;CHEMBL1697861;;
CLD0;confirmatory;;CHEMBL1613933;[];Homo sapiens;[];;;9606.0;;;B;Binding;BAO_0000224;protein format;;Multiple direct protein targets may be assigned;5;PUBCHEM_BIOASSAY: qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1484, AID504370, AID504374, AID504375];CHEMBL1201862;Direct protein target assigned;D;1477;7;CHEMBL2093862;;
CLD0;confirmatory;;CHEMBL1738442;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000019;assay format;;Direct single protein target assigned;9;PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404];CHEMBL1201862;Direct protein target assigned;D;504332;7;CHEMBL6032;;
CLD0;confirmatory;;CHEMBL1738610;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000019;assay format;;Direct single protein target assigned;9;PUBCHEM_BIOASSAY: qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962];CHEMBL1201862;Direct protein target assigned;D;488953;7;CHEMBL1741193;;
CLD0;;;CHEMBL1743267;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000019;assay format;;Direct single protein target assigned;9;Clinically relevant substrates of human liver microsomal P450 enzymes, isoform CYP2B6;CHEMBL1743201;Direct protein target assigned;D;3;1;CHEMBL4729;;
CLD0;;CCRF S-180;CHEMBL1763416;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}, {'assay_class_id': 119, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Xenograft Oncology Models', 'l3': 'Xenograft Models of Anti-Tumor Assays', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '20.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '20.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Oral', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Oral', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307278;Target assigned is non-molecular;1;Antitumor activity against mouse S180 cells xenografted in Kunming mouse assessed as tumor growth inhibition rate at 20 mg/kg, po administered for 10 days relative to control;CHEMBL1759888;Non-molecular target assigned;N;358643;1;CHEMBL614027;;
CLD0;;H22;CHEMBL1763515;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}, {'assay_class_id': 119, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Xenograft Oncology Models', 'l3': 'Xenograft Models of Anti-Tumor Assays', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '20.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '20.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Oral', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Oral', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307751;Target assigned is non-molecular;1;Antitumor activity against mouse H22 cells xenografted in Kunming mouse assessed as tumor growth inhibition rate at 20 mg/kg, po administered for 10 days relative to control;CHEMBL1759888;Non-molecular target assigned;N;358673;1;CHEMBL614998;;
CLD0;;H22;CHEMBL1781339;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '10.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '10.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307751;Target assigned is non-molecular;1;Antitumor activity against mouse H22 tumor-nearing ICR mouse assessed as inhibition of tumor growth at 10 mg/kg, ip for 7 days measured on day 9;CHEMBL1777774;Non-molecular target assigned;N;377850;1;CHEMBL614998;;
CLD0;confirmatory;;CHEMBL1794345;[];Plasmodium falciparum;[];;;5833.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850];CHEMBL1201862;Non-molecular target assigned;N;504834;7;CHEMBL364;;
CLD0;confirmatory;;CHEMBL1794424;[];;[];;;;;;F;Functional;BAO_0000019;assay format;;Homologous single protein target assigned;8;PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488771];CHEMBL1201862;Homologous protein target assigned;H;588453;7;CHEMBL6035;;
CLD0;confirmatory;;CHEMBL1794499;[];;[];;;;;;F;Functional;BAO_0000019;assay format;;Homologous single protein target assigned;8;PUBCHEM_BIOASSAY: Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504856];CHEMBL1201862;Homologous protein target assigned;H;504845;7;CHEMBL1795091;;
CLD0;confirmatory;;CHEMBL1794584;[];;[];;;;;;F;Functional;BAO_0000019;assay format;;Homologous single protein target assigned;8;PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860];CHEMBL1201862;Homologous protein target assigned;H;588855;7;CHEMBL1293258;;
CLD0;;H22;CHEMBL1799635;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}, {'assay_class_id': 119, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Xenograft Oncology Models', 'l3': 'Xenograft Models of Anti-Tumor Assays', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '15.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '15.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307751;Target assigned is non-molecular;1;Antitumor activity against mouse H22 cells xenografted in kunming mouse assessed as inhibition of tumor growth at 15 mg/kg, ip for 7 days;CHEMBL1795221;Non-molecular target assigned;N;382373;1;CHEMBL614998;;
CLD0;;MX1;CHEMBL1806104;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}, {'assay_class_id': 119, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Xenograft Oncology Models', 'l3': 'Xenograft Models of Anti-Tumor Assays', 'source': 'phenotype'}];Homo sapiens;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '120.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '120.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Oral', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Oral', 'type': 'ROUTE', 'units': None, 'value': None}];;;9606.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308046;Target assigned is non-molecular;1;Antitumor activity against human MX1 cells xenografted in nude mouse adjuvant model assessed as increase in mouse survival time at 120 mg/kg, po BID measured up to 3 weeks;CHEMBL1800055;Non-molecular target assigned;N;385129;1;CHEMBL613704;;
CLD0;;HeLa;CHEMBL1827911;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3308376;Target assigned is non-molecular;1;Cytotoxicity against human HeLa cells by MTT assay;CHEMBL1821576;Non-molecular target assigned;N;397800;1;CHEMBL399;;
CLD0;;DU-145;CHEMBL1827912;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3308034;Target assigned is non-molecular;1;Cytotoxicity against human DU145 cells by MTT assay;CHEMBL1821576;Non-molecular target assigned;N;397799;1;CHEMBL613508;;
CLD0;;;CHEMBL1909163;[];Cavia porcellus;[];;;10141.0;In vitro;Lung;B;Binding;BAO_0000221;tissue-based format;;Direct single protein target assigned;9;DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4);CHEMBL1909046;Direct protein target assigned;D;67;15;CHEMBL1909043;CHEMBL3638235;
CLD0;;CHO-K1;CHEMBL1909164;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3307512;Homologous single protein target assigned;8;DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4);CHEMBL1909046;Homologous protein target assigned;H;68;15;CHEMBL1798;;
CLD0;;Reticulocytes;CHEMBL1909165;[];Oryctolagus cuniculus;[];;;9986.0;In vitro;;B;Binding;BAO_0000221;tissue-based format;;Direct single protein target assigned;9;DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid);CHEMBL1909046;Direct protein target assigned;D;69;15;CHEMBL4358;;
CLD0;;HEK293;CHEMBL1909166;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3307715;Homologous single protein target assigned;8;DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH);CHEMBL1909046;Homologous protein target assigned;H;70;15;CHEMBL4644;;
CLD0;;HEK293;CHEMBL1909167;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3307715;Homologous single protein target assigned;8;DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH);CHEMBL1909046;Homologous protein target assigned;H;71;15;CHEMBL259;;
CLD0;;HEK293;CHEMBL1909168;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3307715;Homologous single protein target assigned;8;DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH);CHEMBL1909046;Homologous protein target assigned;H;72;15;CHEMBL4608;;
CLD0;;BTI-TN-5B1-4;CHEMBL1909169;[];;[];;;32644.0;In vitro;;B;Binding;BAO_0000219;cell-based format;CHEMBL3833782;Homologous single protein target assigned;8;DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine);CHEMBL1909046;Homologous protein target assigned;H;73;15;CHEMBL1951;;
CLD0;;CHO-K1;CHEMBL1909170;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3307512;Homologous single protein target assigned;8;DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine);CHEMBL1909046;Homologous protein target assigned;H;74;15;CHEMBL216;;
CLD0;;CHO-K1;CHEMBL1909171;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3307512;Homologous single protein target assigned;8;DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine);CHEMBL1909046;Homologous protein target assigned;H;75;15;CHEMBL211;;
CLD0;;CHO-K1;CHEMBL1909172;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3307512;Homologous single protein target assigned;8;DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine);CHEMBL1909046;Homologous protein target assigned;H;76;15;CHEMBL245;;
CLD0;;CHO-K1;CHEMBL1909173;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3307512;Homologous single protein target assigned;8;DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine);CHEMBL1909046;Homologous protein target assigned;H;77;15;CHEMBL1821;;
CLD0;;CHO-K1;CHEMBL1909174;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3307512;Homologous single protein target assigned;8;DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine);CHEMBL1909046;Homologous protein target assigned;H;78;15;CHEMBL2035;;
CLD0;;SK-N-MC;CHEMBL1909175;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3307551;Homologous single protein target assigned;8;DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY);CHEMBL1909046;Homologous protein target assigned;H;79;15;CHEMBL4777;;
CLD0;;KAN-TS;CHEMBL1909176;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;;Homologous single protein target assigned;8;DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY);CHEMBL1909046;Homologous protein target assigned;H;80;15;CHEMBL4018;;
CLD0;;IMR-32;CHEMBL1909177;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3307656;Default value - Target unknown or has yet to be assigned;0;DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine);CHEMBL1909046;Default value - Target has yet to be curated;U;81;15;CHEMBL612545;;
CLD0;;;CHEMBL1909178;[];Rattus norvegicus;[];;;10116.0;In vitro;Cerebellum;B;Binding;BAO_0000221;tissue-based format;;Direct single protein target assigned;9;DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine);CHEMBL1909046;Direct protein target assigned;D;82;15;CHEMBL3048;CHEMBL3638233;
CLD0;;;CHEMBL1909179;[];Escherichia coli;[];;;562.0;In vitro;;B;Binding;BAO_0000357;single protein format;;Homologous single protein target assigned;8;DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine);CHEMBL1909046;Homologous protein target assigned;H;83;15;CHEMBL3464;;
CLD0;;HEK293;CHEMBL1909180;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3307715;Homologous single protein target assigned;8;DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole);CHEMBL1909046;Homologous protein target assigned;H;84;15;CHEMBL236;;
CLD0;;HEK293;CHEMBL1909181;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3307715;Homologous single protein target assigned;8;DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine);CHEMBL1909046;Homologous protein target assigned;H;85;15;CHEMBL237;;
CLD0;;CHO-K1;CHEMBL1909182;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3307512;Homologous single protein target assigned;8;DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine);CHEMBL1909046;Homologous protein target assigned;H;86;15;CHEMBL233;;
CLD0;;;CHEMBL1909183;[];Mus musculus;[];ICR;Membrane;10090.0;In vitro;Brain;B;Binding;BAO_0000249;cell membrane format;;Default value - Target unknown or has yet to be assigned;0;DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu);CHEMBL1909046;Default value - Target has yet to be curated;U;87;15;CHEMBL612545;CHEMBL3638188;
CLD0;;Platelet;CHEMBL1909184;[];Homo sapiens;[];;;9606.0;In vitro;;B;Binding;BAO_0000221;tissue-based format;CHEMBL3833781;Default value - Target unknown or has yet to be assigned;0;DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP);CHEMBL1909046;Default value - Target has yet to be curated;U;88;15;CHEMBL612545;;
CLD0;;U-937;CHEMBL1909185;[];;[];;;32644.0;In vitro;;B;Binding;BAO_0000219;cell-based format;CHEMBL3308006;Default value - Target unknown or has yet to be assigned;0;DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP);CHEMBL1909046;Default value - Target has yet to be curated;U;89;15;CHEMBL612545;;
CLD0;;Platelet;CHEMBL1909186;[];Homo sapiens;[];;;9606.0;In vitro;;B;Binding;BAO_0000221;tissue-based format;CHEMBL3833781;Direct single protein target assigned;9;DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP);CHEMBL1909046;Direct protein target assigned;D;90;15;CHEMBL1827;;
CLD0;;Platelet;CHEMBL1909187;[];Homo sapiens;[];;;9606.0;In vitro;;B;Binding;BAO_0000221;tissue-based format;CHEMBL3833781;Direct single protein target assigned;9;DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF);CHEMBL1909046;Direct protein target assigned;D;91;15;CHEMBL250;;
CLD0;;NIH3T3;CHEMBL1909188;[];;[];;;32644.0;In vitro;;B;Binding;BAO_0000219;cell-based format;CHEMBL3307716;Default value - Target unknown or has yet to be assigned;0;DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF);CHEMBL1909046;Default value - Target has yet to be curated;U;92;15;CHEMBL612545;;
CLD0;;HIT-T15;CHEMBL1909189;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;;Default value - Target unknown or has yet to be assigned;0;DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide);CHEMBL1909046;Default value - Target has yet to be curated;U;93;15;CHEMBL612545;;
CLD0;;HEK293;CHEMBL1909190;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3307715;Homologous single protein target assigned;8;DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole);CHEMBL1909046;Homologous protein target assigned;H;94;15;CHEMBL240;;
CLD0;;;CHEMBL1909191;[];Bos taurus;[];;;9913.0;In vitro;Uterus;B;Binding;BAO_0000221;tissue-based format;;Direct single protein target assigned;9;DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020);CHEMBL1909046;Direct protein target assigned;D;95;15;CHEMBL1909044;CHEMBL3638197;
CLD0;;;CHEMBL1909192;[];Oryctolagus cuniculus;[];;;9986.0;In vitro;Lung;B;Binding;BAO_0000221;tissue-based format;;Direct single protein target assigned;9;DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG);CHEMBL1909046;Direct protein target assigned;D;96;15;CHEMBL4074;CHEMBL3638235;
CLD0;;;CHEMBL1909193;[];Escherichia coli;[];;;562.0;In vitro;;B;Binding;BAO_0000357;single protein format;;Homologous single protein target assigned;8;DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC);CHEMBL1909046;Homologous protein target assigned;H;97;15;CHEMBL4801;;
CLD0;;Neutrophil;CHEMBL1909194;[];Homo sapiens;[];;;9606.0;In vitro;;B;Binding;BAO_0000221;tissue-based format;CHEMBL3308052;Direct single protein target assigned;9;DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC);CHEMBL1909046;Direct protein target assigned;D;98;15;CHEMBL4071;;
CLD0;;Neutrophil;CHEMBL1909195;[];Homo sapiens;[];;;9606.0;In vitro;;B;Binding;BAO_0000221;tissue-based format;CHEMBL3308052;Direct single protein target assigned;9;DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA);CHEMBL1909046;Direct protein target assigned;D;99;15;CHEMBL248;;
CLD0;;;CHEMBL1909196;[];Homo sapiens;[];;;9606.0;In vitro;Rheumatoid synovial fibroblasts;B;Binding;BAO_0000221;tissue-based format;;Direct single protein target assigned;9;DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2);CHEMBL1909046;Direct protein target assigned;D;100;15;CHEMBL332;;
CLD0;;;CHEMBL1909197;[];;[];;;32644.0;In vitro;;B;Binding;BAO_0000219;cell-based format;;Homologous single protein target assigned;8;DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2);CHEMBL1909046;Homologous protein target assigned;H;101;15;CHEMBL321;;
CLD0;;Sf9;CHEMBL1909198;[];;[];;;32644.0;In vitro;;B;Binding;BAO_0000219;cell-based format;CHEMBL3308860;Homologous single protein target assigned;8;DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone);CHEMBL1909046;Homologous protein target assigned;H;102;15;CHEMBL299;;
CLD0;;;CHEMBL1909199;[];Escherichia coli;[];;;562.0;In vitro;;B;Binding;BAO_0000357;single protein format;;Homologous single protein target assigned;8;DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein);CHEMBL1909046;Homologous protein target assigned;H;103;15;CHEMBL3385;;
CLD0;;;CHEMBL1909200;[];Escherichia coli;[];;;562.0;In vitro;;B;Binding;BAO_0000357;single protein format;;Homologous single protein target assigned;8;DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein);CHEMBL1909046;Homologous protein target assigned;H;104;15;CHEMBL4040;;
CLD0;;;CHEMBL1909201;[];Escherichia coli;[];;;562.0;In vitro;;B;Binding;BAO_0000357;single protein format;;Homologous single protein target assigned;8;DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein);CHEMBL1909046;Homologous protein target assigned;H;105;15;CHEMBL260;;
CLD0;;;CHEMBL1909202;[];Escherichia coli;[];;;562.0;In vitro;;B;Binding;BAO_0000357;single protein format;;Homologous single protein target assigned;8;DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP);CHEMBL1909046;Homologous protein target assigned;H;106;15;CHEMBL4445;;
CLD0;;Insect cells;CHEMBL1909203;[];;[];;;32644.0;In vitro;;B;Binding;BAO_0000219;cell-based format;;Homologous single protein target assigned;8;DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr));CHEMBL1909046;Homologous protein target assigned;H;107;15;CHEMBL203;;
CLD0;;Insect cells;CHEMBL1909204;[];;[];;;32644.0;In vitro;;B;Binding;BAO_0000219;cell-based format;;Homologous single protein target assigned;8;DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr));CHEMBL1909046;Homologous protein target assigned;H;108;15;CHEMBL1841;;
CLD0;;Insect cells;CHEMBL1909205;[];;[];;;32644.0;In vitro;;B;Binding;BAO_0000219;cell-based format;;Homologous single protein target assigned;8;DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr));CHEMBL1909046;Homologous protein target assigned;H;109;15;CHEMBL1824;;
CLD0;;Insect cells;CHEMBL1909206;[];;[];;;32644.0;In vitro;;B;Binding;BAO_0000219;cell-based format;;Homologous single protein target assigned;8;DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr));CHEMBL1909046;Homologous protein target assigned;H;110;15;CHEMBL258;;
CLD0;;;CHEMBL1909207;[];Escherichia coli;[];;;562.0;In vitro;;B;Binding;BAO_0000357;single protein format;;Homologous single protein target assigned;8;DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP);CHEMBL1909046;Homologous protein target assigned;H;111;15;CHEMBL3243;;
CLD0;;;CHEMBL1909208;[];Oryctolagus cuniculus;[];New Zealand albino;Membrane;9986.0;In vitro;Urinary bladder;B;Binding;BAO_0000249;cell membrane format;;Default value - Target unknown or has yet to be assigned;0;DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP);CHEMBL1909046;Default value - Target has yet to be curated;U;112;15;CHEMBL612545;CHEMBL3638205;
CLD0;;CHO-K1;CHEMBL1909209;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3307512;Homologous single protein target assigned;8;DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT);CHEMBL1909046;Homologous protein target assigned;H;113;15;CHEMBL273;;
CLD0;;;CHEMBL1909210;[];Rattus norvegicus;[];Wistar;Membrane;10116.0;In vitro;Cerebral cortex;B;Binding;BAO_0000249;cell membrane format;;Direct single protein target assigned;9;DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol);CHEMBL1909046;Direct protein target assigned;D;114;15;CHEMBL3459;CHEMBL3559724;
CLD0;;CHO-K1;CHEMBL1909211;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3307512;Homologous single protein target assigned;8;DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin);CHEMBL1909046;Homologous protein target assigned;H;115;15;CHEMBL224;;
CLD0;;HEK293;CHEMBL1909212;[];;[];;;32644.0;In vitro;;B;Binding;BAO_0000219;cell-based format;CHEMBL3307715;Homologous single protein target assigned;8;DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine);CHEMBL1909046;Homologous protein target assigned;H;1;15;CHEMBL220;;
CLD0;;CHO;CHEMBL1909213;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3308072;Homologous single protein target assigned;8;DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX);CHEMBL1909046;Homologous protein target assigned;H;2;15;CHEMBL226;;
CLD0;;HEK293;CHEMBL1909214;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3307715;Homologous single protein target assigned;8;DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA);CHEMBL1909046;Homologous protein target assigned;H;3;15;CHEMBL251;;
CLD0;;CHO-K1;CHEMBL1909215;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3307512;Homologous single protein target assigned;8;DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA);CHEMBL1909046;Homologous protein target assigned;H;4;15;CHEMBL256;;
CLD0;;;CHEMBL1909084;[];Cavia porcellus;[];Dunkin-Hartley;Membrane;10141.0;In vitro;Cerebral cortex;B;Binding;BAO_0000249;cell membrane format;;Default value - Target unknown or has yet to be assigned;0;DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine);CHEMBL1909046;Default value - Target has yet to be curated;U;5;15;CHEMBL612545;CHEMBL3559724;
CLD0;;;CHEMBL1909085;[];Rattus norvegicus;[];Wistar;Membrane;10116.0;In vitro;Submaxillary gland;B;Binding;BAO_0000249;cell membrane format;;Direct single protein target assigned;9;DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin);CHEMBL1909046;Direct protein target assigned;D;6;15;CHEMBL319;CHEMBL3987361;
CLD0;;;CHEMBL1909086;[];Rattus norvegicus;[];Wistar;Membrane;10116.0;In vitro;Liver;B;Binding;BAO_0000249;cell membrane format;;Direct single protein target assigned;9;DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin);CHEMBL1909046;Direct protein target assigned;D;7;15;CHEMBL315;CHEMBL3559723;
CLD0;;HEK293;CHEMBL1909087;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3307715;Homologous single protein target assigned;8;DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin);CHEMBL1909046;Homologous protein target assigned;H;8;15;CHEMBL223;;
CLD0;;Sf9;CHEMBL1909088;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3308860;Homologous single protein target assigned;8;DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912);CHEMBL1909046;Homologous protein target assigned;H;9;15;CHEMBL1867;;
CLD0;;CHO-K1;CHEMBL1909089;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3307512;Homologous single protein target assigned;8;DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine);CHEMBL1909046;Homologous protein target assigned;H;10;15;CHEMBL1942;;
CLD0;;Sf9;CHEMBL1909090;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3308860;Homologous single protein target assigned;8;DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912);CHEMBL1909046;Homologous protein target assigned;H;11;15;CHEMBL1916;;
CLD0;;CHO-K1;CHEMBL1909091;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3307512;Homologous single protein target assigned;8;DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol);CHEMBL1909046;Homologous protein target assigned;H;12;15;CHEMBL213;;
CLD0;;CHO;CHEMBL1909092;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3308072;Homologous single protein target assigned;8;DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177);CHEMBL1909046;Homologous protein target assigned;H;13;15;CHEMBL210;;
CLD0;;HEK293;CHEMBL1909093;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3307715;Homologous single protein target assigned;8;DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol);CHEMBL1909046;Homologous protein target assigned;H;14;15;CHEMBL246;;
CLD0;;MDCK;CHEMBL1909094;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3308370;Homologous single protein target assigned;8;DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55);CHEMBL1909046;Homologous protein target assigned;H;15;15;CHEMBL222;;
CLD0;;;CHEMBL1909095;[];Rattus norvegicus;[];;;10116.0;In vitro;Lens of camera-type eye;B;Binding;BAO_0000221;tissue-based format;;Direct single protein target assigned;9;DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde);CHEMBL1909046;Direct protein target assigned;D;16;15;CHEMBL2622;CHEMBL3638191;
CLD0;;CHO-K1;CHEMBL1909096;[];;[];;;32644.0;In vitro;;B;Binding;BAO_0000219;cell-based format;CHEMBL3307512;Homologous single protein target assigned;8;DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A);CHEMBL1909046;Homologous protein target assigned;H;17;15;CHEMBL4607;;
CLD0;;;CHEMBL1909097;[];Sus scrofa;[];;;9823.0;In vitro;Heart;B;Binding;BAO_0000221;tissue-based format;;Default value - Target unknown or has yet to be assigned;0;DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP);CHEMBL1909046;Default value - Target has yet to be curated;U;18;15;CHEMBL612545;CHEMBL3638187;
CLD0;;;CHEMBL1909098;[];Cavia porcellus;[];Dunkin-Hartley;Membrane;10141.0;In vitro;Adrenal gland;B;Binding;BAO_0000249;cell membrane format;;Default value - Target unknown or has yet to be assigned;0;DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat));CHEMBL1909046;Default value - Target has yet to be curated;U;19;15;CHEMBL612545;CHEMBL3638251;
CLD0;;;CHEMBL1909099;[];Bacillus cereus;[];;;1396.0;In vitro;;B;Binding;BAO_0000019;assay format;;Default value - Target unknown or has yet to be assigned;0;DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin);CHEMBL1909046;Default value - Target has yet to be curated;U;20;15;CHEMBL612545;;
CLD0;;Chem-1;CHEMBL1909100;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;;Homologous single protein target assigned;8;DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin);CHEMBL1909046;Homologous protein target assigned;H;21;15;CHEMBL3157;;
CLD0;;T47D;CHEMBL1909101;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3307606;Homologous single protein target assigned;8;DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon));CHEMBL1909046;Homologous protein target assigned;H;22;15;CHEMBL1832;;
CLD0;;;CHEMBL1909102;[];Rattus norvegicus;[];Wistar;Membrane;10116.0;In vitro;Brain;B;Binding;BAO_0000249;cell membrane format;;Default value - Target unknown or has yet to be assigned;0;DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem);CHEMBL1909046;Default value - Target has yet to be curated;U;23;15;CHEMBL612545;CHEMBL3638188;
CLD0;;;CHEMBL1909103;[];Rattus norvegicus;[];Wistar;Membrane;10116.0;In vitro;Cerebral cortex;B;Binding;BAO_0000249;cell membrane format;;Default value - Target unknown or has yet to be assigned;0;DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine);CHEMBL1909046;Default value - Target has yet to be curated;U;24;15;CHEMBL612545;CHEMBL3559724;
CLD0;;CHO-K1;CHEMBL1909104;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3307512;Homologous single protein target assigned;8;DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide);CHEMBL1909046;Homologous protein target assigned;H;116;15;CHEMBL1833;;
CLD0;;CHO-K1;CHEMBL1909105;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3307512;Homologous single protein target assigned;8;DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine);CHEMBL1909046;Homologous protein target assigned;H;117;15;CHEMBL225;;
CLD0;;HEK293;CHEMBL1909106;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3307715;Default value - Target unknown or has yet to be assigned;0;DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630);CHEMBL1909046;Default value - Target has yet to be curated;U;118;15;CHEMBL612545;;
CLD0;;;CHEMBL1909107;[];Cavia porcellus;[];Dunkin-Hartley;Membrane;10141.0;In vitro;Striatum;B;Binding;BAO_0000249;cell membrane format;;Direct single protein target assigned;9;DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808);CHEMBL1909046;Direct protein target assigned;D;119;15;CHEMBL5017;CHEMBL3638255;
CLD0;;HeLa;CHEMBL1909108;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3308376;Homologous single protein target assigned;8;DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide);CHEMBL1909046;Homologous protein target assigned;H;120;15;CHEMBL3371;;
CLD0;;HEK293;CHEMBL1909109;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3307715;Homologous single protein target assigned;8;DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine);CHEMBL1909046;Homologous protein target assigned;H;121;15;CHEMBL228;;
CLD0;;Jurkat;CHEMBL1909110;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3307526;Homologous single protein target assigned;8;DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol);CHEMBL1909046;Homologous protein target assigned;H;122;15;CHEMBL287;;
CLD0;;;CHEMBL1909111;[];Rattus norvegicus;[];Wistar;Membrane;10116.0;In vitro;Brain;B;Binding;BAO_0000249;cell membrane format;;Default value - Target unknown or has yet to be assigned;0;DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil);CHEMBL1909046;Default value - Target has yet to be curated;U;123;15;CHEMBL612545;CHEMBL3638188;
CLD0;;;CHEMBL1909112;[];Rattus norvegicus;[];Wistar;Membrane;10116.0;In vitro;Brain;B;Binding;BAO_0000249;cell membrane format;;Default value - Target unknown or has yet to be assigned;0;DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin);CHEMBL1909046;Default value - Target has yet to be curated;U;124;15;CHEMBL612545;CHEMBL3638188;
CLD0;;CHO;CHEMBL1909113;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3308072;Homologous single protein target assigned;8;DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P);CHEMBL1909046;Homologous protein target assigned;H;125;15;CHEMBL249;;
CLD0;;CHO;CHEMBL1909114;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3308072;Homologous single protein target assigned;8;DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968);CHEMBL1909046;Homologous protein target assigned;H;126;15;CHEMBL2327;;
CLD0;;;CHEMBL1909115;[];Escherichia coli;[];;Membrane;562.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;;Homologous single protein target assigned;8;DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone);CHEMBL1909046;Homologous protein target assigned;H;127;15;CHEMBL3072;;
CLD0;;Platelet;CHEMBL1909116;[];Homo sapiens;[];;;9606.0;In vitro;;B;Binding;BAO_0000221;tissue-based format;CHEMBL3833781;Direct single protein target assigned;9;DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2);CHEMBL1909046;Direct protein target assigned;D;128;15;CHEMBL1835;;
CLD0;;U-937;CHEMBL1909117;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3308006;Default value - Target unknown or has yet to be assigned;0;DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha);CHEMBL1909046;Default value - Target has yet to be curated;U;129;15;CHEMBL612545;;
CLD0;;HUVEC;CHEMBL1909118;[];;[];;;32644.0;In vitro;;B;Binding;BAO_0000219;cell-based format;CHEMBL3307501;Homologous single protein target assigned;8;DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF);CHEMBL1909046;Homologous protein target assigned;H;130;15;CHEMBL1868;;
CLD0;;HT-29;CHEMBL1909119;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3307768;Homologous single protein target assigned;8;DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP);CHEMBL1909046;Homologous protein target assigned;H;131;15;CHEMBL5144;;
CLD0;;HEK293;CHEMBL1909120;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3307715;Homologous single protein target assigned;8;DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr);CHEMBL1909046;Homologous protein target assigned;H;132;15;CHEMBL1889;;
CLD0;;;CHEMBL1909121;[];Rattus norvegicus;[];Wistar;Membrane;10116.0;In vitro;Brain;B;Binding;BAO_0000249;cell membrane format;;Default value - Target unknown or has yet to be assigned;0;DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888));CHEMBL1909046;Default value - Target has yet to be curated;U;25;15;CHEMBL612545;CHEMBL3638188;
CLD0;;Chem-1;CHEMBL1909122;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;;Homologous single protein target assigned;8;DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A);CHEMBL1909046;Homologous protein target assigned;H;26;15;CHEMBL218;;
CLD0;;Erythrocyte;CHEMBL1909123;[];Homo sapiens;[];;;9606.0;In vitro;;B;Binding;BAO_0000221;tissue-based format;CHEMBL3833281;Direct single protein target assigned;9;DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA));CHEMBL1909046;Direct protein target assigned;D;27;15;CHEMBL205;;
CLD0;;CHO-K1;CHEMBL1909124;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3307512;Homologous single protein target assigned;8;DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1);CHEMBL1909046;Homologous protein target assigned;H;28;15;CHEMBL4015;;
CLD0;;Chem-1;CHEMBL1909125;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;;Homologous single protein target assigned;8;DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC);CHEMBL1909046;Homologous protein target assigned;H;29;15;CHEMBL2414;;
CLD0;;HEK293;CHEMBL1909126;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3307715;Homologous single protein target assigned;8;DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha);CHEMBL1909046;Homologous protein target assigned;H;30;15;CHEMBL274;;
CLD0;;;CHEMBL1909127;[];;[];;;32644.0;In vitro;;B;Binding;BAO_0000357;single protein format;;Homologous single protein target assigned;8;DRUGMATRIX: Chemokine CXCR1 (IL-8A);CHEMBL1909046;Homologous protein target assigned;H;31;15;CHEMBL4029;;
CLD0;;CHO-K1;CHEMBL1909128;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3307512;Homologous single protein target assigned;8;DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8);CHEMBL1909046;Homologous protein target assigned;H;32;15;CHEMBL2434;;
CLD0;;1321-N1;CHEMBL1909129;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;;Homologous single protein target assigned;8;DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718);CHEMBL1909046;Homologous protein target assigned;H;33;15;CHEMBL1901;;
CLD0;;Platelet;CHEMBL1909130;[];Homo sapiens;[];;;9606.0;In vitro;;B;Binding;BAO_0000221;tissue-based format;CHEMBL3833781;Direct single protein target assigned;9;DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid);CHEMBL1909046;Direct protein target assigned;D;34;15;CHEMBL221;;
CLD0;;Sf21;CHEMBL1909131;[];;[];;;32644.0;In vitro;;B;Binding;BAO_0000219;cell-based format;CHEMBL4106362;Homologous single protein target assigned;8;DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid);CHEMBL1909046;Homologous protein target assigned;H;35;15;CHEMBL230;;
CLD0;;BTI-TN-5B1-4;CHEMBL1909132;[];;[];;;32644.0;In vitro;;B;Binding;BAO_0000219;cell-based format;CHEMBL3833782;Homologous single protein target assigned;8;DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin);CHEMBL1909046;Homologous protein target assigned;H;36;15;CHEMBL3356;;
CLD0;;BTI-TN-5B1-4;CHEMBL1909133;[];;[];;;32644.0;In vitro;;B;Binding;BAO_0000219;cell-based format;CHEMBL3833782;Homologous single protein target assigned;8;DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin);CHEMBL1909046;Homologous protein target assigned;H;37;15;CHEMBL5282;;
CLD0;;BTI-TN-5B1-4;CHEMBL1909134;[];;[];;;32644.0;In vitro;;B;Binding;BAO_0000219;cell-based format;CHEMBL3833782;Homologous single protein target assigned;8;DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin);CHEMBL1909046;Homologous protein target assigned;H;38;15;CHEMBL3622;;
CLD0;;BTI-TN-5B1-4;CHEMBL1909135;[];;[];;;32644.0;In vitro;;B;Binding;BAO_0000219;cell-based format;CHEMBL3833782;Homologous single protein target assigned;8;DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin);CHEMBL1909046;Homologous protein target assigned;H;39;15;CHEMBL3397;;
CLD0;;BTI-TN-5B1-4;CHEMBL1909136;[];;[];;;32644.0;In vitro;;B;Binding;BAO_0000219;cell-based format;CHEMBL3833782;Homologous single protein target assigned;8;DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin);CHEMBL1909046;Homologous protein target assigned;H;40;15;CHEMBL289;;
CLD0;;BTI-TN-5B1-4;CHEMBL1909137;[];;[];;;32644.0;In vitro;;B;Binding;BAO_0000219;cell-based format;CHEMBL3833782;Homologous single protein target assigned;8;DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin);CHEMBL1909046;Homologous protein target assigned;H;41;15;CHEMBL5281;;
CLD0;;BTI-TN-5B1-4;CHEMBL1909138;[];;[];;;32644.0;In vitro;;B;Binding;BAO_0000219;cell-based format;CHEMBL3833782;Homologous single protein target assigned;8;DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin);CHEMBL1909046;Homologous protein target assigned;H;42;15;CHEMBL340;;
CLD0;;CHO;CHEMBL1909139;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3308072;Homologous single protein target assigned;8;DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390);CHEMBL1909046;Homologous protein target assigned;H;43;15;CHEMBL2056;;
CLD0;;CHO;CHEMBL1909140;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3308072;Homologous single protein target assigned;8;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);CHEMBL1909046;Homologous protein target assigned;H;44;15;CHEMBL217;;
CLD0;;CHO;CHEMBL1909141;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3308072;Homologous single protein target assigned;8;DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone);CHEMBL1909046;Homologous protein target assigned;H;45;15;CHEMBL234;;
CLD0;;CHO-K1;CHEMBL1909142;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3307512;Homologous single protein target assigned;8;DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone);CHEMBL1909046;Homologous protein target assigned;H;46;15;CHEMBL219;;
CLD0;;CHO-K1;CHEMBL1909143;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3307512;Homologous single protein target assigned;8;DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55);CHEMBL1909046;Homologous protein target assigned;H;47;15;CHEMBL238;;
CLD0;;CHO-K1;CHEMBL1909144;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3307512;Homologous single protein target assigned;8;DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1);CHEMBL1909046;Homologous protein target assigned;H;48;15;CHEMBL252;;
CLD0;;Sf9;CHEMBL1909145;[];;[];;;32644.0;In vitro;;B;Binding;BAO_0000219;cell-based format;CHEMBL3308860;Homologous single protein target assigned;8;DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol);CHEMBL1909046;Homologous protein target assigned;H;49;15;CHEMBL206;;
CLD0;;Sf9;CHEMBL1909146;[];;[];;;32644.0;In vitro;;B;Binding;BAO_0000219;cell-based format;CHEMBL3308860;Homologous single protein target assigned;8;DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol);CHEMBL1909046;Homologous protein target assigned;H;50;15;CHEMBL242;;
CLD0;;;CHEMBL1909147;[];Rattus norvegicus;[];Wistar;Membrane;10116.0;In vitro;Brain;B;Binding;BAO_0000249;cell membrane format;;Default value - Target unknown or has yet to be assigned;0;DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol);CHEMBL1909046;Default value - Target has yet to be curated;U;51;15;CHEMBL612545;CHEMBL3638188;
CLD0;;;CHEMBL1909148;[];Rattus norvegicus;[];Wistar;Membrane;10116.0;In vitro;Brain;B;Binding;BAO_0000249;cell membrane format;;Default value - Target unknown or has yet to be assigned;0;DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam);CHEMBL1909046;Default value - Target has yet to be curated;U;52;15;CHEMBL612545;CHEMBL3638188;
CLD0;;;CHEMBL1909149;[];Rattus norvegicus;[];Wistar;Membrane;10116.0;In vitro;Cerebral cortex;B;Binding;BAO_0000249;cell membrane format;;Default value - Target unknown or has yet to be assigned;0;DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB);CHEMBL1909046;Default value - Target has yet to be curated;U;53;15;CHEMBL612545;CHEMBL3559724;
CLD0;;HeLa S3;CHEMBL1909150;[];;[];;;32644.0;In vitro;;B;Binding;BAO_0000219;cell-based format;CHEMBL3886002;Homologous single protein target assigned;8;DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone);CHEMBL1909046;Homologous protein target assigned;H;54;15;CHEMBL2034;;
CLD0;;;CHEMBL1909151;[];Rattus norvegicus;[];Wistar;Membrane;10116.0;In vitro;Cerebral cortex;B;Binding;BAO_0000249;cell membrane format;;Default value - Target unknown or has yet to be assigned;0;DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA);CHEMBL1909046;Default value - Target has yet to be curated;U;55;15;CHEMBL612545;CHEMBL3559724;
CLD0;;;CHEMBL1909152;[];Rattus norvegicus;[];Wistar;Membrane;10116.0;In vitro;Brain;B;Binding;BAO_0000249;cell membrane format;;Default value - Target unknown or has yet to be assigned;0;DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid);CHEMBL1909046;Default value - Target has yet to be curated;U;56;15;CHEMBL612545;CHEMBL3638188;
CLD0;;;CHEMBL1909153;[];Rattus norvegicus;[];Wistar;Membrane;10116.0;In vitro;Cerebral cortex;B;Binding;BAO_0000249;cell membrane format;;Default value - Target unknown or has yet to be assigned;0;DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653);CHEMBL1909046;Default value - Target has yet to be curated;U;57;15;CHEMBL612545;CHEMBL3559724;
CLD0;;;CHEMBL1909154;[];Rattus norvegicus;[];Wistar;Membrane;10116.0;In vitro;Cerebral cortex;B;Binding;BAO_0000249;cell membrane format;;Default value - Target unknown or has yet to be assigned;0;DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP);CHEMBL1909046;Default value - Target has yet to be curated;U;58;15;CHEMBL612545;CHEMBL3559724;
CLD0;;;CHEMBL1909155;[];Rattus norvegicus;[];Wistar;Membrane;10116.0;In vitro;Spinal cord;B;Binding;BAO_0000249;cell membrane format;;Multiple direct protein targets may be assigned;5;DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine);CHEMBL1909046;Direct protein target assigned;D;59;15;CHEMBL3392921;CHEMBL3638246;
CLD0;;CHO-K1;CHEMBL1909156;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3307512;Homologous single protein target assigned;8;DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine);CHEMBL1909046;Homologous protein target assigned;H;60;15;CHEMBL231;;
CLD0;;CHO-K1;CHEMBL1909157;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3307512;Homologous single protein target assigned;8;DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine);CHEMBL1909046;Homologous protein target assigned;H;61;15;CHEMBL1941;;
CLD0;;;CHEMBL1909158;[];Escherichia coli;[];;;562.0;In vitro;;B;Binding;BAO_0000357;single protein format;;Homologous single protein target assigned;8;DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA);CHEMBL1909046;Homologous protein target assigned;H;62;15;CHEMBL402;;
CLD0;;;CHEMBL1909159;[];Rattus norvegicus;[];Wistar;Membrane;10116.0;In vitro;Cerebral cortex;B;Binding;BAO_0000249;cell membrane format;;Default value - Target unknown or has yet to be assigned;0;DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan);CHEMBL1909046;Default value - Target has yet to be curated;U;63;15;CHEMBL612545;CHEMBL3559724;
CLD0;;;CHEMBL1909160;[];Rattus norvegicus;[];Wistar;Membrane;10116.0;In vitro;Liver;B;Binding;BAO_0000249;cell membrane format;;Direct single protein target assigned;9;DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin);CHEMBL1909046;Direct protein target assigned;D;64;15;CHEMBL5486;CHEMBL3559723;
CLD0;;NIH3T3;CHEMBL1909161;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3307716;Default value - Target unknown or has yet to be assigned;0;DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta);CHEMBL1909046;Default value - Target has yet to be curated;U;65;15;CHEMBL612545;;
CLD0;;U-937;CHEMBL1909162;[];;[];;Membrane;32644.0;In vitro;;B;Binding;BAO_0000249;cell membrane format;CHEMBL3308006;Default value - Target unknown or has yet to be assigned;0;DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4);CHEMBL1909046;Default value - Target has yet to be curated;U;66;15;CHEMBL612545;;
CLD0;;;CHEMBL1909292;[];;[];;;;;Liver;T;Toxicity;BAO_0000221;tissue-based format;;Target assigned is non-molecular;1;FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI;CHEMBL1909281;Non-molecular target assigned;N;2;1;CHEMBL1697861;CHEMBL3559723;
CLD0;;;CHEMBL1909307;[];;[];;;;;Liver;A;ADME;BAO_0000221;tissue-based format;;Target assigned is non-molecular;1;"Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia";CHEMBL1909294;Non-molecular target assigned;N;1;1;CHEMBL1697861;CHEMBL3559723;
CLD0;;;CHEMBL1909308;[];;[];;;;;Liver;A;ADME;BAO_0000221;tissue-based format;;Target assigned is non-molecular;1;"Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis";CHEMBL1909294;Non-molecular target assigned;N;2;1;CHEMBL1697861;CHEMBL3559723;
CLD0;;;CHEMBL1909309;[];;[];;;;;Liver;A;ADME;BAO_0000221;tissue-based format;;Target assigned is non-molecular;1;"Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis";CHEMBL1909294;Non-molecular target assigned;N;3;1;CHEMBL1697861;CHEMBL3559723;
CLD0;;;CHEMBL1909310;[];;[];;;;;Liver;A;ADME;BAO_0000221;tissue-based format;;Target assigned is non-molecular;1;"Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis";CHEMBL1909294;Non-molecular target assigned;N;4;1;CHEMBL1697861;CHEMBL3559723;
CLD0;;;CHEMBL1909311;[];;[];;;;;Liver;A;ADME;BAO_0000221;tissue-based format;;Target assigned is non-molecular;1;"Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests";CHEMBL1909294;Non-molecular target assigned;N;5;1;CHEMBL1697861;CHEMBL3559723;
CLD0;;;CHEMBL1909312;[];;[];;;;;Liver;A;ADME;BAO_0000221;tissue-based format;;Target assigned is non-molecular;1;"Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure";CHEMBL1909294;Non-molecular target assigned;N;6;1;CHEMBL1697861;CHEMBL3559723;
CLD0;;;CHEMBL1909313;[];;[];;;;;Liver;A;ADME;BAO_0000221;tissue-based format;;Target assigned is non-molecular;1;"Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis";CHEMBL1909294;Non-molecular target assigned;N;7;1;CHEMBL1697861;CHEMBL3559723;
CLD0;;;CHEMBL1909314;[];;[];;;;;Liver;A;ADME;BAO_0000221;tissue-based format;;Target assigned is non-molecular;1;"Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis";CHEMBL1909294;Non-molecular target assigned;N;8;1;CHEMBL1697861;CHEMBL3559723;
CLD0;;;CHEMBL1909315;[];;[];;;;;Liver;A;ADME;BAO_0000221;tissue-based format;;Target assigned is non-molecular;1;"Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly";CHEMBL1909294;Non-molecular target assigned;N;9;1;CHEMBL1697861;CHEMBL3559723;
CLD0;;;CHEMBL1909316;[];;[];;;;;Liver;A;ADME;BAO_0000221;tissue-based format;;Target assigned is non-molecular;1;"Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice";CHEMBL1909294;Non-molecular target assigned;N;10;1;CHEMBL1697861;CHEMBL3559723;
CLD0;;;CHEMBL1909317;[];;[];;;;;Liver;A;ADME;BAO_0000221;tissue-based format;;Target assigned is non-molecular;1;"Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease";CHEMBL1909294;Non-molecular target assigned;N;11;1;CHEMBL1697861;CHEMBL3559723;
CLD0;;;CHEMBL1909318;[];;[];;;;;Liver;A;ADME;BAO_0000221;tissue-based format;;Target assigned is non-molecular;1;"Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty";CHEMBL1909294;Non-molecular target assigned;N;12;1;CHEMBL1697861;CHEMBL3559723;
CLD0;;;CHEMBL1909319;[];;[];;;;;Liver;A;ADME;BAO_0000221;tissue-based format;;Target assigned is non-molecular;1;"Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal";CHEMBL1909294;Non-molecular target assigned;N;13;1;CHEMBL1697861;CHEMBL3559723;
CLD0;;;CHEMBL1909320;[];;[];;;;;Liver;A;ADME;BAO_0000221;tissue-based format;;Target assigned is non-molecular;1;"Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score";CHEMBL1909294;Non-molecular target assigned;N;14;1;CHEMBL1697861;CHEMBL3559723;
CLD0;;H22;CHEMBL1948800;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}, {'assay_class_id': 119, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Xenograft Oncology Models', 'l3': 'Xenograft Models of Anti-Tumor Assays', 'source': 'phenotype'}];Homo sapiens;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '20.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '20.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Oral', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Oral', 'type': 'ROUTE', 'units': None, 'value': None}];;;9606.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307751;Target assigned is non-molecular;1;Antitumor activity against human H22 cells xenografted in Kunming mouse assessed as reduction in tumor volume at 20 mg/kg, po qd for 10 days;CHEMBL1944612;Non-molecular target assigned;N;428624;1;CHEMBL614998;;
CLD0;;H22;CHEMBL1948867;[];Mus musculus;[];Kunming;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307751;Target assigned is non-molecular;1;Immunostimulatory activity in Kunming mouse xenografted with human H22 cells assessed as change in thymus mass at 20 mg/kg, po qd for 10 days (Rvb = 1.83 +/- 0.85 mg/kg);CHEMBL1944612;Non-molecular target assigned;N;428633;1;CHEMBL375;;
CLD0;;H22;CHEMBL1948872;[];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '20.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '20.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Oral', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Oral', 'type': 'ROUTE', 'units': None, 'value': None}];Kunming;;10090.0;;;T;Toxicity;BAO_0000218;organism-based format;CHEMBL3307751;Target assigned is non-molecular;1;Toxicity in Kunming mouse xenografted with human H22 cells assessed as change in body weight at 20 mg/kg, po qd for 10 days (Rvb = 25.3 +/- 1.5 g);CHEMBL1944612;Non-molecular target assigned;N;428627;1;CHEMBL375;;
CLD0;;H22;CHEMBL1948875;[];Mus musculus;[];Kunming;;10090.0;;Spleen;F;Functional;BAO_0000218;organism-based format;CHEMBL3307751;Target assigned is non-molecular;1;Immunostimulatory activity in Kunming mouse xenografted with human H22 cells assessed as change in spleen mass at 20 mg/kg, po qd for 10 days (Rvb = 6.61 +/- 1.84 mg/kg);CHEMBL1944612;Non-molecular target assigned;N;428630;1;CHEMBL375;CHEMBL3559722;
CLD0;confirmatory;MDA-N;CHEMBL1963976;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307532;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MDA-N Breast cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;87;7;CHEMBL614078;;
CLD0;confirmatory;SN12C;CHEMBL1963981;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307518;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;145;7;CHEMBL614054;;
CLD0;confirmatory;NCI-H23;CHEMBL1963985;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307750;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;1;7;CHEMBL614997;;
CLD0;confirmatory;ACHN;CHEMBL1963989;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307633;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;139;7;CHEMBL614519;;
CLD0;confirmatory;UO-31;CHEMBL1963990;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307612;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;143;7;CHEMBL614388;;
CLD0;confirmatory;HOP-92;CHEMBL1963991;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3308091;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;13;7;CHEMBL613889;;
CLD0;confirmatory;HL-60;CHEMBL1963994;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307654;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;125;7;CHEMBL383;;
CLD0;confirmatory;DU-145;CHEMBL1964017;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3308034;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the DU-145 Prostate cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;43;7;CHEMBL613508;;
CLD0;confirmatory;SF-539;CHEMBL1964018;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307721;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;49;7;CHEMBL614860;;
CLD0;confirmatory;SK-MEL-5;CHEMBL1964021;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307744;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;37;7;CHEMBL614922;;
CLD0;confirmatory;Malme-3M;CHEMBL1964025;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307507;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;29;7;CHEMBL614021;;
CLD0;confirmatory;K562;CHEMBL1964030;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3308378;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the K-562 Leukemia cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;121;7;CHEMBL385;;
CLD0;confirmatory;A498;CHEMBL1964034;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3308425;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the A498 Renal cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;129;7;CHEMBL614516;;
CLD0;confirmatory;OVCAR-3;CHEMBL1964037;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307564;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the OVCAR-3 Ovarian cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;99;7;CHEMBL614213;;
CLD0;confirmatory;MOLT-4;CHEMBL1964040;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307557;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MOLT-4 Leukemia cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;123;7;CHEMBL614177;;
CLD0;confirmatory;HOP-62;CHEMBL1964043;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307671;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HOP-62 Non-Small Cell Lung cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;9;7;CHEMBL614643;;
CLD0;confirmatory;NCI/ADR-RES;CHEMBL1964045;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3308057;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the NCI/ADR-RES Breast cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;93;7;CHEMBL613829;;
CLD0;confirmatory;U-251;CHEMBL1964047;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307756;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the U251 Central Nervous System cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;59;7;CHEMBL615022;;
CLD0;confirmatory;OVCAR-8;CHEMBL1964048;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307975;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the OVCAR-8 Ovarian cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;109;7;CHEMBL612555;;
CLD0;confirmatory;OVCAR-5;CHEMBL1964049;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307565;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the OVCAR-5 Ovarian cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;107;7;CHEMBL614214;;
CLD0;confirmatory;SNB-19;CHEMBL1964059;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307552;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SNB-19 Central Nervous System cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;53;7;CHEMBL614164;;
CLD0;confirmatory;DMS-273;CHEMBL1964062;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3308487;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the DMS 273 Small Cell Lung cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;61;7;CHEMBL614034;;
CLD0;confirmatory;MDA-MB-231;CHEMBL1964063;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307960;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-231/ATCC Breast cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;95;7;CHEMBL400;;
CLD0;confirmatory;SR;CHEMBL1964065;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307586;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SR Leukemia cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;115;7;CHEMBL614300;;
CLD0;confirmatory;TK-10;CHEMBL1964066;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3308453;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the TK-10 Renal cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;141;7;CHEMBL614056;;
CLD0;confirmatory;SW-620;CHEMBL1964072;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307944;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SW-620 Colon cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;81;7;CHEMBL612262;;
CLD0;confirmatory;M19-MEL;CHEMBL1964074;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307506;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the M19-MEL Melanoma cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;27;7;CHEMBL614019;;
CLD0;confirmatory;NCI-H522;CHEMBL1964075;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3308392;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the NCI-H522 Non-Small Cell Lung cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;15;7;CHEMBL614387;;
CLD0;confirmatory;KM12;CHEMBL1964077;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307689;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the KM12 Colon cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;73;7;CHEMBL614709;;
CLD0;confirmatory;M14;CHEMBL1964085;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307591;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the M14 Melanoma cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;25;7;CHEMBL614317;;
CLD0;confirmatory;XF498;CHEMBL1964086;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3308037;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the XF 498 Central Nervous System cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;51;7;CHEMBL613533;;
CLD0;confirmatory;NCI-H322M;CHEMBL1964087;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307710;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the NCI-H322M Non-Small Cell Lung cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;5;7;CHEMBL614803;;
CLD0;confirmatory;RPMI-8226;CHEMBL1964088;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307732;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the RPMI-8226 Leukemia cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;113;7;CHEMBL614882;;
CLD0;confirmatory;OVCAR-4;CHEMBL1964091;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307517;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the OVCAR-4 Ovarian cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;105;7;CHEMBL614051;;
CLD0;confirmatory;LOX IMVI ;CHEMBL1964092;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307535;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the LOX IMVI Melanoma cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;23;7;CHEMBL614096;;
CLD0;confirmatory;P388;CHEMBL1964095;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3308401;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the P388 Leukemia cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;111;7;CHEMBL389;;
CLD0;confirmatory;BT-549;CHEMBL1964099;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3308490;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the BT-549 Breast cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;89;7;CHEMBL614072;;
CLD0;confirmatory;SK-MEL-2;CHEMBL1963844;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307743;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-2 Melanoma cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;35;7;CHEMBL614917;;
CLD0;confirmatory;KM-20L2;CHEMBL1963848;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307782;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the KM20L2 Colon cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;75;7;CHEMBL614791;;
CLD0;confirmatory;A549;CHEMBL1963854;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307651;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the A549/ATCC Non-Small Cell Lung cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;19;7;CHEMBL392;;
CLD0;confirmatory;HCC 2998;CHEMBL1963860;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3308074;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HCC-2998 Colon cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;77;7;CHEMBL613855;;
CLD0;confirmatory;SNB-75;CHEMBL1963866;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307616;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SNB-75 Central Nervous System cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;55;7;CHEMBL614451;;
CLD0;confirmatory;HCT-15;CHEMBL1963868;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307945;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HCT-15 Colon cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;71;7;CHEMBL612263;;
CLD0;confirmatory;HCT-116;CHEMBL1963874;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3308372;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HCT-116 Colon cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;79;7;CHEMBL394;;
CLD0;confirmatory;SF-268;CHEMBL1963876;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307499;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SF-268 Central Nervous System cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;45;7;CHEMBL613977;;
CLD0;confirmatory;EKVX ;CHEMBL1963880;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307626;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the EKVX Non-Small Cell Lung cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;21;7;CHEMBL614487;;
CLD0;confirmatory;MCF7;CHEMBL1963882;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3308403;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MCF7 Breast cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;83;7;CHEMBL387;;
CLD0;confirmatory;PC-3;CHEMBL1963885;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307570;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the PC-3 Prostate cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;41;7;CHEMBL390;;
CLD0;confirmatory;DMS-114;CHEMBL1963887;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307670;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the DMS 114 Small Cell Lung cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;63;7;CHEMBL614642;;
CLD0;confirmatory;LXFL 529;CHEMBL1963889;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307537;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the LXFL 529 Non-Small Cell Lung cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;17;7;CHEMBL614110;;
CLD0;confirmatory;SK-OV-3;CHEMBL1963895;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307746;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SK-OV-3 Ovarian cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;103;7;CHEMBL614925;;
CLD0;confirmatory;T47D;CHEMBL1963900;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307606;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the T-47D Breast cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;91;7;CHEMBL614361;;
CLD0;confirmatory;NCI-H460;CHEMBL1963901;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307677;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the NCI-H460 Non-Small Cell Lung cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;7;7;CHEMBL396;;
CLD0;confirmatory;UACC-62;CHEMBL1963903;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307660;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the UACC-62 Melanoma cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;31;7;CHEMBL614610;;
CLD0;confirmatory;CAKI-1;CHEMBL1963911;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307522;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the CAKI-1 Renal cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;131;7;CHEMBL614067;;
CLD0;confirmatory;P388/ADR;CHEMBL1963918;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307566;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the P388/ADR Leukemia cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;117;7;CHEMBL614218;;
CLD0;confirmatory;MDA-MB-435;CHEMBL1963921;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307686;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-435 Breast cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;85;7;CHEMBL614697;;
CLD0;confirmatory;SF-295;CHEMBL1963922;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307738;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SF-295 Central Nervous System cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;47;7;CHEMBL614908;;
CLD0;confirmatory;IGROV-1;CHEMBL1963929;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307502;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the IGROV1 Ovarian cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;101;7;CHEMBL613984;;
CLD0;confirmatory;RXF 631;CHEMBL1963935;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307735;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the RXF-631 Renal cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;135;7;CHEMBL614888;;
CLD0;confirmatory;Hs-578T;CHEMBL1963945;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307672;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HS 578T Breast cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;97;7;CHEMBL614645;;
CLD0;confirmatory;786-0;CHEMBL1963953;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3308018;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the 786-0 Renal cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;137;7;CHEMBL613102;;
CLD0;confirmatory;SNB-78;CHEMBL1963954;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307969;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SNB-78 Central Nervous System cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;57;7;CHEMBL612543;;
CLD0;confirmatory;UACC-257;CHEMBL1963960;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3308008;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the UACC-257 Melanoma cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;33;7;CHEMBL612796;;
CLD0;confirmatory;CCRF-CEM;CHEMBL1963961;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307641;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the CCRF-CEM Leukemia cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;119;7;CHEMBL382;;
CLD0;confirmatory;DLD-1;CHEMBL1963963;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307580;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the DLD-1 Colon cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;69;7;CHEMBL614285;;
CLD0;confirmatory;NCI-H226;CHEMBL1964004;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307697;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the NCI-H226 Non-Small Cell Lung cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;3;7;CHEMBL614740;;
CLD0;confirmatory;HT-29;CHEMBL1964006;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307768;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HT29 Colon cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;65;7;CHEMBL384;;
CLD0;confirmatory;SK-MEL-28;CHEMBL1964007;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3308494;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-28 Melanoma cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;39;7;CHEMBL614919;;
CLD0;confirmatory;RXF 393;CHEMBL1964009;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307734;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the RXF 393 Renal cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;133;7;CHEMBL614886;;
CLD0;confirmatory;COLO 205;CHEMBL1964012;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3308348;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the COLO 205 Colon cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;67;7;CHEMBL614561;;
CLD0;confirmatory;HOP-18;CHEMBL1964014;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307783;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HOP-18 Non-Small Cell Lung cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;11;7;CHEMBL614809;;
CLD0;confirmatory;SN12K1;CHEMBL1964015;[];;[];;;;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307784;Target assigned is non-molecular;1;PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SN12K1 Renal cell line. (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;127;7;CHEMBL1909241;;
CLD0;;;CHEMBL2071962;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000357;single protein format;;Direct single protein target assigned;9;Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins;CHEMBL2069259;Direct protein target assigned;D;467794;1;CHEMBL3356;;
CLD0;;;CHEMBL2071963;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000357;single protein format;;Direct single protein target assigned;9;Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins;CHEMBL2069259;Direct protein target assigned;D;467795;1;CHEMBL3397;;
CLD0;;;CHEMBL2071964;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000357;single protein format;;Direct single protein target assigned;9;Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins;CHEMBL2069259;Direct protein target assigned;D;467796;1;CHEMBL3622;;
CLD0;;;CHEMBL2071965;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000357;single protein format;;Direct single protein target assigned;9;Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins;CHEMBL2069259;Direct protein target assigned;D;467797;1;CHEMBL289;;
CLD0;;;CHEMBL2071966;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000357;single protein format;;Direct single protein target assigned;9;Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins;CHEMBL2069259;Direct protein target assigned;D;467798;1;CHEMBL340;;
CLD0;;;CHEMBL2071967;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000357;single protein format;;Direct single protein target assigned;9;Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins;CHEMBL2069259;Direct protein target assigned;D;467799;1;CHEMBL340;;
CLD0;;;CHEMBL2071969;[];Homo sapiens;[];;Microsome;9606.0;;Liver;A;ADME;BAO_0000251;microsome format;;Target assigned is subcellular fraction;2;Metabolic stability in human liver microsomes assessed as medium signal/noise ratio (S/N of 10 to 100) by measuring GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis;CHEMBL2069259;Subcellular target assigned;S;467801;1;CHEMBL613373;CHEMBL3559723;
CLD0;;;CHEMBL2071972;[];Homo sapiens;[];;Microsome;9606.0;;Liver;A;ADME;BAO_0000251;microsome format;;Target assigned is subcellular fraction;2;Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH;CHEMBL2069259;Subcellular target assigned;S;467804;1;CHEMBL613373;CHEMBL3559723;
CLD0;;NIH-3T3-G185;CHEMBL2076240;[];;[];;;;In vitro;;F;Functional;BAO_0000219;cell-based format;CHEMBL3988465;Homologous single protein target assigned;8;TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells;CHEMBL2073899;Homologous protein target assigned;H;41;18;CHEMBL4302;;
CLD0;confirmatory;;CHEMBL2114890;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000019;assay format;;Direct single protein target assigned;9;PubChem BioAssay. qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway. (Class of assay: confirmatory) ;CHEMBL1201862;Direct protein target assigned;D;651741;7;CHEMBL1075094;;
CLD0;confirmatory;;CHEMBL2114775;[];;[];;;;;;F;Functional;BAO_0000019;assay format;;Default value - Target unknown or has yet to be assigned;0;PubChem BioAssay. qHTS Assay for Inhibitors of Hepatitis C Virus (HCV). (Class of assay: confirmatory) ;CHEMBL1201862;Default value - Target has yet to be curated;U;651820;7;CHEMBL612545;;
CLD0;confirmatory;;CHEMBL2114777;[];;[];;;;;;F;Functional;BAO_0000019;assay format;;Default value - Target unknown or has yet to be assigned;0;PubChem BioAssay. Cell Proliferation Assay against a hMSC Cell Line. (Class of assay: confirmatory) ;CHEMBL1201862;Default value - Target has yet to be curated;U;651696;7;CHEMBL612545;;
CLD0;confirmatory;SW480;CHEMBL2114780;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307758;Direct single protein target assigned;9;PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells. (Class of assay: confirmatory) ;CHEMBL1201862;Direct protein target assigned;D;624297;7;CHEMBL1293278;;
CLD0;;H22;CHEMBL2150145;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '30.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '30.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307751;Target assigned is non-molecular;1;Anticancer activity against mouse H22 cells allografted in Kunming mouse at 30 mg/kg, ip for 7 days measured after 7 days;CHEMBL2146364;Non-molecular target assigned;N;470154;1;CHEMBL614998;;
CLD0;;H22;CHEMBL2150146;[];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '30.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '30.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];Kunming;;10090.0;;;T;Toxicity;BAO_0000218;organism-based format;CHEMBL3307751;Target assigned is non-molecular;1;Toxicity in Kunming mouse xenografted with mouse H22 cells assessed as increase in body weight at 30 mg/kg, ip for 7 days measured after 7 days;CHEMBL2146364;Non-molecular target assigned;N;470155;1;CHEMBL375;;
CLD0;;Lewis lung carcinoma cell line;CHEMBL2149357;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}, {'assay_class_id': 119, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Xenograft Oncology Models', 'l3': 'Xenograft Models of Anti-Tumor Assays', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307859;Target assigned is non-molecular;1;Antineoplastic activity against mouse LLC cells xenografted in C57BL/6 mouse assessed as tumor growth inhibition at 100 mg/kg/day measured on day 17;CHEMBL2146434;Non-molecular target assigned;N;473423;1;CHEMBL614088;;
CLD0;;Lewis lung carcinoma cell line;CHEMBL2150746;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}, {'assay_class_id': 119, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Xenograft Oncology Models', 'l3': 'Xenograft Models of Anti-Tumor Assays', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307859;Target assigned is non-molecular;1;Antineoplastic activity against mouse LLC cells xenografted in C57BL/6 mouse assessed as tumor growth inhibition at 100 mg/kg/day measured on day 11;CHEMBL2146434;Non-molecular target assigned;N;473414;1;CHEMBL614088;;
CLD0;;Lewis lung carcinoma cell line;CHEMBL2150747;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}, {'assay_class_id': 119, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Xenograft Oncology Models', 'l3': 'Xenograft Models of Anti-Tumor Assays', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307859;Target assigned is non-molecular;1;Antineoplastic activity against mouse LLC cells xenografted in C57BL/6 mouse assessed as tumor growth inhibition at 100 mg/kg/day measured on day 14;CHEMBL2146434;Non-molecular target assigned;N;473415;1;CHEMBL614088;;
CLD0;;Lewis lung carcinoma cell line;CHEMBL2150748;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}, {'assay_class_id': 119, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Xenograft Oncology Models', 'l3': 'Xenograft Models of Anti-Tumor Assays', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307859;Target assigned is non-molecular;1;Antineoplastic activity against mouse LLC cells xenografted in C57BL/6 mouse assessed as tumor growth inhibition at 100 mg/kg/day measured on day 16;CHEMBL2146434;Non-molecular target assigned;N;473416;1;CHEMBL614088;;
CLD0;;Lewis lung carcinoma cell line;CHEMBL2150749;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}, {'assay_class_id': 119, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Xenograft Oncology Models', 'l3': 'Xenograft Models of Anti-Tumor Assays', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307859;Target assigned is non-molecular;1;Antineoplastic activity against mouse LLC cells xenografted in C57BL/6 mouse assessed as tumor growth inhibition at 100 mg/kg/day measured on day 18;CHEMBL2146434;Non-molecular target assigned;N;473417;1;CHEMBL614088;;
CLD0;;Lewis lung carcinoma cell line;CHEMBL2150750;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}, {'assay_class_id': 119, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Xenograft Oncology Models', 'l3': 'Xenograft Models of Anti-Tumor Assays', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307859;Target assigned is non-molecular;1;Antineoplastic activity against mouse LLC cells xenografted in C57BL/6 mouse assessed as tumor growth inhibition at 100 mg/kg/day measured on day 21;CHEMBL2146434;Non-molecular target assigned;N;473418;1;CHEMBL614088;;
CLD0;;Lewis lung carcinoma cell line;CHEMBL2150751;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}, {'assay_class_id': 119, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Xenograft Oncology Models', 'l3': 'Xenograft Models of Anti-Tumor Assays', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307859;Target assigned is non-molecular;1;Antineoplastic activity against mouse LLC cells xenografted in C57BL/6 mouse assessed as tumor growth inhibition at 100 mg/kg/day measured on day 23;CHEMBL2146434;Non-molecular target assigned;N;473419;1;CHEMBL614088;;
CLD0;;Lewis lung carcinoma cell line;CHEMBL2150752;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}, {'assay_class_id': 119, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Xenograft Oncology Models', 'l3': 'Xenograft Models of Anti-Tumor Assays', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307859;Target assigned is non-molecular;1;Antineoplastic activity against mouse LLC cells xenografted in C57BL/6 mouse assessed as tumor growth inhibition at 100 mg/kg/day measured on day 12;CHEMBL2146434;Non-molecular target assigned;N;473422;1;CHEMBL614088;;
CLD0;;Lewis lung carcinoma cell line;CHEMBL2150753;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}, {'assay_class_id': 119, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Xenograft Oncology Models', 'l3': 'Xenograft Models of Anti-Tumor Assays', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307859;Target assigned is non-molecular;1;Antineoplastic activity against mouse LLC cells xenografted in C57BL/6 mouse assessed as tumor growth inhibition at 100 mg/kg/day measured on day 19;CHEMBL2146434;Non-molecular target assigned;N;473424;1;CHEMBL614088;;
CLD0;;Lewis lung carcinoma cell line;CHEMBL2150754;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}, {'assay_class_id': 119, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Xenograft Oncology Models', 'l3': 'Xenograft Models of Anti-Tumor Assays', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307859;Target assigned is non-molecular;1;Antineoplastic activity against mouse LLC cells xenografted in C57BL/6 mouse assessed as tumor growth inhibition at 100 mg/kg/day measured on day 24;CHEMBL2146434;Non-molecular target assigned;N;473425;1;CHEMBL614088;;
CLD0;;Lymphocyte;CHEMBL2154618;[];Homo sapiens;[];;Liver S9 fraction;9606.0;;Liver;T;Toxicity;BAO_0000219;cell-based format;CHEMBL3308002;Target assigned is non-molecular;1;Genotoxicity in human lymphocytes assessed as micronucleated binucleate cells level at 12.5 ug/mL incubated for 3 hrs measured post 21 hrs recovery in presence of rat liver S9 fraction (Rvb = 0.40%);CHEMBL2150875;Non-molecular target assigned;N;475687;1;CHEMBL614892;CHEMBL3559723;
CLD0;;Lymphocyte;CHEMBL2154740;[];Homo sapiens;[];;Liver S9 fraction;9606.0;;Liver;T;Toxicity;BAO_0000219;cell-based format;CHEMBL3308002;Target assigned is non-molecular;1;Genotoxicity in human lymphocytes assessed as micronucleated binucleate cells level at 6.25 ug/mL incubated for 3 hrs measured post 45 hrs recovery in presence of rat liver S9 fraction (Rvb = 0.5%);CHEMBL2150875;Non-molecular target assigned;N;475712;1;CHEMBL614892;CHEMBL3559723;
CLD0;;Lymphocyte;CHEMBL2154753;[];Homo sapiens;[];;Liver S9 fraction;9606.0;;Liver;T;Toxicity;BAO_0000219;cell-based format;CHEMBL3308002;Target assigned is non-molecular;1;Genotoxicity in human lymphocytes assessed as micronucleated binucleate cells level at 12.5 ug/mL incubated for 3 hrs measured post 45 hrs recovery in presence of rat liver S9 fraction (Rvb = 0.0%);CHEMBL2150875;Non-molecular target assigned;N;475725;1;CHEMBL614892;CHEMBL3559723;
CLD0;;Lymphocyte;CHEMBL2154845;[];Homo sapiens;[];;Liver S9 fraction;9606.0;;Liver;T;Toxicity;BAO_0000219;cell-based format;CHEMBL3308002;Target assigned is non-molecular;1;Genotoxicity in human lymphocytes assessed as micronucleated binucleate cells level at 6.25 ug/mL incubated for 3 hrs measured post 45 hrs recovery in presence of rat liver S9 fraction (Rvb = 0.8%);CHEMBL2150875;Non-molecular target assigned;N;475739;1;CHEMBL614892;CHEMBL3559723;
CLD0;;HepG2;CHEMBL3061435;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307718;Target assigned is non-molecular;1;Growth inhibition of Homo sapiens (human) HepG2 cells at 10 uM after 48 hr by SRB assay;CHEMBL3045644;Non-molecular target assigned;N;507008;1;CHEMBL395;;
CLD0;;HCT-15;CHEMBL3061436;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307945;Target assigned is non-molecular;1;Growth inhibition of Homo sapiens (human) HCT15 cells at 10 uM after 48 hr by SRB assay;CHEMBL3045644;Non-molecular target assigned;N;507007;1;CHEMBL612263;;
CLD0;;T47D;CHEMBL3061437;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307606;Target assigned is non-molecular;1;Growth inhibition of Homo sapiens (human) T47D cells at 10 uM after 48 hr by SRB assay;CHEMBL3045644;Non-molecular target assigned;N;507006;1;CHEMBL614361;;
CLD0;;PA-1;CHEMBL3061438;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3308812;Target assigned is non-molecular;1;Growth inhibition of Homo sapiens (human) PA1 cells at 10 uM after 48 hr by SRB assay;CHEMBL3045644;Non-molecular target assigned;N;507005;1;CHEMBL614949;;
CLD0;;MDA-MB-231;CHEMBL3061797;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307960;Target assigned is non-molecular;1;Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells after 48 hr by MTT assay;CHEMBL3045968;Non-molecular target assigned;N;504549;1;CHEMBL400;;
CLD0;;HepG2;CHEMBL3061798;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307718;Target assigned is non-molecular;1;Cytotoxicity against Homo sapiens (human) HepG2 cells after 48 hr by MTT assay;CHEMBL3045968;Non-molecular target assigned;N;504550;1;CHEMBL395;;
CLD0;;;CHEMBL3061799;[];;[];;;;;;P;Physicochemical;BAO_0000100;small-molecule physicochemical format;;Default value - Target unknown or has yet to be assigned;0;Lipophilicity, log P of the compound;CHEMBL3045968;Default value - Target has yet to be curated;U;504551;1;CHEMBL2362975;;
CLD0;;K562;CHEMBL3061800;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3308378;Target assigned is non-molecular;1;Cytotoxicity against Homo sapiens (human) K562 cells after 48 hr by MTT assay;CHEMBL3045968;Non-molecular target assigned;N;504548;1;CHEMBL385;;
CLD0;;;CHEMBL3062730;[];;[];;;;;;P;Physicochemical;BAO_0000100;small-molecule physicochemical format;;Default value - Target unknown or has yet to be assigned;0;Lipophilicity, log P of the compound;CHEMBL3046386;Default value - Target has yet to be curated;U;511796;1;CHEMBL2362975;;
CLD0;;;CHEMBL3062731;[];;[];;;;;;P;Physicochemical;BAO_0000100;small-molecule physicochemical format;;Default value - Target unknown or has yet to be assigned;0;Distribution coefficient, log D of the compound;CHEMBL3046386;Default value - Target has yet to be curated;U;511797;1;CHEMBL2362975;;
CLD0;;K562;CHEMBL3062732;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3308378;Target assigned is non-molecular;1;Antiproliferative activity against Homo sapiens (human) K562 cells after 48 hr by MTT assay;CHEMBL3046386;Non-molecular target assigned;N;511795;1;CHEMBL385;;
CLD0;;NCI-H522;CHEMBL3062877;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3308392;Target assigned is non-molecular;1;Growth inhibition of Homo sapiens (human) NCI-H522 cells at 10 uM after 48 hr by SRB assay;CHEMBL3045644;Non-molecular target assigned;N;507004;1;CHEMBL614387;;
CLD0;;HepG2;CHEMBL3063278;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307718;Target assigned is non-molecular;1;Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as growth inhibition at 1 x 10'-5 M after 48 hr by SRB assay;CHEMBL3045323;Non-molecular target assigned;N;508197;1;CHEMBL395;;
CLD0;;HCT-15;CHEMBL3063279;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307945;Target assigned is non-molecular;1;Cytotoxicity against Homo sapiens (human) HCT15 cells assessed as growth inhibition at 1 x 10'-5 M after 48 hr by SRB assay;CHEMBL3045323;Non-molecular target assigned;N;508195;1;CHEMBL612263;;
CLD0;;T47D;CHEMBL3063280;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307606;Target assigned is non-molecular;1;Cytotoxicity against Homo sapiens (human) T47D cells assessed as growth inhibition at 1 x 10'-5 M after 48 hr by SRB assay;CHEMBL3045323;Non-molecular target assigned;N;508192;1;CHEMBL614361;;
CLD0;;PA-1;CHEMBL3063281;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3308812;Target assigned is non-molecular;1;Cytotoxicity against Homo sapiens (human) PA1 cells assessed as growth inhibition at 1 x 10'-5 M after 48 hr by SRB assay;CHEMBL3045323;Non-molecular target assigned;N;508170;1;CHEMBL614949;;
CLD0;;NCI-H522;CHEMBL3063282;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3308392;Target assigned is non-molecular;1;Cytotoxicity against Homo sapiens (human) NCI-H522 cells assessed as growth inhibition at 1 x 10'-5 M after 48 hr by SRB assay;CHEMBL3045323;Non-molecular target assigned;N;508169;1;CHEMBL614387;;
CLD0;;MCF7;CHEMBL3054945;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3308403;Target assigned is non-molecular;1;Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by trypan blue assay;CHEMBL3045043;Non-molecular target assigned;N;513222;1;CHEMBL387;;
CLD0;;COLO 320;CHEMBL3070108;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307577;Target assigned is non-molecular;1;Cytotoxicity against Homo sapiens (human) COLO320 cells at 156 ug/mL by MTT assay;CHEMBL3045925;Non-molecular target assigned;N;545163;1;CHEMBL614257;;
CLD0;;PA-1;CHEMBL3071878;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3308812;Target assigned is non-molecular;1;Growth inhibition of Homo sapiens (human) PA1 cells at 10 uM after 48 hr by SRB assay;CHEMBL3046244;Non-molecular target assigned;N;540190;1;CHEMBL614949;;
CLD0;;HepG2;CHEMBL3071879;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307718;Target assigned is non-molecular;1;Growth inhibition of Homo sapiens (human) HepG2 cells at 10 uM after 48 hr by SRB assay;CHEMBL3046244;Non-molecular target assigned;N;540191;1;CHEMBL395;;
CLD0;;HCT-15;CHEMBL3071880;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307945;Target assigned is non-molecular;1;Growth inhibition of Homo sapiens (human) HCT15 cells at 10 uM after 48 hr by SRB assay;CHEMBL3046244;Non-molecular target assigned;N;540187;1;CHEMBL612263;;
CLD0;;T47D;CHEMBL3071881;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307606;Target assigned is non-molecular;1;Growth inhibition of Homo sapiens (human) T47D cells at 10 uM after 48 hr by SRB assay;CHEMBL3046244;Non-molecular target assigned;N;540185;1;CHEMBL614361;;
CLD0;;NCI-H522;CHEMBL3070542;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3308392;Target assigned is non-molecular;1;Growth inhibition of Homo sapiens (human) NCI-H522 cells at 10 uM after 48 hr by SRB assay;CHEMBL3046244;Non-molecular target assigned;N;540186;1;CHEMBL614387;;
CLD0;;HepG2;CHEMBL3070543;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307718;Target assigned is non-molecular;1;Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as growth inhibition at 10 uM after 48 hr by SRB assay;CHEMBL3044972;Non-molecular target assigned;N;544106;1;CHEMBL395;;
CLD0;;HCT-15;CHEMBL3070544;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307945;Target assigned is non-molecular;1;Cytotoxicity against Homo sapiens (human) HCT15 cells assessed as growth inhibition at 10 uM after 48 hr by SRB assay;CHEMBL3044972;Non-molecular target assigned;N;544104;1;CHEMBL612263;;
CLD0;;PA-1;CHEMBL3070545;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3308812;Target assigned is non-molecular;1;Cytotoxicity against Homo sapiens (human) PA1 cells assessed as growth inhibition at 10 uM after 48 hr by SRB assay;CHEMBL3044972;Non-molecular target assigned;N;544105;1;CHEMBL614949;;
CLD0;;NCI-H522;CHEMBL3070546;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3308392;Target assigned is non-molecular;1;Cytotoxicity against Homo sapiens (human) NCI-H522 cells assessed as growth inhibition at 10 uM after 48 hr by SRB assay;CHEMBL3044972;Non-molecular target assigned;N;544103;1;CHEMBL614387;;
CLD0;;T47D;CHEMBL3070547;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307606;Target assigned is non-molecular;1;Cytotoxicity against Homo sapiens (human) T47D cells assessed as growth inhibition at 10 uM after 48 hr by SRB assay;CHEMBL3044972;Non-molecular target assigned;N;544102;1;CHEMBL614361;;
CLD0;;H22;CHEMBL2319268;[];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307751;Target assigned is non-molecular;1;Antitumor activity in mouse H22 liver cancer cells inoculated mouse assessed as tumor inhibition rate at one fifth of LD50 concentration once a day for consecutive 7 days by ip;CHEMBL2311304;Non-molecular target assigned;N;524032;1;CHEMBL614998;;
CLD0;;B16;CHEMBL2319269;[];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3308454;Target assigned is non-molecular;1;Antitumor activity in mouse B16 melanoma cell lines cells inoculated mouse assessed as tumor inhibition rate at one fifth of LD50 concentration once a day for consecutive 7 days by ip;CHEMBL2311304;Non-molecular target assigned;N;524033;1;CHEMBL381;;
CLD0;;Sarcoma-180;CHEMBL2319270;[];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3308362;Target assigned is non-molecular;1;Antitumor activity in mouse Sarcoma 180 cells inoculated mouse assessed as tumor inhibition rate at one fifth of LD50 concentration once a day for consecutive 7 days by ip;CHEMBL2311304;Non-molecular target assigned;N;524031;1;CHEMBL3879801;;
CLD0;;Cancer cell lines;CHEMBL2319271;[];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307923;Target assigned is non-molecular;1;Antitumor activity in mouse Lewis lung cancer cells inoculated mouse assessed as tumor inhibition rate at one fifth of LD50 concentration once a day for consecutive 7 days by ip;CHEMBL2311304;Non-molecular target assigned;N;524026;1;CHEMBL3879801;;
CLD0;;CT26;CHEMBL2319272;[];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3308079;Target assigned is non-molecular;1;Antitumor activity in mouse CT26 colon cancer cells inoculated mouse assessed as tumor inhibition rate at one fifth of LD50 concentration once a day for consecutive 7 days by ip;CHEMBL2311304;Non-molecular target assigned;N;524017;1;CHEMBL613866;;
CLD0;;;CHEMBL2319274;[];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '50.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '50.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];C57BL/6;;10090.0;;;T;Toxicity;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Toxicity in C57BL/6 mouse assessed as maximum weight loss at 50 mg/kg, ip;CHEMBL2311304;Non-molecular target assigned;N;524009;1;CHEMBL375;;
CLD0;;Lewis lung carcinoma cell line;CHEMBL2319610;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}, {'assay_class_id': 119, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Xenograft Oncology Models', 'l3': 'Xenograft Models of Anti-Tumor Assays', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '30.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '30.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307859;Target assigned is non-molecular;1;Antitumor activity against mouse LLC cells xenografted in mouse assessed as tumor inhibition at 30 mg/kg, ip qd for 7 days measured every 3 days for 21 days;CHEMBL2311271;Non-molecular target assigned;N;524667;1;CHEMBL614088;;
CLD0;;Sarcoma-180;CHEMBL2321011;[];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '30.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '30.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308362;Target assigned is non-molecular;1;Antitumor activity against mouse Sarcoma 180 cells xenografted in mouse assessed as tumor inhibition at 30 mg/kg, ip qd for 7 days measured every 3 days for 21 days;CHEMBL2311271;Non-molecular target assigned;N;524653;1;CHEMBL3879801;;
CLD0;;;CHEMBL2321020;[];Mus musculus;[];C57BL/6;;10090.0;;;T;Toxicity;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Neurotoxicity in ip dosed C57BL/6 mouse assessed as tremble, twitch, jumping and supination response;CHEMBL2311271;Non-molecular target assigned;N;524632;1;CHEMBL375;;
CLD0;;COS-1;CHEMBL2321076;[];Chlorocebus aethiops;[];;;9534.0;;;A;ADME;BAO_0000219;cell-based format;CHEMBL3308351;Target assigned is non-molecular;1;Cytotoxicity against african green monkey COS1 cells after 24 hrs by MTT assay;CHEMBL2311276;Non-molecular target assigned;N;524124;1;CHEMBL614563;;
CLD0;;PA-1;CHEMBL2321077;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3308812;Target assigned is non-molecular;1;Cytotoxicity against human PA1 cells after 24 hrs by MTT assay;CHEMBL2311276;Non-molecular target assigned;N;524122;1;CHEMBL614949;;
CLD0;;HepG2;CHEMBL2321078;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307718;Target assigned is non-molecular;1;Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay;CHEMBL2311276;Non-molecular target assigned;N;524123;1;CHEMBL395;;
CLD0;;NCI-H522;CHEMBL2321079;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3308392;Target assigned is non-molecular;1;Cytotoxicity against human NCI-H522 cells after 24 hrs by MTT assay;CHEMBL2311276;Non-molecular target assigned;N;524120;1;CHEMBL614387;;
CLD0;;HCT-15;CHEMBL2321080;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307945;Target assigned is non-molecular;1;Cytotoxicity against human HCT15 cells after 24 hrs by MTT assay;CHEMBL2311276;Non-molecular target assigned;N;524121;1;CHEMBL612263;;
CLD0;;HCT-15;CHEMBL2321081;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307945;Target assigned is non-molecular;1;Cytotoxicity against human HCT15 cells assessed as growth inhibition at 1 x 10 '-5 M after 24 hrs by MTT assay;CHEMBL2311276;Non-molecular target assigned;N;524118;1;CHEMBL612263;;
CLD0;;T47D;CHEMBL2321082;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307606;Target assigned is non-molecular;1;Cytotoxicity against human T47D cells after 24 hrs by MTT assay;CHEMBL2311276;Non-molecular target assigned;N;524119;1;CHEMBL614361;;
CLD0;;HepG2;CHEMBL2321083;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307718;Target assigned is non-molecular;1;Cytotoxicity against human HepG2 cells assessed as growth inhibition at 1 x 10 '-5 M after 24 hrs by MTT assay;CHEMBL2311276;Non-molecular target assigned;N;524116;1;CHEMBL395;;
CLD0;;PA-1;CHEMBL2321084;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3308812;Target assigned is non-molecular;1;Cytotoxicity against human PA1 cells assessed as growth inhibition at 1 x 10 '-5 M after 24 hrs by MTT assay;CHEMBL2311276;Non-molecular target assigned;N;524115;1;CHEMBL614949;;
CLD0;;NCI-H522;CHEMBL2321085;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3308392;Target assigned is non-molecular;1;Cytotoxicity against human NCI-H522 cells assessed as growth inhibition at 1 x 10 '-5 M after 24 hrs by MTT assay;CHEMBL2311276;Non-molecular target assigned;N;524114;1;CHEMBL614387;;
CLD0;;T47D;CHEMBL2321086;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307606;Target assigned is non-molecular;1;Cytotoxicity against human T47D cells assessed as growth inhibition at 1 x 10 '-5 M after 24 hrs by MTT assay;CHEMBL2311276;Non-molecular target assigned;N;524113;1;CHEMBL614361;;
CLD0;confirmatory;;CHEMBL2354287;[];;[];;;;;;F;Functional;BAO_0000019;assay format;;Homologous single protein target assigned;8;PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) ;CHEMBL1201862;Homologous protein target assigned;H;652104;7;CHEMBL2362981;;
CLD0;;Lewis lung carcinoma cell line;CHEMBL2406884;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '30.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '30.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307859;Target assigned is non-molecular;1;Antitumor activity against mouse LLC cells allografted in mouse assessed as tumor growth inhibition at 30 mg/kg, ip qd administered for 7 days measured after 21 days relative to control;CHEMBL2401724;Non-molecular target assigned;N;581344;1;CHEMBL614088;;
CLD0;;Sarcoma-180;CHEMBL2406890;[];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '30.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '30.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308362;Target assigned is non-molecular;1;Antitumor activity against mouse Sarcoma 180 cells allografted in mouse assessed as tumor growth inhibition at 30 mg/kg, ip qd administered for 7 days measured after 21 days relative to control;CHEMBL2401724;Non-molecular target assigned;N;581337;1;CHEMBL3879801;;
CLD0;;;CHEMBL2423209;[];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '50.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '50.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];Swiss albino;;10090.0;;;T;Toxicity;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Mutagenicity in Swiss albino mouse at 50 mg/kg, ip after 30 hrs by micronucleus test;CHEMBL2417455;Non-molecular target assigned;N;593106;1;CHEMBL375;;
CLD0;;;CHEMBL3137722;[];Homo sapiens;[];;;9606.0;;Liver;T;Toxicity;BAO_0000221;tissue-based format;;Target assigned is non-molecular;1;Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source];CHEMBL3137667;Non-molecular target assigned;N;1;1;CHEMBL3879801;CHEMBL3559723;
CLD0;;;CHEMBL3137723;[];Homo sapiens;[];;;9606.0;;Liver;T;Toxicity;BAO_0000221;tissue-based format;;Target assigned is non-molecular;1;Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source];CHEMBL3137667;Non-molecular target assigned;N;2;1;CHEMBL3879801;CHEMBL3559723;
CLD0;;;CHEMBL3137724;[];Homo sapiens;[];;;9606.0;;Liver;T;Toxicity;BAO_0000221;tissue-based format;;Default value - Target unknown or has yet to be assigned;0;Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source];CHEMBL3137667;Default value - Target has yet to be curated;U;3;1;CHEMBL612545;CHEMBL3559723;
CLD0;;;CHEMBL3137725;[];Homo sapiens;[];;;9606.0;;Liver;T;Toxicity;BAO_0000221;tissue-based format;;Target assigned is non-molecular;1;Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source];CHEMBL3137667;Non-molecular target assigned;N;4;1;CHEMBL3879801;CHEMBL3559723;
CLD0;;;CHEMBL3137726;[];Homo sapiens;[];;;9606.0;;Liver;T;Toxicity;BAO_0000221;tissue-based format;;Default value - Target unknown or has yet to be assigned;0;Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source];CHEMBL3137667;Default value - Target has yet to be curated;U;5;1;CHEMBL612545;CHEMBL3559723;
CLD0;;;CHEMBL3137727;[];Homo sapiens;[];;;9606.0;;Liver;T;Toxicity;BAO_0000221;tissue-based format;;Default value - Target unknown or has yet to be assigned;0;Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source];CHEMBL3137667;Default value - Target has yet to be curated;U;6;1;CHEMBL612545;CHEMBL3559723;
CLD0;;;CHEMBL3137728;[];Homo sapiens;[];;;9606.0;;Liver;T;Toxicity;BAO_0000221;tissue-based format;;Default value - Target unknown or has yet to be assigned;0;Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source];CHEMBL3137667;Default value - Target has yet to be curated;U;7;1;CHEMBL612545;CHEMBL3559723;
CLD0;;;CHEMBL3137729;[];Homo sapiens;[];;;9606.0;;Liver;T;Toxicity;BAO_0000221;tissue-based format;;Default value - Target unknown or has yet to be assigned;0;Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source];CHEMBL3137667;Default value - Target has yet to be curated;U;8;1;CHEMBL612545;CHEMBL3559723;
CLD0;;;CHEMBL3137730;[];Homo sapiens;[];;;9606.0;;;T;Toxicity;BAO_0000019;assay format;;Default value - Target unknown or has yet to be assigned;0;Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source];CHEMBL3137667;Default value - Target has yet to be curated;U;9;1;CHEMBL612545;;
CLD0;;;CHEMBL3137731;[];Homo sapiens;[];;;9606.0;;Liver;T;Toxicity;BAO_0000221;tissue-based format;;Target assigned is non-molecular;1;Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source];CHEMBL3137667;Non-molecular target assigned;N;10;1;CHEMBL3879801;CHEMBL3559723;
CLD0;;;CHEMBL3137732;[];Homo sapiens;[];;;9606.0;;;T;Toxicity;BAO_0000019;assay format;;Default value - Target unknown or has yet to be assigned;0;Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source];CHEMBL3137667;Default value - Target has yet to be curated;U;11;1;CHEMBL612545;;
CLD0;;;CHEMBL3137733;[];Homo sapiens;[];;;9606.0;;;T;Toxicity;BAO_0000019;assay format;;Default value - Target unknown or has yet to be assigned;0;Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source];CHEMBL3137667;Default value - Target has yet to be curated;U;12;1;CHEMBL612545;;
CLD0;;;CHEMBL3137734;[];Homo sapiens;[];;;9606.0;;;T;Toxicity;BAO_0000019;assay format;;Default value - Target unknown or has yet to be assigned;0;Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source];CHEMBL3137667;Default value - Target has yet to be curated;U;13;1;CHEMBL612545;;
CLD0;;;CHEMBL3137735;[];Homo sapiens;[];;;9606.0;;;T;Toxicity;BAO_0000019;assay format;;Target assigned is non-molecular;1;Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source];CHEMBL3137667;Non-molecular target assigned;N;14;1;CHEMBL3879801;;
CLD0;;;CHEMBL3137736;[];Homo sapiens;[];;;9606.0;;;T;Toxicity;BAO_0000019;assay format;;Target assigned is non-molecular;1;Animal toxicity known. [column 'TOXIC' in source];CHEMBL3137667;Non-molecular target assigned;N;15;1;CHEMBL3879801;;
CLD0;;;CHEMBL3137737;[];Homo sapiens;[];;;9606.0;;;T;Toxicity;BAO_0000019;assay format;;Default value - Target unknown or has yet to be assigned;0;Presence of at least one case with successful reintroduction. [column 'REINT' in source];CHEMBL3137667;Default value - Target has yet to be curated;U;16;1;CHEMBL612545;;
CLD0;;;CHEMBL3137738;[];Homo sapiens;[];;;9606.0;;;T;Toxicity;BAO_0000019;assay format;;Default value - Target unknown or has yet to be assigned;0;Comments (NB not yet translated). [column 'COMMENTAIRES' in source];CHEMBL3137667;Default value - Target has yet to be curated;U;17;1;CHEMBL612545;;
CLD0;;;CHEMBL3137739;[];Homo sapiens;[];;;9606.0;;;T;Toxicity;BAO_0000019;assay format;;Target assigned is non-molecular;1;Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source];CHEMBL3137667;Non-molecular target assigned;N;18;1;CHEMBL3879801;;
CLD0;;;CHEMBL3137740;[];Homo sapiens;[];;;9606.0;;Liver;T;Toxicity;BAO_0000221;tissue-based format;;Target assigned is non-molecular;1;Proposed mechanism(s) of liver damage. [column 'MEC' in source];CHEMBL3137667;Non-molecular target assigned;N;19;1;CHEMBL3879801;CHEMBL3559723;
CLD0;confirmatory;;CHEMBL3214945;[];;[];;;;;;F;Functional;BAO_0000019;assay format;;Target assigned is non-molecular;1;PubChem BioAssay. qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation.   (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;743344;7;CHEMBL3879801;;
CLD0;confirmatory;;CHEMBL3214990;[];;[];;;;;;F;Functional;BAO_0000019;assay format;;Target assigned is non-molecular;1;PubChem BioAssay. qHTS profiling for inhibitors of Plasmodium falciparum (3D7) proliferation.   (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;743322;7;CHEMBL3879801;;
CLD0;confirmatory;;CHEMBL3214997;[];;[];;;;;;F;Functional;BAO_0000019;assay format;;Default value - Target unknown or has yet to be assigned;0;PubChem BioAssay. Cell Proliferation Assay Versus the ED40515 IL2 Dependent  ATL cell lines.   (Class of assay: confirmatory) ;CHEMBL1201862;Default value - Target has yet to be curated;U;1053195;7;CHEMBL612545;;
CLD0;confirmatory;;CHEMBL3215001;[];;[];;;;;;F;Functional;BAO_0000019;assay format;;Target assigned is non-molecular;1;PubChem BioAssay. qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation.   (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;743345;7;CHEMBL3879801;;
CLD0;confirmatory;;CHEMBL3215086;[];;[];;;;;;F;Functional;BAO_0000019;assay format;;Target assigned is non-molecular;1;PubChem BioAssay. qHTS profiling for inhibitors of Plasmodium falciparum (HB3) proliferation.   (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;743324;7;CHEMBL3879801;;
CLD0;confirmatory;;CHEMBL3215154;[];;[];;;;;;F;Functional;BAO_0000019;assay format;;Default value - Target unknown or has yet to be assigned;0;PubChem BioAssay. Cell Proliferation Assay Versus the ED40515 IL2 Independent  ATL cell lines.   (Class of assay: confirmatory) ;CHEMBL1201862;Default value - Target has yet to be curated;U;1053194;7;CHEMBL612545;;
CLD0;confirmatory;;CHEMBL3215181;[];;[];;;;;;F;Functional;BAO_0000019;assay format;;Default value - Target unknown or has yet to be assigned;0;"PubChem BioAssay. qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen.   (Class of assay: confirmatory) ";CHEMBL1201862;Default value - Target has yet to be curated;U;720542;7;CHEMBL612545;;
CLD0;confirmatory;;CHEMBL3214813;[];;[];;;;;;F;Functional;BAO_0000019;assay format;;Target assigned is non-molecular;1;PubChem BioAssay. qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2).   (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;743346;7;CHEMBL3879801;;
CLD0;confirmatory;;CHEMBL3214842;[];;[];;;;;;F;Functional;BAO_0000019;assay format;;Target assigned is non-molecular;1;PubChem BioAssay. qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation.   (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;743347;7;CHEMBL3879801;;
CLD0;confirmatory;;CHEMBL3214892;[];;[];;;;;;F;Functional;BAO_0000019;assay format;;Target assigned is non-molecular;1;PubChem BioAssay. qHTS profiling for inhibitors of Plasmodium falciparum (DD2) proliferation.   (Class of assay: confirmatory) ;CHEMBL1201862;Non-molecular target assigned;N;743323;7;CHEMBL3879801;;
CLD0;confirmatory;;CHEMBL3214913;[];;[];;;;;;B;Binding;BAO_0000019;assay format;;Default value - Target unknown or has yet to be assigned;0;PubChem BioAssay. qHTS for Inhibitors of binding or entry into cells for Marburg Virus.   (Class of assay: confirmatory) ;CHEMBL1201862;Default value - Target has yet to be curated;U;720532;7;CHEMBL612545;;
CLD0;;L1210;CHEMBL3232302;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '250.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '250.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308391;Target assigned is non-molecular;1;Antitumor activity against mouse L1210 cells allografted in mouse assessed as increase in survival rate at 250 mg/kg, ip administered on day 1 measured on day 30 relative to control;CHEMBL3227956;Non-molecular target assigned;N;656010;1;CHEMBL386;;
CLD0;;L1210;CHEMBL3232306;[];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '250.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '250.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;T;Toxicity;BAO_0000218;organism-based format;CHEMBL3308391;Target assigned is non-molecular;1;Toxicity in mouse allografted with mouse L1210 cells assessed as survival rate at 250 mg/kg, ip administered on day 1 measured on day 30 relative to control;CHEMBL3227956;Non-molecular target assigned;N;656015;1;CHEMBL375;;
CLD0;;ADJ/PC6;CHEMBL3232311;[];Mus musculus;[];;;10090.0;;;T;Toxicity;BAO_0000218;organism-based format;CHEMBL3307899;Target assigned is non-molecular;1;Toxicity in mouse allografted with mouse ADJ/PC6 cells;CHEMBL3227956;Non-molecular target assigned;N;656158;1;CHEMBL375;;
CLD0;;ADJ/PC6;CHEMBL3232312;[];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307899;Target assigned is non-molecular;1;Antitumor activity against mouse ADJ/PC6 cells allografted in mouse;CHEMBL3227956;Non-molecular target assigned;N;656166;1;CHEMBL614265;;
CLD0;;ADJ/PC6;CHEMBL3232313;[];Mus musculus;[];;;10090.0;;;A;ADME;BAO_0000218;organism-based format;CHEMBL3307899;Default value - Target unknown or has yet to be assigned;0;Therapeutic index, ratio of LD50 for mouse allografted with mouse ADJ/PC6 cells to ED90 for mouse ADJ/PC6 cells allografted in mouse;CHEMBL3227956;Default value - Target has yet to be curated;U;656173;1;CHEMBL612558;;
CLD0;;W256;CHEMBL3232315;[];Rattus norvegicus;[];;;10116.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307248;Target assigned is non-molecular;1;Cytotoxicity against rat Walker 256 cells assessed as growth inhibition in absence of microsomal activation;CHEMBL3227956;Non-molecular target assigned;N;656196;1;CHEMBL612803;;
CLD0;;W256;CHEMBL3232316;[];Rattus norvegicus;[];;;10116.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307248;Target assigned is non-molecular;1;Cytotoxicity against rat Walker 256 cells assessed as growth inhibition in presence of microsomal activation;CHEMBL3227956;Non-molecular target assigned;N;656206;1;CHEMBL612803;;
CLD0;;L1210;CHEMBL3252496;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 114, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'Spontaneous Autoimmune Diseases In Animals', 'source': 'Vogel_2008'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '50.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '50.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308391;Target assigned is non-molecular;1;Antileukemic activity against mouse L1210 cells allografted in BDF1 mouse assessed as mean survival time at 50 mg/kg, ip administered 24 hrs (Rvb 4.6 +/- 0.16 days);CHEMBL3244168;Non-molecular target assigned;N;669692;1;CHEMBL386;;
CLD0;;L1210;CHEMBL3252924;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 114, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'Spontaneous Autoimmune Diseases In Animals', 'source': 'Vogel_2008'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '100.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '100.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308391;Target assigned is non-molecular;1;Antileukemic activity against mouse L1210 cells allografted in BDF1 mouse assessed as mean survival time at 100 mg/kg, ip administered 24 hrs (Rvb 4.6 +/- 0.16 days);CHEMBL3244168;Non-molecular target assigned;N;669693;1;CHEMBL386;;
CLD0;;L1210;CHEMBL3252926;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 114, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'Spontaneous Autoimmune Diseases In Animals', 'source': 'Vogel_2008'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '200.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '200.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308391;Target assigned is non-molecular;1;Antileukemic activity against mouse L1210 cells allografted in BDF1 mouse assessed as mean survival time at 200 mg/kg, ip administered 24 hrs (Rvb 4.6 +/- 0.16 days);CHEMBL3244168;Non-molecular target assigned;N;669695;1;CHEMBL386;;
CLD0;;L1210;CHEMBL3252927;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 114, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'Spontaneous Autoimmune Diseases In Animals', 'source': 'Vogel_2008'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '400.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '400.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308391;Target assigned is non-molecular;1;Antileukemic activity against mouse L1210 cells allografted in BDF1 mouse assessed as mean survival time at 400 mg/kg, ip administered 24 hrs (Rvb 4.6 +/- 0.16 days);CHEMBL3244168;Non-molecular target assigned;N;669696;1;CHEMBL386;;
CLD0;;L1210;CHEMBL3257083;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 114, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'Spontaneous Autoimmune Diseases In Animals', 'source': 'Vogel_2008'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '50.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '50.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308391;Target assigned is non-molecular;1;Antileukemic activity against mouse L1210 cells allografted in BDF1 mouse assessed as increase in life span at 50 mg/kg, ip administered 24 hrs relative to control;CHEMBL3244168;Non-molecular target assigned;N;669703;1;CHEMBL386;;
CLD0;;L1210;CHEMBL3257084;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 114, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'Spontaneous Autoimmune Diseases In Animals', 'source': 'Vogel_2008'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '100.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '100.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308391;Target assigned is non-molecular;1;Antileukemic activity against mouse L1210 cells allografted in BDF1 mouse assessed as increase in life span at 100 mg/kg, ip administered 24 hrs relative to control;CHEMBL3244168;Non-molecular target assigned;N;669704;1;CHEMBL386;;
CLD0;;L1210;CHEMBL3257519;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 114, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'Spontaneous Autoimmune Diseases In Animals', 'source': 'Vogel_2008'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '200.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '200.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308391;Target assigned is non-molecular;1;Antileukemic activity against mouse L1210 cells allografted in BDF1 mouse assessed as increase in life span at 200 mg/kg, ip administered 24 hrs relative to control;CHEMBL3244168;Non-molecular target assigned;N;669706;1;CHEMBL386;;
CLD0;;L1210;CHEMBL3257520;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 114, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'Spontaneous Autoimmune Diseases In Animals', 'source': 'Vogel_2008'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '400.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '400.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308391;Target assigned is non-molecular;1;Antileukemic activity against mouse L1210 cells allografted in BDF1 mouse assessed as increase in life span at 400 mg/kg, ip administered 24 hrs relative to control;CHEMBL3244168;Non-molecular target assigned;N;669707;1;CHEMBL386;;
CLD0;;L1210;CHEMBL3257525;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 114, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'Spontaneous Autoimmune Diseases In Animals', 'source': 'Vogel_2008'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308391;Target assigned is non-molecular;1;Antileukemic activity against mouse L1210 cells allografted in iv dosed BDF1 mouse assessed as survival over 60 days administered 24 hrs;CHEMBL3244168;Non-molecular target assigned;N;669715;1;CHEMBL386;;
CLD0;;L1210;CHEMBL3257526;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 114, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'Spontaneous Autoimmune Diseases In Animals', 'source': 'Vogel_2008'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308391;Target assigned is non-molecular;1;Antileukemic activity against mouse L1210 cells allografted in ip dosed BDF1 mouse assessed as survival over 60 days administered 24 hrs;CHEMBL3244168;Non-molecular target assigned;N;669717;1;CHEMBL386;;
CLD0;;L1210;CHEMBL3257527;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 114, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'Spontaneous Autoimmune Diseases In Animals', 'source': 'Vogel_2008'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308391;Target assigned is non-molecular;1;Antileukemic activity against mouse L1210 cells allografted in po dosed BDF1 mouse assessed as survival over 60 days administered 24 hrs;CHEMBL3244168;Non-molecular target assigned;N;669718;1;CHEMBL386;;
CLD0;;L1210;CHEMBL3257528;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 114, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'Spontaneous Autoimmune Diseases In Animals', 'source': 'Vogel_2008'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308391;Target assigned is non-molecular;1;Antileukemic activity against mouse L1210 cells allografted in iv dosed BDF1 mouse assessed as maximum tolerated dose for survival over 60 days administered 24 hrs;CHEMBL3244168;Non-molecular target assigned;N;669721;1;CHEMBL386;;
CLD0;;L1210;CHEMBL3257529;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 114, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'Spontaneous Autoimmune Diseases In Animals', 'source': 'Vogel_2008'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308391;Target assigned is non-molecular;1;Antileukemic activity against mouse L1210 cells allografted in ip dosed BDF1 mouse assessed as maximum tolerated dose for survival over 60 days administered 24 hrs;CHEMBL3244168;Non-molecular target assigned;N;669722;1;CHEMBL386;;
CLD0;;L1210;CHEMBL3257530;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 114, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'Spontaneous Autoimmune Diseases In Animals', 'source': 'Vogel_2008'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308391;Target assigned is non-molecular;1;Antileukemic activity against mouse L1210 cells allografted in po dosed BDF1 mouse assessed as maximum tolerated dose for survival over 60 days administered 24 hrs;CHEMBL3244168;Non-molecular target assigned;N;669723;1;CHEMBL386;;
CLD0;;L1210;CHEMBL3257531;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 114, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'Spontaneous Autoimmune Diseases In Animals', 'source': 'Vogel_2008'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308391;Target assigned is non-molecular;1;Ratio of Cmax to Cmin for antileukemic activity against mouse L1210 cells allografted in iv dosed BDF1 mouse assessed as survival over 60 days;CHEMBL3244168;Non-molecular target assigned;N;669734;1;CHEMBL386;;
CLD0;;L1210;CHEMBL3257532;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 114, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'Spontaneous Autoimmune Diseases In Animals', 'source': 'Vogel_2008'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308391;Target assigned is non-molecular;1;Ratio of Cmax to Cmin for antileukemic activity against mouse L1210 cells allografted in ip dosed BDF1 mouse assessed as survival over 60 days;CHEMBL3244168;Non-molecular target assigned;N;669736;1;CHEMBL386;;
CLD0;;L1210;CHEMBL3257533;[{'assay_class_id': 87, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'General Leukemia', 'source': 'phenotype'}, {'assay_class_id': 114, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'Spontaneous Autoimmune Diseases In Animals', 'source': 'Vogel_2008'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308391;Target assigned is non-molecular;1;Ratio of Cmax to Cmin for antileukemic activity against mouse L1210 cells allografted in po dosed BDF1 mouse assessed as survival over 60 days;CHEMBL3244168;Non-molecular target assigned;N;669737;1;CHEMBL386;;
CLD0;;P388;CHEMBL3252590;[{'assay_class_id': 89, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'P388 Experimental Leukemia', 'source': 'phenotype'}, {'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308401;Target assigned is non-molecular;1;Antitumor activity against mouse P388 cells allografted in ip dosed mouse assessed as minimum effective dose administered as single dose;CHEMBL3244336;Non-molecular target assigned;N;667312;1;CHEMBL389;;
CLD0;;P388;CHEMBL3253039;[{'assay_class_id': 89, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'P388 Experimental Leukemia', 'source': 'phenotype'}, {'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308401;Target assigned is non-molecular;1;Antitumor activity against mouse P388 cells allografted in ip dosed mouse assessed as minimum effective dose administered as once each 4 days for 3 total injection;CHEMBL3244336;Non-molecular target assigned;N;667313;1;CHEMBL389;;
CLD0;;P388;CHEMBL3253040;[{'assay_class_id': 89, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'P388 Experimental Leukemia', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;T;Toxicity;BAO_0000218;organism-based format;CHEMBL3308401;Target assigned is non-molecular;1;Toxicity in mouse P388 cells allografted ip dosed mouse assessed as maximum tolerated dose administered as single dose;CHEMBL3244336;Non-molecular target assigned;N;667314;1;CHEMBL375;;
CLD0;;P388;CHEMBL3253041;[{'assay_class_id': 89, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'P388 Experimental Leukemia', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;T;Toxicity;BAO_0000218;organism-based format;CHEMBL3308401;Target assigned is non-molecular;1;Toxicity in mouse P388 cells allografted ip dosed mouse assessed as maximum tolerated dose administered as once each 4 days for 3 total injection;CHEMBL3244336;Non-molecular target assigned;N;667315;1;CHEMBL375;;
CLD0;;P388;CHEMBL3253042;[{'assay_class_id': 89, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'P388 Experimental Leukemia', 'source': 'phenotype'}, {'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308401;Target assigned is non-molecular;1;Antitumor activity against mouse P388 cells allografted in ip dosed mouse assessed as dose providing 40% increase in life span administered as single dose;CHEMBL3244336;Non-molecular target assigned;N;667317;1;CHEMBL389;;
CLD0;;P388;CHEMBL3253043;[{'assay_class_id': 89, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Leukemia Oncology Models', 'l3': 'P388 Experimental Leukemia', 'source': 'phenotype'}, {'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308401;Target assigned is non-molecular;1;Antitumor activity against mouse P388 cells allografted in ip dosed mouse assessed as dose providing 40% increase in life span administered as once each 4 days for 3 total injection;CHEMBL3244336;Non-molecular target assigned;N;667318;1;CHEMBL389;;
CLD0;;P388;CHEMBL3253044;[];Mus musculus;[];;;10090.0;;;A;ADME;BAO_0000218;organism-based format;CHEMBL3308401;Default value - Target unknown or has yet to be assigned;0;Therapeutic index, ratio of MTD for mouse P388 cells allografted ip dosed mouse to MED for mouse P388 cells allografted in ip dosed mouse administered as single dose;CHEMBL3244336;Default value - Target has yet to be curated;U;667321;1;CHEMBL612558;;
CLD0;;P388;CHEMBL3253045;[];Mus musculus;[];;;10090.0;;;A;ADME;BAO_0000218;organism-based format;CHEMBL3308401;Default value - Target unknown or has yet to be assigned;0;Therapeutic index, ratio of MTD for mouse P388 cells allografted ip dosed mouse to MED for mouse P388 cells allografted in ip dosed mouse administered as once each 4 days for 3 total injection;CHEMBL3244336;Default value - Target has yet to be curated;U;667322;1;CHEMBL612558;;
CLD0;;;CHEMBL3285886;[];;[];;;;;;P;Physicochemical;BAO_0000100;small-molecule physicochemical format;;Default value - Target unknown or has yet to be assigned;0;Octanol-water partition coefficient, log P of the compound;CHEMBL3272203;Default value - Target has yet to be curated;U;668743;1;CHEMBL2362975;;
CLD0;;;CHEMBL3301365;[];Homo sapiens;[];;;9606.0;In vitro;Plasma;A;ADME;BAO_0000366;cell-free format;;Default value - Target unknown or has yet to be assigned;0;ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole human plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.;CHEMBL3301361;Default value - Target has yet to be curated;U;4;27;CHEMBL612558;CHEMBL3559721;
CLD0;;;CHEMBL3301366;[];Rattus norvegicus;[];SD, HW or BN;;10116.0;In vitro;Plasma;A;ADME;BAO_0000366;cell-free format;;Default value - Target unknown or has yet to be assigned;0;ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole rat plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.;CHEMBL3301361;Default value - Target has yet to be curated;U;5;27;CHEMBL612558;CHEMBL3559721;
CLD0;;H22;CHEMBL3383273;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Homo sapiens;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '30.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '30.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intravenous', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intravenous', 'type': 'ROUTE', 'units': None, 'value': None}];;;9606.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307751;Target assigned is non-molecular;1;Antitumor activity against human H22 cells transplanted in ICR mouse assessed as tumor growth inhibition at 30 mg/kg, iv administered 7 days post tumor transplantation;CHEMBL3351759;Non-molecular target assigned;N;711030;1;CHEMBL614998;;
CLD0;;H22;CHEMBL3383277;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '30.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '30.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intravenous', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intravenous', 'type': 'ROUTE', 'units': None, 'value': None}];ICR;;10090.0;;;T;Toxicity;BAO_0000218;organism-based format;CHEMBL3307751;Target assigned is non-molecular;1;Toxicity in human H22 cells transplanted ICR mouse assessed as mouse survival at 30 mg/kg, iv administered 7 days post tumor transplantation;CHEMBL3351759;Non-molecular target assigned;N;711034;1;CHEMBL375;;
CLD0;;H22;CHEMBL3383279;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '30.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '30.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intravenous', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intravenous', 'type': 'ROUTE', 'units': None, 'value': None}];ICR;;10090.0;;;T;Toxicity;BAO_0000218;organism-based format;CHEMBL3307751;Target assigned is non-molecular;1;Toxicity in human H22 cells transplanted ICR mouse assessed as mouse body weight at 30 mg/kg, iv administered 7 days post tumor transplantation (Rvb = 18.1 +/- 1g);CHEMBL3351759;Non-molecular target assigned;N;711037;1;CHEMBL375;;
CLD0;;H22;CHEMBL3377228;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}, {'assay_class_id': 119, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Xenograft Oncology Models', 'l3': 'Xenograft Models of Anti-Tumor Assays', 'source': 'phenotype'}];Homo sapiens;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '30.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '30.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intravenous', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intravenous', 'type': 'ROUTE', 'units': None, 'value': None}];;;9606.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307751;Target assigned is non-molecular;1;Antitumor activity against human H22 cells xenografted in ICR mouse assessed as tumor growth inhibition at 30 mg/kg, iv administered 7 days post inoculation measured at day 25 of tumor transplantation;CHEMBL3352575;Non-molecular target assigned;N;723213;1;CHEMBL614998;;
CLD0;;CCRF S-180;CHEMBL3366072;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '40.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '40.0'}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307278;Target assigned is non-molecular;1;Antitumor activity against mouse S180 cells implanted in mouse assessed as inhibition of tumor growth at 40 mg/kg;CHEMBL3352306;Non-molecular target assigned;N;703169;1;CHEMBL612567;;
CLD0;;;CHEMBL3411289;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000357;single protein format;;Direct single protein target assigned;9;Stimulation of human OATP1B1-mediated [3H]estrone 3-sulfate at 100 uM after 5 mins relative to control;CHEMBL3407465;Direct protein target assigned;D;732528;1;CHEMBL1697668;;
CLD0;;;CHEMBL3411293;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000357;single protein format;;Direct single protein target assigned;9;Stimulation of human OATP1B3-mediated [3H]CCK-8 at 100 uM after 5 mins relative to control;CHEMBL3407465;Direct protein target assigned;D;732533;1;CHEMBL1743121;;
CLD0;;HT-29;CHEMBL3418965;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}, {'assay_class_id': 119, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Xenograft Oncology Models', 'l3': 'Xenograft Models of Anti-Tumor Assays', 'source': 'phenotype'}];Homo sapiens;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '30.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '30.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;9606.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307768;Target assigned is non-molecular;1;Antitumor activity against human HT-29 cells xenografted in BALB/c mouse assessed as reduction in tumor volume at 30 mg/kg, ip administered once daily for 18 days;CHEMBL3414539;Non-molecular target assigned;N;737543;1;CHEMBL384;;
CLD0;;HT-29;CHEMBL3418968;[];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '30.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '30.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];BALB/c;;10090.0;;;T;Toxicity;BAO_0000218;organism-based format;CHEMBL3307768;Target assigned is non-molecular;1;Toxicity in human HT-29 cells xenografted BALB/c mouse assessed as change in body weight at 30 mg/kg, ip administered once daily for 18 days (Rvb = 2.5 g);CHEMBL3414539;Non-molecular target assigned;N;737549;1;CHEMBL375;;
CLD0;;Lewis lung carcinoma cell line;CHEMBL3420835;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '60.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '60.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307859;Target assigned is non-molecular;1;Antitumor activity against mouse LLC cells allografted in C57BL/6 mouse assessed as tumor growth inhibition at 60 mg/kg, ip administerd for 14 days measured on day 15 relative to control;CHEMBL3414479;Non-molecular target assigned;N;739109;1;CHEMBL614088;;
CLD0;;H22;CHEMBL3428018;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}, {'assay_class_id': 119, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Xenograft Oncology Models', 'l3': 'Xenograft Models of Anti-Tumor Assays', 'source': 'phenotype'}];Homo sapiens;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '30.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '30.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;9606.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307751;Target assigned is non-molecular;1;In vivo antitumor activity against human H22 cells xenografted in mouse assessed as tumor growth inhibitory ratio at 30 mg/kg, ip administered after 7 days of tumor transplantation measured at 25th day after tumor inoculation;CHEMBL3425458;Non-molecular target assigned;N;742878;1;CHEMBL614998;;
CLD0;;H22;CHEMBL3428020;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}, {'assay_class_id': 119, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Xenograft Oncology Models', 'l3': 'Xenograft Models of Anti-Tumor Assays', 'source': 'phenotype'}];Mus musculus;[{'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'DOSE', 'standard_type_fixed': 0, 'standard_units': 'mg.kg-1', 'standard_value': '30.0', 'text_value': None, 'type': 'DOSE', 'units': 'mg/kg', 'value': '30.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Intraperitoneal', 'standard_type': 'ROUTE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Intraperitoneal', 'type': 'ROUTE', 'units': None, 'value': None}];;;10090.0;;;T;Toxicity;BAO_0000218;organism-based format;CHEMBL3307751;Target assigned is non-molecular;1;Toxicity against mouse xenografted with human H22 cells assessed as body weight at 30 mg/kg, ip administered after 7 days of tumor transplantation (Rvb = 18.1 to 18.6 gms);CHEMBL3425458;Non-molecular target assigned;N;742880;1;CHEMBL375;;
CLD0;confirmatory;;CHEMBL3562036;[];;[];;;;;;F;Functional;BAO_0000019;assay format;;Default value - Target unknown or has yet to be assigned;0;PubChem BioAssay. Immunotoxin (HA22) sensitization/mitigation study - treatment arm (High Dose).   (Class of assay: confirmatory) ;CHEMBL1201862;Default value - Target has yet to be curated;U;1159530;7;CHEMBL612545;;
CLD0;confirmatory;;CHEMBL3562064;[];;[];;;;;;F;Functional;BAO_0000019;assay format;;Default value - Target unknown or has yet to be assigned;0;PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel.   (Class of assay: confirmatory) ;CHEMBL1201862;Default value - Target has yet to be curated;U;1117314;7;CHEMBL612545;;
CLD0;confirmatory;;CHEMBL3562088;[];;[];;;;;;F;Functional;BAO_0000019;assay format;;Default value - Target unknown or has yet to be assigned;0;PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, green channel.   (Class of assay: confirmatory) ;CHEMBL1201862;Default value - Target has yet to be curated;U;1117315;7;CHEMBL612545;;
CLD0;confirmatory;;CHEMBL3562112;[];;[];;;;;;F;Functional;BAO_0000019;assay format;;Default value - Target unknown or has yet to be assigned;0;PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, blue channel.   (Class of assay: confirmatory) ;CHEMBL1201862;Default value - Target has yet to be curated;U;1117311;7;CHEMBL612545;;
CLD0;confirmatory;;CHEMBL3562133;[];;[];;;;;;F;Functional;BAO_0000019;assay format;;Default value - Target unknown or has yet to be assigned;0;PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen1 green channel.   (Class of assay: confirmatory) ;CHEMBL1201862;Default value - Target has yet to be curated;U;1117302;7;CHEMBL612545;;
CLD0;confirmatory;;CHEMBL3562135;[];;[];;;;;;F;Functional;BAO_0000019;assay format;;Default value - Target unknown or has yet to be assigned;0;PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 blue channel.   (Class of assay: confirmatory) ;CHEMBL1201862;Default value - Target has yet to be curated;U;1117301;7;CHEMBL612545;;
CLD0;confirmatory;;CHEMBL3562136;[];;[];;;;;;F;Functional;BAO_0000019;assay format;;Default value - Target unknown or has yet to be assigned;0;PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel.   (Class of assay: confirmatory) ;CHEMBL1201862;Default value - Target has yet to be curated;U;1117304;7;CHEMBL612545;;
CLD0;;;CHEMBL3582837;[];Mus musculus;[];KM;;10090.0;;Blood;T;Toxicity;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Toxicity in KM mouse assessed as peripheral WBC number in blood per liter at 60 mg/kg, po single dose after 48 hrs (Rvb = 11.10 x 2.69/L x 10'-9);CHEMBL3580594;Non-molecular target assigned;N;745441;1;CHEMBL375;CHEMBL3638178;
CLD0;;Erythrocyte;CHEMBL3582841;[];Mus musculus;[];KM;;10090.0;;;T;Toxicity;BAO_0000218;organism-based format;CHEMBL3833281;Target assigned is non-molecular;1;Toxicity in KM mouse assessed as micronucleus frequency in bone marrow polychromatic erythrocyte at 60 mg/kg, po single dose after 48 hrs (Rvb = 2.20 +/- 0.84 %);CHEMBL3580594;Non-molecular target assigned;N;745446;1;CHEMBL375;;
CLD0;;;CHEMBL3582845;[];Mus musculus;[];KM;;10090.0;;Blood;T;Toxicity;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Toxicity in KM mouse assessed as peripheral WBC number in blood per liter at 30 mg/kg/day, po 5 doses (Rvb = 7.47 +/- 33.77 /L x 10'-9 cells);CHEMBL3580594;Non-molecular target assigned;N;745451;1;CHEMBL375;CHEMBL3638178;
CLD0;;Erythrocyte;CHEMBL3582849;[];Mus musculus;[];KM;;10090.0;;;T;Toxicity;BAO_0000218;organism-based format;CHEMBL3833281;Target assigned is non-molecular;1;Toxicity in KM mouse assessed as micronucleus frequency in bone marrow polychromatic erythrocyte at 30 mg/kg, po single dose after 48 hrs (Rvb = 1.20 +/- 0.45 %);CHEMBL3580594;Non-molecular target assigned;N;745456;1;CHEMBL375;;
CLD0;;CT26;CHEMBL3587742;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308079;Target assigned is non-molecular;1;Antitumor activity against mouse CT26 cells implanted in mouse assessed as tumor growth inhibition at 114.9 umol/kg, ip qd administered for 7 days starting 24 hrs post tumor implantation measured after day 21 relative to control;CHEMBL3585290;Non-molecular target assigned;N;750119;1;CHEMBL613866;;
CLD0;;Lewis lung carcinoma cell line;CHEMBL3587852;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307859;Target assigned is non-molecular;1;Antitumor activity against mouse LLC cells implanted in mouse assessed as tumor growth inhibition at 114.9 umol/kg, ip qd administered for 7 days starting 24 hrs post tumor implantation measured after day 21 relative to control;CHEMBL3585290;Non-molecular target assigned;N;750126;1;CHEMBL614088;;
CLD0;;Bone marrow cell;CHEMBL3737302;[];Mus musculus;[];Kunming;;10090.0;;;T;Toxicity;BAO_0000219;cell-based format;CHEMBL3833841;Default value - Target unknown or has yet to be assigned;0;Mutagenicity in Kunming mouse bone marrow cells assessed as micronucleated polychromatic erythrocytes level at 0.1 g/kg by May-Grunwald-Giemsa staining-based microscopic analysis (Rvb = 3.2 +/- 1.62 No_unit );CHEMBL3734751;Default value - Target has yet to be curated;U;780020;1;CHEMBL612558;;
CLD0;;Bone marrow cell;CHEMBL3737306;[];Mus musculus;[];Kunming;;10090.0;;;T;Toxicity;BAO_0000219;cell-based format;CHEMBL3833841;Default value - Target unknown or has yet to be assigned;0;Mutagenicity in Kunming mouse bone marrow cells assessed as ratio of polychromatic erythrocyte level to norchromatic erythrocyte level at 0.1 g/kg by May-Grunwald-Giemsa staining-based microscopic analysis (Rvb = 1.32 +/- 0.22 No_unit );CHEMBL3734751;Default value - Target has yet to be curated;U;780031;1;CHEMBL612558;;
CLD0;;;CHEMBL3788634;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;First order inter-compartment transfer rate constant from central to peripheral compartment in iv dosed patient (7 patients) with renal insufficiency;CHEMBL3785078;Non-molecular target assigned;N;821949;1;CHEMBL372;;
CLD0;;;CHEMBL3788635;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Drug excretion in human assessed as unchanged parent compound level;CHEMBL3785078;Non-molecular target assigned;N;821932;1;CHEMBL372;;
CLD0;;;CHEMBL3788636;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Disposition rate constant in iv dosed patient (7 patients) with renal insufficiency;CHEMBL3785078;Non-molecular target assigned;N;821933;1;CHEMBL372;;
CLD0;;;CHEMBL3788637;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Terminal half life in iv dosed patient (7 patients) with renal insufficiency;CHEMBL3785078;Non-molecular target assigned;N;821934;1;CHEMBL372;;
CLD0;;;CHEMBL3788638;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Apparent volume of distribution in beta-phase in iv dosed patient (7 patients) with renal insufficiency;CHEMBL3785078;Non-molecular target assigned;N;821935;1;CHEMBL372;;
CLD0;;;CHEMBL3788639;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Apparent volume of distribution at central compartment in iv dosed patient (7 patients) with renal insufficiency;CHEMBL3785078;Non-molecular target assigned;N;821936;1;CHEMBL372;;
CLD0;;;CHEMBL3788640;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Apparent volume of distribution at steady state in iv dosed patient (7 patients) with renal insufficiency;CHEMBL3785078;Non-molecular target assigned;N;821937;1;CHEMBL372;;
CLD0;;;CHEMBL3788641;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Total body clearance in iv dosed patient (7 patients) with renal insufficiency;CHEMBL3785078;Non-molecular target assigned;N;821938;1;CHEMBL372;;
CLD0;;;CHEMBL3788642;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Disposition rate constant in patient (7 patients) with renal insufficiency at 350 mg/kg, po;CHEMBL3785078;Non-molecular target assigned;N;821939;1;CHEMBL372;;
CLD0;;;CHEMBL3788643;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Terminal half life in patient (7 patients) with renal insufficiency at 350 mg/kg, po;CHEMBL3785078;Non-molecular target assigned;N;821940;1;CHEMBL372;;
CLD0;;;CHEMBL3788644;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Disposition rate constant in patient (7 patients) with renal insufficiency at 50 mg/kg, po;CHEMBL3785078;Non-molecular target assigned;N;821941;1;CHEMBL372;;
CLD0;;;CHEMBL3788645;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Terminal half life in patient (7 patients) with renal insufficiency at 50 mg/kg, po;CHEMBL3785078;Non-molecular target assigned;N;821942;1;CHEMBL372;;
CLD0;;;CHEMBL3788646;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Disposition rate constant in iv dosed patient with normal renal function;CHEMBL3785078;Non-molecular target assigned;N;821943;1;CHEMBL372;;
CLD0;;;CHEMBL3788647;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Terminal half life in iv dosed patient with normal renal function;CHEMBL3785078;Non-molecular target assigned;N;821944;1;CHEMBL372;;
CLD0;;;CHEMBL3788648;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Apparent volume of distribution in beta-phase iv dosed patient with normal renal function;CHEMBL3785078;Non-molecular target assigned;N;821945;1;CHEMBL372;;
CLD0;;;CHEMBL3788649;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Apparent volume of distribution at central compartment in iv dosed patient with normal renal function;CHEMBL3785078;Non-molecular target assigned;N;821946;1;CHEMBL372;;
CLD0;;;CHEMBL3788650;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Apparent volume of distribution at steady state in iv dosed patient with normal renal function;CHEMBL3785078;Non-molecular target assigned;N;821947;1;CHEMBL372;;
CLD0;;;CHEMBL3788651;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Total body clearance in iv dosed patient with normal renal function;CHEMBL3785078;Non-molecular target assigned;N;821948;1;CHEMBL372;;
CLD0;;;CHEMBL3788652;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;First order inter-compartment transfer rate constant from peripheral to central compartment in iv dosed patient (7 patients) with renal insufficiency;CHEMBL3785078;Non-molecular target assigned;N;821950;1;CHEMBL372;;
CLD0;;;CHEMBL3788653;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Apparent first order elimination rate constant from the central compartment in iv dosed patient (7 patients) with renal insufficiency;CHEMBL3785078;Non-molecular target assigned;N;821951;1;CHEMBL372;;
CLD0;;;CHEMBL3788654;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;First order inter-compartment transfer rate constant from central to peripheral compartment in iv dosed patient with normal renal function;CHEMBL3785078;Non-molecular target assigned;N;821952;1;CHEMBL372;;
CLD0;;;CHEMBL3788909;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;First order inter-compartment transfer rate constant from peripheral to central compartment in iv dosed patient with normal renal function;CHEMBL3785078;Non-molecular target assigned;N;821953;1;CHEMBL372;;
CLD0;;;CHEMBL3788910;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Apparent first order elimination rate constant from the central compartment in iv dosed patient with normal renal function;CHEMBL3785078;Non-molecular target assigned;N;821954;1;CHEMBL372;;
CLD0;;;CHEMBL3788911;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Plasma alkylating activity in patient (7 patients) with renal insufficiency assessed as elimination rate constant for total NBP alkylating activity at 300 mg/kg by NBP based colorimetric assay;CHEMBL3785078;Non-molecular target assigned;N;821955;1;CHEMBL372;;
CLD0;;;CHEMBL3788912;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Plasma alkylating activity in patient (7 patients) with renal insufficiency assessed as half life for total NBP alkylating activity at 300 mg/kg by NBP based colorimetric assay;CHEMBL3785078;Non-molecular target assigned;N;821956;1;CHEMBL372;;
CLD0;;;CHEMBL3788913;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Plasma alkylating activity in patient (7 patients) with renal insufficiency assessed as AUC for total NBP alkylating activity at 300 mg/kg by NBP based colorimetric assay;CHEMBL3785078;Non-molecular target assigned;N;821957;1;CHEMBL372;;
CLD0;;;CHEMBL3788914;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Plasma alkylating activity in patient with normal renal function assessed as elimination rate constant for total NBP alkylating activity at 300 mg/kg by NBP based colorimetric assay;CHEMBL3785078;Non-molecular target assigned;N;821958;1;CHEMBL372;;
CLD0;;;CHEMBL3788915;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Plasma alkylating activity in patient with normal renal function assessed as half life for total NBP alkylating activity at 300 mg/kg by NBP based colorimetric assay;CHEMBL3785078;Non-molecular target assigned;N;821959;1;CHEMBL372;;
CLD0;;;CHEMBL3788916;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Plasma alkylating activity in patient with normal renal function assessed as AUC for total NBP alkylating activity at 300 mg/kg by NBP based colorimetric assay;CHEMBL3785078;Non-molecular target assigned;N;821960;1;CHEMBL372;;
CLD0;;;CHEMBL3788921;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Drug elimination in patient (5 patients) with severe renal insufficiency using 14C labeled compound measured over 72 hrs;CHEMBL3785078;Non-molecular target assigned;N;821965;1;CHEMBL372;;
CLD0;;;CHEMBL3788922;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Drug elimination in patient with normal renal function using 14C labeled compound measured over 72 hrs;CHEMBL3785078;Non-molecular target assigned;N;821966;1;CHEMBL372;;
CLD0;;;CHEMBL3788923;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Half life in patient (5 patients) with severe renal insufficiency assessed as unchanged compound level using 14C labeled compound measured over 72 hrs;CHEMBL3785078;Non-molecular target assigned;N;821967;1;CHEMBL372;;
CLD0;;;CHEMBL3788924;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Half life in patient with normal renal function assessed as unchanged compound level using 14C labeled compound measured over 72 hrs;CHEMBL3785078;Non-molecular target assigned;N;821968;1;CHEMBL372;;
CLD0;;;CHEMBL3790802;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000019;assay format;;Default value - Target unknown or has yet to be assigned;0;Drug recovery in dialysate of patient (6 patients) with hemodialysis-dependent end-stage renal disease at 1.2 +/- 0.4 g/m'2 administered as pulse therapy with 1 hr infusion followed by hemodialysis for 3 hrs started 7 hrs post dose measured during hemodialysis treatment by HPLC analysis;CHEMBL3784959;Default value - Target has yet to be curated;U;821465;1;CHEMBL612558;;
CLD0;;;CHEMBL3790803;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;AUC (0 to infinity) in patient ( 12 patients) with normal renal function at 0.83 +/- 0.05 g/m'2 administered as pulse therapy with 1 hr infusion by HPLC analysis;CHEMBL3784959;Non-molecular target assigned;N;821469;1;CHEMBL372;;
CLD0;;;CHEMBL3790804;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;AUC (0 to infinity) in patient (6 patients) with moderate renal insufficiency at 1.4 +/- 0.1 g/m'2 administered as pulse therapy with 1 hr infusion by HPLC analysis;CHEMBL3784959;Non-molecular target assigned;N;821470;1;CHEMBL372;;
CLD0;;;CHEMBL3790805;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;AUC (0 to infinity) in patient (6 patients) with severe renal insufficiency at 1.1 +/- 0.2 g/m'2 administered as pulse therapy with 1 hr infusion by HPLC analysis;CHEMBL3784959;Non-molecular target assigned;N;821471;1;CHEMBL372;;
CLD0;;;CHEMBL3790806;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Elimination half life in patient ( 12 patients) with normal renal function at 0.83 +/- 0.05 g/m'2 administered as pulse therapy with 1 hr infusion by HPLC analysis;CHEMBL3784959;Non-molecular target assigned;N;821474;1;CHEMBL372;;
CLD0;;;CHEMBL3790807;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;AUC (0 to infinity) in patient (6 patients) with hemodialysis-dependent end-stage renal disease at 1.2 +/- 0.4 g/m'2 administered as pulse therapy with 1 hr infusion followed by hemodialysis for 3 hrs started 7 hrs post dose measured during hemodialysis treatment by HPLC analysis;CHEMBL3784959;Non-molecular target assigned;N;821473;1;CHEMBL372;;
CLD0;;;CHEMBL3790808;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Elimination half life in patient (6 patients) with moderate renal insufficiency at 1.4 +/- 0.1 g/m'2 administered as pulse therapy with 1 hr infusion by HPLC analysis;CHEMBL3784959;Non-molecular target assigned;N;821475;1;CHEMBL372;;
CLD0;;;CHEMBL3790809;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Elimination half life in patient (6 patients) with severe renal insufficiency at 1.1 +/- 0.2 g/m'2 administered as pulse therapy with 1 hr infusion by HPLC analysis;CHEMBL3784959;Non-molecular target assigned;N;821476;1;CHEMBL372;;
CLD0;;;CHEMBL3790810;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Elimination half life in patient (6 patients) with hemodialysis-dependent end-stage renal disease at 1.2 +/- 0.4 g/m'2 administered as pulse therapy with 1 hr infusion followed by hemodialysis for 3 hrs started 7 hrs post dose measured during hemodialysis treatment by HPLC analysis;CHEMBL3784959;Non-molecular target assigned;N;821477;1;CHEMBL372;;
CLD0;;;CHEMBL3790811;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Systemic clearance in patient ( 12 patients) with normal renal function at 0.83 +/- 0.05 g/m'2 administered as pulse therapy with 1 hr infusion by HPLC analysis;CHEMBL3784959;Non-molecular target assigned;N;821478;1;CHEMBL372;;
CLD0;;;CHEMBL3790812;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Systemic clearance in patient (6 patients) with moderate renal insufficiency at 1.4 +/- 0.1 g/m'2 administered as pulse therapy with 1 hr infusion by HPLC analysis;CHEMBL3784959;Non-molecular target assigned;N;821479;1;CHEMBL372;;
CLD0;;;CHEMBL3791045;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Systemic clearance in patient (6 patients) with severe renal insufficiency at 1.1 +/- 0.2 g/m'2 administered as pulse therapy with 1 hr infusion by HPLC analysis;CHEMBL3784959;Non-molecular target assigned;N;821480;1;CHEMBL372;;
CLD0;;;CHEMBL3788258;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Systemic clearance in patient (6 patients) with hemodialysis-dependent end-stage renal disease at 1.2 +/- 0.4 g/m'2 administered as pulse therapy with 1 hr infusion followed by hemodialysis for 3 hrs started 7 hrs post dose measured during hemodialysis treatment by HPLC analysis;CHEMBL3784959;Non-molecular target assigned;N;821481;1;CHEMBL372;;
CLD0;;;CHEMBL3788259;[];Homo sapiens;[];;;9606.0;;Urine;A;ADME;BAO_0000221;tissue-based format;;Default value - Target unknown or has yet to be assigned;0;Drug excretion in urine of patient ( 12 patients) with normal renal function at 0.83 +/- 0.05 g/m'2 administered as pulse therapy with 1 hr infusion by HPLC analysis;CHEMBL3784959;Default value - Target has yet to be curated;U;821483;1;CHEMBL612558;CHEMBL3638201;
CLD0;;;CHEMBL3788260;[];Homo sapiens;[];;;9606.0;;Urine;A;ADME;BAO_0000221;tissue-based format;;Default value - Target unknown or has yet to be assigned;0;Drug excretion in urine of patient (6 patients) with moderate renal insufficiency at 1.4 +/- 0.1 g/m'2 administered as pulse therapy with 1 hr infusion by HPLC analysis;CHEMBL3784959;Default value - Target has yet to be curated;U;821484;1;CHEMBL612558;CHEMBL3638201;
CLD0;;;CHEMBL3788261;[];Homo sapiens;[];;;9606.0;;Urine;A;ADME;BAO_0000221;tissue-based format;;Default value - Target unknown or has yet to be assigned;0;Drug excretion in urine of patient (6 patients) with severe renal insufficiency at 1.1 +/- 0.2 g/m'2 administered as pulse therapy with 1 hr infusion by HPLC analysis;CHEMBL3784959;Default value - Target has yet to be curated;U;821486;1;CHEMBL612558;CHEMBL3638201;
CLD0;;;CHEMBL3788262;[];Homo sapiens;[];;;9606.0;;Urine;A;ADME;BAO_0000221;tissue-based format;;Default value - Target unknown or has yet to be assigned;0;Drug excretion in urine of patient (6 patients) with hemodialysis-dependent end-stage renal disease at 1.2 +/- 0.4 g/m'2 administered as pulse therapy with 1 hr infusion followed by hemodialysis for 3 hrs started 7 hrs post dose measured during hemodialysis treatment by HPLC analysis;CHEMBL3784959;Default value - Target has yet to be curated;U;821488;1;CHEMBL612558;CHEMBL3638201;
CLD0;;;CHEMBL3788263;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Volume of distribution at steady state in patient ( 12 patients) with normal renal function at 0.83 +/- 0.05 g/m'2 administered as pulse therapy with 1 hr infusion by HPLC analysis;CHEMBL3784959;Non-molecular target assigned;N;821489;1;CHEMBL372;;
CLD0;;;CHEMBL3788264;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Volume of distribution at steady state in patient (6 patients) with moderate renal insufficiency at 1.4 +/- 0.1 g/m'2 administered as pulse therapy with 1 hr infusion by HPLC analysis;CHEMBL3784959;Non-molecular target assigned;N;821490;1;CHEMBL372;;
CLD0;;;CHEMBL3788265;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Volume of distribution at steady state in patient (6 patients) with severe renal insufficiency at 1.1 +/- 0.2 g/m'2 administered as pulse therapy with 1 hr infusion by HPLC analysis;CHEMBL3784959;Non-molecular target assigned;N;821491;1;CHEMBL372;;
CLD0;;;CHEMBL3788266;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Volume of distribution at steady state in patient (6 patients) with hemodialysis-dependent end-stage renal disease at 1.2 +/- 0.4 g/m'2 administered as pulse therapy with 1 hr infusion followed by hemodialysis for 3 hrs started 7 hrs post dose measured during hemodialysis treatment by HPLC analysis;CHEMBL3784959;Non-molecular target assigned;N;821493;1;CHEMBL372;;
CLD0;;;CHEMBL3788267;[];Homo sapiens;[];;;9606.0;;Kidney;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Renal clearance in patient ( 12 patients) with normal renal function at 0.83 +/- 0.05 g/m'2 administered as pulse therapy with 1 hr infusion by HPLC analysis;CHEMBL3784959;Non-molecular target assigned;N;821495;1;CHEMBL372;CHEMBL3638241;
CLD0;;;CHEMBL3788268;[];Homo sapiens;[];;;9606.0;;Kidney;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Renal clearance in patient (6 patients) with moderate renal insufficiency at 1.4 +/- 0.1 g/m'2 administered as pulse therapy with 1 hr infusion by HPLC analysis;CHEMBL3784959;Non-molecular target assigned;N;821496;1;CHEMBL372;CHEMBL3638241;
CLD0;;;CHEMBL3788269;[];Homo sapiens;[];;;9606.0;;Kidney;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Renal clearance in patient (6 patients) with severe renal insufficiency at 1.1 +/- 0.2 g/m'2 administered as pulse therapy with 1 hr infusion by HPLC analysis;CHEMBL3784959;Non-molecular target assigned;N;821497;1;CHEMBL372;CHEMBL3638241;
CLD0;;;CHEMBL3788270;[];Homo sapiens;[];;;9606.0;;Kidney;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Renal clearance in patient (6 patients) with hemodialysis-dependent end-stage renal disease at 1.2 +/- 0.4 g/m'2 administered as pulse therapy with 1 hr infusion followed by hemodialysis for 3 hrs started 7 hrs post dose measured during hemodialysis treatment by HPLC analysis;CHEMBL3784959;Non-molecular target assigned;N;821498;1;CHEMBL372;CHEMBL3638241;
CLD0;;;CHEMBL3788271;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Default value - Target unknown or has yet to be assigned;0;Drug excretion in dialysate of patient (4 patients) with chronic renal failure at 100 mg, iv administered over 10 mins followed by hemodialysis for 4 hrs measured during hemodialysis treatment by GLC analysis;CHEMBL3784959;Default value - Target has yet to be curated;U;821512;1;CHEMBL612558;;
CLD0;;;CHEMBL3788272;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Default value - Target unknown or has yet to be assigned;0;Drug recovery in dialysate of patient (4 patients) with chronic renal failure at 100 mg, iv administered over 10 mins followed by hemodialysis for 6 hrs measured during hemodialysis treatment by GLC analysis;CHEMBL3784959;Default value - Target has yet to be curated;U;821514;1;CHEMBL612558;;
CLD0;;;CHEMBL3788273;[];Homo sapiens;[];;;9606.0;;Urine;A;ADME;BAO_0000221;tissue-based format;;Default value - Target unknown or has yet to be assigned;0;Drug recovery in normal human urine;CHEMBL3784959;Default value - Target has yet to be curated;U;821519;1;CHEMBL612558;CHEMBL3638201;
CLD0;;;CHEMBL3788305;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;First order rate constant for rapid dissolution phase in iv dosed lymphoma patient (6 patients) by two-compartmental open model;CHEMBL3785022;Non-molecular target assigned;N;822102;1;CHEMBL372;;
CLD0;;;CHEMBL3788306;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;First order rate constant for slow elimination phase in iv dosed lymphoma patient (6 patients) by two-compartmental open model;CHEMBL3785022;Non-molecular target assigned;N;822113;1;CHEMBL372;;
CLD0;;;CHEMBL3788307;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Elimination half life in iv dosed lymphoma patient (6 patients) by two-compartmental open model;CHEMBL3785022;Non-molecular target assigned;N;822116;1;CHEMBL372;;
CLD0;;;CHEMBL3788308;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Apparent volume of distribution of central compartment in iv dosed lymphoma patient (6 patients) by two-compartmental open model;CHEMBL3785022;Non-molecular target assigned;N;822118;1;CHEMBL372;;
CLD0;;;CHEMBL3788309;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Apparent volume of distribution during terminal log-linear elimination phase in iv dosed lymphoma patient (6 patients) by two-compartmental open model;CHEMBL3785022;Non-molecular target assigned;N;822120;1;CHEMBL372;;
CLD0;;;CHEMBL3788310;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;First order inter-compartment transfer rate constant from peripheral to central compartment in iv dosed lymphoma patient (6 patients) by two-compartmental open model;CHEMBL3785022;Non-molecular target assigned;N;822217;1;CHEMBL372;;
CLD0;;;CHEMBL3788311;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;First order inter-compartment transfer rate constant from central to peripheral compartment in iv dosed lymphoma patient (6 patients) by two-compartmental open model;CHEMBL3785022;Non-molecular target assigned;N;822218;1;CHEMBL372;;
CLD0;;;CHEMBL3788312;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Elimination rate constant from central compartment in iv dosed lymphoma patient (6 patients) by two-compartmental open model;CHEMBL3785022;Non-molecular target assigned;N;822219;1;CHEMBL372;;
CLD0;;;CHEMBL3788313;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Clearance in iv dosed lymphoma patient (6 patients) by two-compartmental open model;CHEMBL3785022;Non-molecular target assigned;N;822220;1;CHEMBL372;;
CLD0;;;CHEMBL3788314;[];Homo sapiens;[];;;9606.0;;Plasma;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Initial plasma concentration in lymphoma patient at 11.3 mg/kg, iv by one compartment open model;CHEMBL3785022;Non-molecular target assigned;N;822221;1;CHEMBL372;CHEMBL3559721;
CLD0;;;CHEMBL3788315;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Elimination rate constant in lymphoma patient at 11.3 mg/kg, iv by one compartment open model;CHEMBL3785022;Non-molecular target assigned;N;822222;1;CHEMBL372;;
CLD0;;;CHEMBL3788316;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Elimination half life in lymphoma patient at 11.3 mg/kg, iv by one compartment open model;CHEMBL3785022;Non-molecular target assigned;N;822223;1;CHEMBL372;;
CLD0;;;CHEMBL3788317;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Volume of distribution in lymphoma patient at 11.3 mg/kg, iv by one compartment open model;CHEMBL3785022;Non-molecular target assigned;N;822224;1;CHEMBL372;;
CLD0;;;CHEMBL3788318;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Clearance in lymphoma patient at 11.3 mg/kg, iv by one compartment open model;CHEMBL3785022;Non-molecular target assigned;N;822225;1;CHEMBL372;;
CLD0;;;CHEMBL3788319;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Elimination rate constant in po dosed lymphoma patient (7 patients) by one compartment open model;CHEMBL3785022;Non-molecular target assigned;N;822226;1;CHEMBL372;;
CLD0;;;CHEMBL3788320;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Half life in po dosed lymphoma patient (7 patients) by one compartment open model;CHEMBL3785022;Non-molecular target assigned;N;822227;1;CHEMBL372;;
CLD0;;;CHEMBL3788321;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;First order absorption rate constant in po dosed lymphoma patient (7 patients) by one compartment open model;CHEMBL3785022;Non-molecular target assigned;N;822228;1;CHEMBL372;;
CLD0;;;CHEMBL3788322;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Volume of distribution in po dosed lymphoma patient (7 patients) by one compartment open model;CHEMBL3785022;Non-molecular target assigned;N;822229;1;CHEMBL372;;
CLD0;;;CHEMBL3788323;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Clearance in po dosed lymphoma patient (7 patients) by one compartment open model;CHEMBL3785022;Non-molecular target assigned;N;822230;1;CHEMBL372;;
CLD0;;;CHEMBL3788324;[];Homo sapiens;[];;;9606.0;;Urine;A;ADME;BAO_0000221;tissue-based format;;Default value - Target unknown or has yet to be assigned;0;Drug excretion in lymphoma patient (7 patients) assessed as unchanged parent compound in urine relative to control;CHEMBL3785022;Default value - Target has yet to be curated;U;822232;1;CHEMBL612558;CHEMBL3638201;
CLD0;;;CHEMBL3788325;[];Homo sapiens;[];;;9606.0;;Urine;A;ADME;BAO_0000218;organism-based format;;Default value - Target unknown or has yet to be assigned;0;Drug excretion in po dosed lymphoma patient (7 patients) assessed as unchanged parent compound in urine;CHEMBL3785022;Default value - Target has yet to be curated;U;822234;1;CHEMBL612558;CHEMBL3638201;
CLD0;;;CHEMBL3788326;[];Homo sapiens;[];;;9606.0;;Kidney;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Renal clearance in lymphoma patient (7 patients);CHEMBL3785022;Non-molecular target assigned;N;822235;1;CHEMBL372;CHEMBL3638241;
CLD0;;;CHEMBL3788327;[];Homo sapiens;[];;;9606.0;;Plasma;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Drug metabolism in iv dosed lymphoma patient (6 patients) assessed as dose normalised AUC for plasma alkylating activity;CHEMBL3785022;Non-molecular target assigned;N;822236;1;CHEMBL372;CHEMBL3559721;
CLD0;;;CHEMBL3788328;[];Homo sapiens;[];;;9606.0;;Plasma;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Drug metabolism in po dosed lymphoma patient (6 patients) assessed as dose normalised AUC for plasma alkylating activity;CHEMBL3785022;Non-molecular target assigned;N;822237;1;CHEMBL372;CHEMBL3559721;
CLD0;;;CHEMBL3788329;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Drug metabolism in lymphoma patient (6 patients) assessed as ratio of dose normalised AUC in po dosed patient to dose normalised AUC in iv dosed patient;CHEMBL3785022;Non-molecular target assigned;N;822238;1;CHEMBL372;;
CLD0;;;CHEMBL3788330;[];Homo sapiens;[];;;9606.0;;Plasma;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Drug metabolism in iv dosed lymphoma patient (6 patients) assessed as half life of plasma alkylating activity;CHEMBL3785022;Non-molecular target assigned;N;822239;1;CHEMBL372;CHEMBL3559721;
CLD0;;;CHEMBL3788331;[];Homo sapiens;[];;;9606.0;;Plasma;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Drug metabolism in po dosed lymphoma patient (6 patients) assessed as half life of plasma alkylating activity;CHEMBL3785022;Non-molecular target assigned;N;822240;1;CHEMBL372;CHEMBL3559721;
CLD0;;;CHEMBL3788332;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Systemic availability in lymphoma patient (7 patients) relative to control;CHEMBL3785022;Non-molecular target assigned;N;822242;1;CHEMBL372;;
CLD0;;;CHEMBL3788333;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Extraction ratio in lymphoma patient (7 patients);CHEMBL3785022;Non-molecular target assigned;N;822243;1;CHEMBL372;;
CLD0;;;CHEMBL3788334;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Metabolic clearance in lymphoma patient (7 patients);CHEMBL3785022;Non-molecular target assigned;N;822244;1;CHEMBL372;;
CLD0;;;CHEMBL3788572;[];Homo sapiens;[];;;9606.0;;Liver;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Intrinsic hepatic clearance in lymphoma patient (7 patients);CHEMBL3785022;Non-molecular target assigned;N;822245;1;CHEMBL372;CHEMBL3559723;
859734;;HepG2;CHEMBL3854304;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307718;Target assigned is non-molecular;1;Antitumor activity against human HepG2 cells xenografted in nude mouse assessed as tumor growth inhibition at 10 mg/kg, ip administered every day for 15 times measured from day 12 to 26;CHEMBL3853295;Non-molecular target assigned;N;;1;CHEMBL3879801;;
859735;;HepG2;CHEMBL3854305;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307718;Target assigned is non-molecular;1;Antitumor activity against human HepG2 cells xenografted in nude mouse assessed as tumor growth inhibition at 20 mg/kg, ip administered every day for 15 times measured from day 12 to 26;CHEMBL3853295;Non-molecular target assigned;N;;1;CHEMBL3879801;;
859745;;HepG2;CHEMBL3854306;[];Mus musculus;[];;;10090.0;;;T;Toxicity;BAO_0000218;organism-based format;CHEMBL3307718;Target assigned is non-molecular;1;Toxicity in nude mouse xenografted with human HepG2 cells assessed as body weight change at 10 mg/kg, ip administered every day for 15 times measured from day 12 to 26;CHEMBL3853295;Non-molecular target assigned;N;;1;CHEMBL375;;
859746;;HepG2;CHEMBL3854307;[];Mus musculus;[];;;10090.0;;;T;Toxicity;BAO_0000218;organism-based format;CHEMBL3307718;Target assigned is non-molecular;1;Toxicity in nude mouse xenografted with human HepG2 cells assessed as body weight change at 20 mg/kg, ip administered every day for 15 times measured from day 12 to 26;CHEMBL3853295;Non-molecular target assigned;N;;1;CHEMBL375;;
1;;;CHEMBL3885862;[];Schistosoma mansoni;[{'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': None, 'standard_type': 'AGE', 'standard_type_fixed': 0, 'standard_units': 'weeks', 'standard_value': '6.0', 'text_value': None, 'type': 'AGE', 'units': 'weeks', 'value': '6.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Male', 'standard_type': 'GENDER', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Male', 'type': 'GENDER', 'units': None, 'value': None}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Daily Repeat', 'standard_type': 'REGIMEN', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Daily Repeat', 'type': 'REGIMEN', 'units': None, 'value': None}];Puerto Rican;;6183.0;In vivo;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;In vitro activity on S. mansoni schistosomula at 50 uM;CHEMBL3885861;Non-molecular target assigned;N;;11;CHEMBL612893;;
2;;;CHEMBL3885863;[];Schistosoma mansoni;[{'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': None, 'standard_type': 'AGE', 'standard_type_fixed': 0, 'standard_units': 'weeks', 'standard_value': '6.0', 'text_value': None, 'type': 'AGE', 'units': 'weeks', 'value': '6.0'}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Male', 'standard_type': 'GENDER', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Male', 'type': 'GENDER', 'units': None, 'value': None}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Single', 'standard_type': 'REGIMEN', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Single', 'type': 'REGIMEN', 'units': None, 'value': None}];Puerto Rican;;6183.0;In vivo;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;In vitro activity on S. mansoni schistosomula at 10 uM;CHEMBL3885861;Non-molecular target assigned;N;;11;CHEMBL612893;;
1;;;CHEMBL3885882;[];Schistosoma mansoni;[{'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': '6-8', 'standard_type': 'AGE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': '6-8', 'type': 'AGE', 'units': 'weeks', 'value': None}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Male', 'standard_type': 'GENDER', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Male', 'type': 'GENDER', 'units': None, 'value': None}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Daily Repeat', 'standard_type': 'REGIMEN', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Daily Repeat', 'type': 'REGIMEN', 'units': None, 'value': None}];Puerto Rican;;6183.0;In vivo;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;In vitro activity on S. mansoni schistosomula at 50 uM;CHEMBL3885881;Non-molecular target assigned;N;;15;CHEMBL612893;;
898050;;H22-H8D8;CHEMBL3992945;[];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Default value - Target unknown or has yet to be assigned;0;Antitumor activity against mouse H22-H8D8 cells implanted in ICR mouse assessed as tumor growth inhibition at 20 mg/kg, iv relative to control;CHEMBL3992500;Default value - Target has yet to be curated;U;;1;CHEMBL612545;;
898057;;;CHEMBL3992948;[];Mus musculus;[];ICR;;10090.0;;;T;Toxicity;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Toxicity in ICR mouse implanted with mouse H22-H8D8 cells assessed as body weight at 20 mg/kg, iv (Rvb = 29.89 to 33.78 g);CHEMBL3992500;Non-molecular target assigned;N;;1;CHEMBL375;;
898269;;NCI-H522;CHEMBL3993836;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}, {'assay_class_id': 119, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Xenograft Oncology Models', 'l3': 'Xenograft Models of Anti-Tumor Assays', 'source': 'phenotype'}];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308392;Target assigned is non-molecular;1;Antitumor activity against human NCI-H522 cells xenografted in Balb/c nude mouse assessed as tumor growth inhibition at 50 mg/kg, ig administered once daily for 28 days relative to control;CHEMBL3992535;Non-molecular target assigned;N;;1;CHEMBL614387;;
903268;;MCF7;CHEMBL3999443;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}, {'assay_class_id': 119, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Xenograft Oncology Models', 'l3': 'Xenograft Models of Anti-Tumor Assays', 'source': 'phenotype'}];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308403;Target assigned is non-molecular;1;Antitumor activity against human MCF7 cells xenografted in Balb/c nude mouse assessed as tumor growth inhibition at 20 mg/kg/day, iv for 4 weeks relative to control;CHEMBL3997810;Non-molecular target assigned;N;;1;CHEMBL387;;
891023;;H22;CHEMBL4000852;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307751;Target assigned is non-molecular;1;Antitumor activity against mouse H22 cells implanted in Kunming mouse assessed as tumor growth inhibition at 100 mg/kg, ip administered twice relative to control;CHEMBL4000174;Non-molecular target assigned;N;;1;CHEMBL614998;;
891185;;;CHEMBL4000899;[];Mus musculus;[];Kunming;;10090.0;;;T;Toxicity;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Toxicity in Kunming mouse implanted with mouse H22 cells assessed as body weight at 100 mg/kg, ip administered twice (Rvb = 31.1 g);CHEMBL4000174;Non-molecular target assigned;N;;1;CHEMBL375;;
906938;;;CHEMBL4011663;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000019;assay format;;Direct single protein target assigned;9;Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-taurocholate by topcount based membrane vesicle transport assay;CHEMBL4011581;Direct protein target assigned;D;;1;CHEMBL6020;;
934524;;H22;CHEMBL4025703;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}, {'assay_class_id': 119, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Xenograft Oncology Models', 'l3': 'Xenograft Models of Anti-Tumor Assays', 'source': 'phenotype'}];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307751;Target assigned is non-molecular;1;Antitumor activity against human H22 cells xenografted in ICR mouse assessed as tumor growth inhibition at 20 mg/kg, iv administered once daily for 21 days measured post last dose relative to control;CHEMBL4024711;Non-molecular target assigned;N;;1;CHEMBL614998;;
934527;;H22;CHEMBL4025706;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}, {'assay_class_id': 119, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Xenograft Oncology Models', 'l3': 'Xenograft Models of Anti-Tumor Assays', 'source': 'phenotype'}];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307751;Target assigned is non-molecular;1;Antitumor activity against human H22 cells xenografted in ICR mouse assessed as tumor weight at 20 mg/kg, iv administered once daily for 21 days measured post last dose (Rvb = 4.38 +/- 0.16 g);CHEMBL4024711;Non-molecular target assigned;N;;1;CHEMBL614998;;
934537;;;CHEMBL4025709;[];Mus musculus;[];ICR;;10090.0;;;T;Toxicity;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Toxicity in ICR mouse xenografted with human H22 cells assessed as body weight at 20 mg/kg, iv administered once daily for 21 days measured post last dose (Rvb = 26 +/- 0.6 g);CHEMBL4024711;Non-molecular target assigned;N;;1;CHEMBL375;;
906943;;;CHEMBL4028921;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000219;cell-based format;;Direct single protein target assigned;9;Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay;CHEMBL4028801;Direct protein target assigned;D;;1;CHEMBL6020;;
906944;;;CHEMBL4028922;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000219;cell-based format;;Direct single protein target assigned;9;Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay;CHEMBL4028801;Direct protein target assigned;D;;1;CHEMBL5748;;
906945;;;CHEMBL4028923;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000219;cell-based format;;Direct single protein target assigned;9;Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay;CHEMBL4028801;Direct protein target assigned;D;;1;CHEMBL5918;;
906946;;;CHEMBL4028924;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000219;cell-based format;;Direct single protein target assigned;9;Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay;CHEMBL4028801;Direct protein target assigned;D;;1;CHEMBL1743128;;
911630;;;CHEMBL4029349;[];Homo sapiens;[];;;9606.0;;;T;Toxicity;BAO_0000019;assay format;;Target assigned is non-molecular;1;Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index;CHEMBL4028802;Non-molecular target assigned;N;;1;CHEMBL372;;
911633;;;CHEMBL4029350;[];Homo sapiens;[];;;9606.0;;;T;Toxicity;BAO_0000019;assay format;;Target assigned is non-molecular;1;Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status;CHEMBL4028802;Non-molecular target assigned;N;;1;CHEMBL372;;
932056;;;CHEMBL4029762;[{'assay_class_id': 57, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ALIMENTARY TRACT AND METABOLISM', 'l2': 'Liver Function', 'l3': 'General Models of Hepatotoxic and Hepatoprotective Activity', 'source': 'phenotype'}];Mus musculus;[];BALB/c;;10090.0;;Liver;T;Toxicity;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Hepatotoxicity in BALB/c mdb mouse implanted with mouse 4T1 cells assessed as liver weight at 25 mg/kg, ip administered three times weekly measured at 29 day post cell innoculum (Rvb = 1.2 +/- 0.13 g);CHEMBL4028815;Non-molecular target assigned;N;;1;CHEMBL375;CHEMBL3559723;
932057;;;CHEMBL4029763;[{'assay_class_id': 270, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'GENITO URINARY SYSTEM AND SEX HORMONES', 'l2': 'Impaired Renal Function', 'l3': 'General Nephrotoxic and Nephroprotective Models', 'source': 'phenotype'}];Mus musculus;[];BALB/c;;10090.0;;;T;Toxicity;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Nephrotoxicity in BALB/c mdb mouse implanted with mouse 4T1 cells assessed as kidney weight at 25 mg/kg, ip administered three times weekly measured at 29 day post cell innoculum (Rvb = 0.136 +/- 0.006 g);CHEMBL4028815;Non-molecular target assigned;N;;1;CHEMBL375;;
932058;;;CHEMBL4029764;[];Mus musculus;[];BALB/c;;10090.0;;Spleen;T;Toxicity;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Toxicity in BALB/c mdb mouse implanted with mouse 4T1 cells assessed as spleen weight at 25 mg/kg, ip administered three times weekly measured at 29 day post cell innoculum (Rvb = 0.603 +/- 0.133 g);CHEMBL4028815;Non-molecular target assigned;N;;1;CHEMBL375;CHEMBL3559722;
932059;;;CHEMBL4029765;[];Mus musculus;[];BALB/c;;10090.0;;Lung;T;Toxicity;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Toxicity in BALB/c mdb mouse implanted with mouse 4T1 cells assessed as lung weight at 25 mg/kg, ip administered three times weekly measured at 29 day post cell innoculum (Rvb = 0.2 +/- 0.018 g);CHEMBL4028815;Non-molecular target assigned;N;;1;CHEMBL375;CHEMBL3638235;
932062;;4T1;CHEMBL4029766;[{'assay_class_id': 93, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Metastatic Oncology Models', 'l3': 'Metastatic Activity', 'source': 'phenotype'}, {'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[];BALB/c;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307995;Target assigned is non-molecular;1;Anti-tumor activity against mouse 4T1 cells implanted in BALB/c mdb mouse assessed as lung metastasis at 25 mg/kg, ip administered three times weekly measured at 29 days post cell innoculum (Rvb = 56 +/- 25 No_unit);CHEMBL4028815;Non-molecular target assigned;N;;1;CHEMBL612589;;
932066;;;CHEMBL4029767;[];Mus musculus;[];BALB/c;;10090.0;;;T;Toxicity;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Toxicity in BALB/c mdb mouse implanted with mouse 4T1 cells assessed as WBC level at 25 mg/kg, ip administered three times weekly measured at 29 day post cell innoculum (Rvb = 212.3 +/- 82.8 10'3/uL);CHEMBL4028815;Non-molecular target assigned;N;;1;CHEMBL375;;
932067;;;CHEMBL4029768;[];Mus musculus;[];BALB/c;;10090.0;;;T;Toxicity;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Toxicity in BALB/c mdb mouse implanted with mouse 4T1 cells assessed as RBC level at 25 mg/kg, ip administered three times weekly measured at 29 day post cell innoculum (Rvb = 8.6 +/- 0.9 10'6/uL);CHEMBL4028815;Non-molecular target assigned;N;;1;CHEMBL375;;
932070;;;CHEMBL4029769;[];Mus musculus;[];BALB/c;;10090.0;;;T;Toxicity;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Toxicity in BALB/c mdb mouse implanted with mouse 4T1 cells assessed as hemoglobin level at 25 mg/kg, ip administered three times weekly measured at 29 day post cell innoculum (Rvb = 15.1 +/- 1.5 g/dl);CHEMBL4028815;Non-molecular target assigned;N;;1;CHEMBL375;;
932073;;;CHEMBL4029770;[];Mus musculus;[];BALB/c;;10090.0;;;T;Toxicity;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Toxicity in BALB/c mdb mouse implanted with mouse 4T1 cells assessed as hematocrit at 25 mg/kg, ip administered three times weekly measured at 29 day post cell innoculum (Rvb = 39.9 +/- 3.7 %);CHEMBL4028815;Non-molecular target assigned;N;;1;CHEMBL375;;
932075;;;CHEMBL4029771;[];Mus musculus;[];BALB/c;;10090.0;;;T;Toxicity;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Toxicity in BALB/c mdb mouse implanted with mouse 4T1 cells assessed as serum PLT level at 25 mg/kg, ip administered three times weekly measured at 29 day post cell innoculum (Rvb = 972 +/- 157 10'3/uL);CHEMBL4028815;Non-molecular target assigned;N;;1;CHEMBL375;;
932076;;;CHEMBL4029772;[];Mus musculus;[];BALB/c;;10090.0;;;T;Toxicity;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Toxicity in BALB/c mdb mouse implanted with mouse 4T1 cells assessed as serum ALT level at 25 mg/kg, ip administered three times weekly measured at 29 day post cell innoculum (Rvb = 23.8 +/- 2.2 U/L);CHEMBL4028815;Non-molecular target assigned;N;;1;CHEMBL375;;
932077;;;CHEMBL4029773;[];Mus musculus;[];BALB/c;;10090.0;;;T;Toxicity;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Toxicity in BALB/c mdb mouse implanted with mouse 4T1 cells assessed as serum AST level at 25 mg/kg, ip administered three times weekly measured at 29 day post cell innoculum (Rvb = 136 +/- 10.3 U/L);CHEMBL4028815;Non-molecular target assigned;N;;1;CHEMBL375;;
932078;;;CHEMBL4029774;[{'assay_class_id': 254, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'GENITO URINARY SYSTEM AND SEX HORMONES', 'l2': 'Assessment of Renal Function', 'l3': 'Assessment of Glomerular Filtration Rate (GFR) by Plasma Chemistry', 'source': 'Hock_2016'}];Mus musculus;[];BALB/c;;10090.0;;;T;Toxicity;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Toxicity in BALB/c mdb mouse implanted with mouse 4T1 cells assessed as serum creatinine level at 25 mg/kg, ip administered three times weekly measured at 29 day post cell innoculum (Rvb = 9.3 +/- 1.2 umol/L);CHEMBL4028815;Non-molecular target assigned;N;;1;CHEMBL375;;
932079;;;CHEMBL4029775;[];Mus musculus;[];BALB/c;;10090.0;;;T;Toxicity;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Toxicity in BALB/c mdb mouse implanted with mouse 4T1 cells assessed as serum urea level at 25 mg/kg, ip administered three times weekly measured at 29 day post cell innoculum (Rvb = 3.8 +/- 0.3 umol/L);CHEMBL4028815;Non-molecular target assigned;N;;1;CHEMBL375;;
932314;;4T1;CHEMBL4029819;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307995;Target assigned is non-molecular;1;Anti-tumor activity against mouse 4T1 cells implanted in BALB/c mdb mouse assessed as tumor growth inhibition at 25 umol/kg, ip administered 3 times weekly measured on day 29 post cell innoculum relative to control;CHEMBL4028815;Non-molecular target assigned;N;;1;CHEMBL612589;;
921711;;U2932;CHEMBL4039428;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}, {'assay_class_id': 119, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Xenograft Oncology Models', 'l3': 'Xenograft Models of Anti-Tumor Assays', 'source': 'phenotype'}];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL4295421;Target assigned is non-molecular;1;Antitumor activity against human U2932 cells xenografted in SCID mouse assessed as reduction in tumor burden at 50 mg/kg, ip administered for 5 consecutive days measured up to day 40 post cell injection;CHEMBL4038303;Non-molecular target assigned;N;;1;CHEMBL4296507;;
920901;;;CHEMBL4039775;[];Rattus norvegicus;[];;;10116.0;;;T;Toxicity;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Genotoxicity in rat assessed as change in polychromatic erythrocytes in bone marrow at 40 mg/kg administered via oral gavage measured after 24 hrs post dose by micronucleus assay relative to control;CHEMBL4038305;Non-molecular target assigned;N;;1;CHEMBL376;;
920942;;;CHEMBL4039781;[];Rattus norvegicus;[];;;10116.0;;;T;Toxicity;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Genotoxicity in rat assessed as micronucleated polychromatic erythrocytes in bone marrow at 40 mg/kg administered via oral gavage measured after 24 hrs post dose by micronucleus assay (Rvb = 0.07 +/- 0.05%);CHEMBL4038305;Non-molecular target assigned;N;;1;CHEMBL376;;
890649;;T47D;CHEMBL4042860;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307606;Target assigned is non-molecular;1;Growth inhibition of human T47D cells at 1 x 10'-5 M after 24 hrs by MTT assay relative to control;CHEMBL4041541;Non-molecular target assigned;N;;1;CHEMBL614361;;
890651;;NCI-H522;CHEMBL4042861;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3308392;Target assigned is non-molecular;1;Growth inhibition of human NCI-H522 cells at 1 x 10'-5 M after 24 hrs by MTT assay relative to control;CHEMBL4041541;Non-molecular target assigned;N;;1;CHEMBL614387;;
890652;;HCT-15;CHEMBL4042862;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307945;Target assigned is non-molecular;1;Growth inhibition of human HCT15 cells at 1 x 10'-5 M after 24 hrs by MTT assay relative to control;CHEMBL4041541;Non-molecular target assigned;N;;1;CHEMBL612263;;
890653;;PA-1;CHEMBL4042863;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3308812;Target assigned is non-molecular;1;Growth inhibition of human PA1 cells at 1 x 10'-5 M after 24 hrs by MTT assay relative to control;CHEMBL4041541;Non-molecular target assigned;N;;1;CHEMBL614949;;
890654;;HepG2;CHEMBL4042864;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307718;Target assigned is non-molecular;1;Growth inhibition of human HepG2 cells at 1 x 10'-5 M after 24 hrs by MTT assay relative to control;CHEMBL4041541;Non-molecular target assigned;N;;1;CHEMBL395;;
890657;;T47D;CHEMBL4042865;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307606;Target assigned is non-molecular;1;Growth inhibition of human T47D cells after 24 hrs by MTT assay;CHEMBL4041541;Non-molecular target assigned;N;;1;CHEMBL614361;;
890658;;NCI-H522;CHEMBL4042866;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3308392;Target assigned is non-molecular;1;Growth inhibition of human NCI-H522 cells after 24 hrs by MTT assay;CHEMBL4041541;Non-molecular target assigned;N;;1;CHEMBL614387;;
890659;;HCT-15;CHEMBL4042867;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307945;Target assigned is non-molecular;1;Growth inhibition of human HCT15 cells after 24 hrs by MTT assay;CHEMBL4041541;Non-molecular target assigned;N;;1;CHEMBL612263;;
890660;;PA-1;CHEMBL4042868;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3308812;Target assigned is non-molecular;1;Growth inhibition of human PA1 cells after 24 hrs by MTT assay;CHEMBL4041541;Non-molecular target assigned;N;;1;CHEMBL614949;;
890661;;HepG2;CHEMBL4042869;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307718;Target assigned is non-molecular;1;Growth inhibition of human HepG2 cells after 24 hrs by MTT assay;CHEMBL4041541;Non-molecular target assigned;N;;1;CHEMBL395;;
890662;;HEK-293T;CHEMBL4042870;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000219;cell-based format;CHEMBL3706569;Target assigned is non-molecular;1;Growth inhibition of HEK293T cells after 24 hrs by MTT assay;CHEMBL4041541;Non-molecular target assigned;N;;1;CHEMBL3706568;;
1001083;;MDA-MB-231;CHEMBL4139666;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}, {'assay_class_id': 119, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Xenograft Oncology Models', 'l3': 'Xenograft Models of Anti-Tumor Assays', 'source': 'phenotype'}];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307960;Target assigned is non-molecular;1;Antitumor activity against human MDA-MB-231 cells xenografted in BALB/c nude mouse assessed as tumor size at 30 mg/kg administered every other day for 28 days measured after 30 days relative to control;CHEMBL4138107;Non-molecular target assigned;N;;1;CHEMBL400;;
1011194;;Ehrlich;CHEMBL4146308;[{'assay_class_id': 83, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Carcinoma Oncology Models', 'l3': 'Erhlich ascites carcinoma', 'source': 'phenotype'}, {'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307669;Target assigned is non-molecular;1;Antitumor activity against mouse EAC cells implanted in ICR mouse assessed as tumor growth inhibition at 30 mg/kg, ip qd dosed for 10 consecutive days relative to control;CHEMBL4145456;Non-molecular target assigned;N;;1;CHEMBL614641;;
1011199;;;CHEMBL4146312;[{'assay_class_id': 83, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Carcinoma Oncology Models', 'l3': 'Erhlich ascites carcinoma', 'source': 'phenotype'}];Mus musculus;[];ICR;;10090.0;;Spleen;T;Toxicity;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Toxicity in ICR mouse implanted with EAC cells assessed as decrease in spleen index at 30 mg/kg, ip qd dosed for 10 consecutive days;CHEMBL4145456;Non-molecular target assigned;N;;1;CHEMBL375;CHEMBL3559722;
1011200;;;CHEMBL4146313;[{'assay_class_id': 83, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Carcinoma Oncology Models', 'l3': 'Erhlich ascites carcinoma', 'source': 'phenotype'}];Mus musculus;[];ICR;;10090.0;;Thymus;T;Toxicity;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Toxicity in ICR mouse implanted with EAC cells assessed as decrease in thymus index at 30 mg/kg, ip qd dosed for 10 consecutive days;CHEMBL4145456;Non-molecular target assigned;N;;1;CHEMBL375;CHEMBL3638252;
1014978;;Sarcoma-180;CHEMBL4148733;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}, {'assay_class_id': 117, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Sarcoma Oncology Models', 'l3': 'Sarcoma', 'source': 'phenotype'}, {'assay_class_id': 118, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Sarcoma Oncology Models', 'l3': 'Sarcoma 180', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3308362;Target assigned is non-molecular;1;Antitumor activity against mouse Sarcoma 180 cells implanted in mouse assessed as tumor growth inhibition at 30 mg/kg, ip administered once per day for 7 consecutive days starting from 24 hrs post tumor inoculation and measured on day 21 post tumor inoculation relative to control;CHEMBL4145545;Non-molecular target assigned;N;;1;CHEMBL614895;;
1014990;;Lewis lung carcinoma cell line;CHEMBL4148738;[{'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}];Mus musculus;[];;;10090.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307859;Target assigned is non-molecular;1;Antitumor activity against mouse LLC cells implanted in mouse assessed as tumor growth inhibition at 30 mg/kg, ip administered once per day for 7 consecutive days starting from 24 hrs post tumor inoculation and measured on day 21 post tumor inoculation relative to control;CHEMBL4145545;Non-molecular target assigned;N;;1;CHEMBL614088;;
GP_020;;;CHEMBL4296184;[];Staphylococcus aureus subsp. aureus;"[{'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Inhibition of Bacterial Growth', 'standard_type': 'ASSAY_TEST', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Inhibition of Bacterial Growth', 'type': 'ASSAY_TEST', 'units': None, 'value': None}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Absorption (OD600)', 'standard_type': 'DETECTION_METHOD', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Absorption (OD600)', 'type': 'DETECTION_METHOD', 'units': None, 'value': None}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'CAMHB', 'standard_type': 'MEDIA', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'CAMHB', 'type': 'MEDIA', 'units': None, 'value': None}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': '384well; NBS; CORNING #3640 ', 'standard_type': 'PLATE_TYPE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': '384well; NBS; CORNING #3640 ', 'type': 'PLATE_TYPE', 'units': None, 'value': None}, {'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_type_fixed': 0, 'standard_units': 'hr', 'standard_value': '18.0', 'text_value': None, 'type': 'TIME', 'units': 'hr', 'value': '18.0'}]";ATCC 43300;;46170.0;In vitro;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;"Antibacterial activity against Staphylococcus aureus MRSA ATCC 43300 (CO-ADD:GP_020); MIC in CAMBH media, using NBS plates, by OD(600)";CHEMBL4296181;Non-molecular target assigned;N;;40;CHEMBL2366800;;
GN_001;;;CHEMBL4296185;[];Escherichia coli;"[{'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Inhibition of Bacterial Growth', 'standard_type': 'ASSAY_TEST', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Inhibition of Bacterial Growth', 'type': 'ASSAY_TEST', 'units': None, 'value': None}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Absorption (OD600)', 'standard_type': 'DETECTION_METHOD', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Absorption (OD600)', 'type': 'DETECTION_METHOD', 'units': None, 'value': None}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'CAMHB', 'standard_type': 'MEDIA', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'CAMHB', 'type': 'MEDIA', 'units': None, 'value': None}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': '384well; NBS; CORNING #3640 ', 'standard_type': 'PLATE_TYPE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': '384well; NBS; CORNING #3640 ', 'type': 'PLATE_TYPE', 'units': None, 'value': None}, {'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_type_fixed': 0, 'standard_units': 'hr', 'standard_value': '18.0', 'text_value': None, 'type': 'TIME', 'units': 'hr', 'value': '18.0'}]";ATCC 25922;;562.0;In vitro;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;"Antibacterial activity against Escherichia coli ATCC 25922 (CO-ADD:GN_001); MIC in CAMBH media using NBS plates, by OD(600)";CHEMBL4296181;Non-molecular target assigned;N;;40;CHEMBL354;;
GN_003;;;CHEMBL4296186;[];Klebsiella pneumoniae;"[{'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Inhibition of Bacterial Growth', 'standard_type': 'ASSAY_TEST', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Inhibition of Bacterial Growth', 'type': 'ASSAY_TEST', 'units': None, 'value': None}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Absorption (OD600)', 'standard_type': 'DETECTION_METHOD', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Absorption (OD600)', 'type': 'DETECTION_METHOD', 'units': None, 'value': None}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'CAMHB', 'standard_type': 'MEDIA', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'CAMHB', 'type': 'MEDIA', 'units': None, 'value': None}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': '384well; NBS; CORNING #3640 ', 'standard_type': 'PLATE_TYPE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': '384well; NBS; CORNING #3640 ', 'type': 'PLATE_TYPE', 'units': None, 'value': None}, {'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_type_fixed': 0, 'standard_units': 'hr', 'standard_value': '18.0', 'text_value': None, 'type': 'TIME', 'units': 'hr', 'value': '18.0'}]";ATCC 700603;;573.0;In vitro;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;"Antibacterial activity against Klebsiella pneumoniae MDR ATCC 70063 (CO-ADD:GN_003); MIC in CAMBH media using NBS plates, by OD(600)";CHEMBL4296181;Non-molecular target assigned;N;;40;CHEMBL350;;
GN_042;;;CHEMBL4296187;[];Pseudomonas aeruginosa;"[{'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Inhibition of Bacterial Growth', 'standard_type': 'ASSAY_TEST', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Inhibition of Bacterial Growth', 'type': 'ASSAY_TEST', 'units': None, 'value': None}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Absorption (OD600)', 'standard_type': 'DETECTION_METHOD', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Absorption (OD600)', 'type': 'DETECTION_METHOD', 'units': None, 'value': None}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'CAMHB', 'standard_type': 'MEDIA', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'CAMHB', 'type': 'MEDIA', 'units': None, 'value': None}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': '384well; NBS; CORNING #3640 ', 'standard_type': 'PLATE_TYPE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': '384well; NBS; CORNING #3640 ', 'type': 'PLATE_TYPE', 'units': None, 'value': None}, {'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_type_fixed': 0, 'standard_units': 'hr', 'standard_value': '18.0', 'text_value': None, 'type': 'TIME', 'units': 'hr', 'value': '18.0'}]";ATCC 27853;;287.0;In vitro;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;"Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 (CO-ADD:GN_042); MIC in CAMBH media using NBS plates, by OD(600)";CHEMBL4296181;Non-molecular target assigned;N;;40;CHEMBL348;;
GN_034;;;CHEMBL4296188;[];Acinetobacter baumannii;"[{'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Inhibition of Bacterial Growth', 'standard_type': 'ASSAY_TEST', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Inhibition of Bacterial Growth', 'type': 'ASSAY_TEST', 'units': None, 'value': None}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Absorption (OD600)', 'standard_type': 'DETECTION_METHOD', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Absorption (OD600)', 'type': 'DETECTION_METHOD', 'units': None, 'value': None}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'CAMHB', 'standard_type': 'MEDIA', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'CAMHB', 'type': 'MEDIA', 'units': None, 'value': None}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': '384well; NBS; CORNING #3640 ', 'standard_type': 'PLATE_TYPE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': '384well; NBS; CORNING #3640 ', 'type': 'PLATE_TYPE', 'units': None, 'value': None}, {'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_type_fixed': 0, 'standard_units': 'hr', 'standard_value': '18.0', 'text_value': None, 'type': 'TIME', 'units': 'hr', 'value': '18.0'}]";ATCC 19606;;470.0;In vitro;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;"Antibacterial activity against Acinetobacter baumannii ATCC 19606 (CO-ADD:GN_034); MIC in CAMBH media using NBS plates, by OD600";CHEMBL4296181;Non-molecular target assigned;N;;40;CHEMBL614425;;
FG_001;;;CHEMBL4296189;[];Candida albicans;"[{'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Inhibition of Fungal Growth', 'standard_type': 'ASSAY_TEST', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Inhibition of Fungal Growth', 'type': 'ASSAY_TEST', 'units': None, 'value': None}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Absorption (OD530)', 'standard_type': 'DETECTION_METHOD', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Absorption (OD530)', 'type': 'DETECTION_METHOD', 'units': None, 'value': None}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'CAMHB', 'standard_type': 'MEDIA', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'CAMHB', 'type': 'MEDIA', 'units': None, 'value': None}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': '384well; NBS; CORNING #3640 ', 'standard_type': 'PLATE_TYPE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': '384well; NBS; CORNING #3640 ', 'type': 'PLATE_TYPE', 'units': None, 'value': None}, {'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_type_fixed': 0, 'standard_units': 'hr', 'standard_value': '18.0', 'text_value': None, 'type': 'TIME', 'units': 'hr', 'value': '18.0'}]";ATCC 90028;;5476.0;In vitro;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;"Antifungal activity against Candida albicans ATCC 90028 (CO-ADD:FG_001); MIC in YNB media using NBS plates, by OD630";CHEMBL4296181;Non-molecular target assigned;N;;40;CHEMBL366;;
FG_002R;;;CHEMBL4296190;[];Cryptococcus neoformans;"[{'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Inhibition of Fungal Growth', 'standard_type': 'ASSAY_TEST', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Inhibition of Fungal Growth', 'type': 'ASSAY_TEST', 'units': None, 'value': None}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Resazurin; Absorption (OD600-OD570)', 'standard_type': 'DETECTION_METHOD', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Resazurin; Absorption (OD600-OD570)', 'type': 'DETECTION_METHOD', 'units': None, 'value': None}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'CAMHB', 'standard_type': 'MEDIA', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'CAMHB', 'type': 'MEDIA', 'units': None, 'value': None}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': '384well; NBS; CORNING #3640 ', 'standard_type': 'PLATE_TYPE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': '384well; NBS; CORNING #3640 ', 'type': 'PLATE_TYPE', 'units': None, 'value': None}, {'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_type_fixed': 0, 'standard_units': 'hr', 'standard_value': '18.0', 'text_value': None, 'type': 'TIME', 'units': 'hr', 'value': '18.0'}]";ATCC 208821;;5207.0;In vitro;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;"Antifungal activity against Cryptococcus neoformans H99 ATCC 208821 (CO-ADD:FG_002); MIC in YNB media using NBS plates, by Resazurin OD(600-570)";CHEMBL4296181;Non-molecular target assigned;N;;40;CHEMBL365;;
GP_020F;;;CHEMBL4296192;[];Staphylococcus aureus subsp. aureus;"[{'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Inhibition of Bacterial Growth', 'standard_type': 'ASSAY_TEST', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Inhibition of Bacterial Growth', 'type': 'ASSAY_TEST', 'units': None, 'value': None}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Resazurin; Fluorescence (ex560/em590)', 'standard_type': 'DETECTION_METHOD', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Resazurin; Fluorescence (ex560/em590)', 'type': 'DETECTION_METHOD', 'units': None, 'value': None}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'CAMHB', 'standard_type': 'MEDIA', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'CAMHB', 'type': 'MEDIA', 'units': None, 'value': None}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': '384well; NBS; CORNING #3640 ', 'standard_type': 'PLATE_TYPE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': '384well; NBS; CORNING #3640 ', 'type': 'PLATE_TYPE', 'units': None, 'value': None}, {'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_type_fixed': 0, 'standard_units': 'hr', 'standard_value': '18.0', 'text_value': None, 'type': 'TIME', 'units': 'hr', 'value': '18.0'}]";ATCC 43300;;46170.0;In vitro;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;"Antibacterial activity against Staphylococcus aureus MRSA ATCC 43300 (CO-ADD:GP_020); MIC in CAMBH media using NBS plates, by Resazurin F(560/590)";CHEMBL4296181;Non-molecular target assigned;N;;40;CHEMBL2366800;;
GN_034F;;;CHEMBL4296193;[];Acinetobacter baumannii;"[{'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Inhibition of Bacterial Growth', 'standard_type': 'ASSAY_TEST', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Inhibition of Bacterial Growth', 'type': 'ASSAY_TEST', 'units': None, 'value': None}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Resazurin; Fluorescence (ex560/em590)', 'standard_type': 'DETECTION_METHOD', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Resazurin; Fluorescence (ex560/em590)', 'type': 'DETECTION_METHOD', 'units': None, 'value': None}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'CAMHB', 'standard_type': 'MEDIA', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'CAMHB', 'type': 'MEDIA', 'units': None, 'value': None}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': '384well; NBS; CORNING #3640 ', 'standard_type': 'PLATE_TYPE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': '384well; NBS; CORNING #3640 ', 'type': 'PLATE_TYPE', 'units': None, 'value': None}, {'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_type_fixed': 0, 'standard_units': 'hr', 'standard_value': '18.0', 'text_value': None, 'type': 'TIME', 'units': 'hr', 'value': '18.0'}]";ATCC 19606;;470.0;In vitro;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;"Antibacterial activity against Acinetobacter baumannii ATCC 19606 (CO-ADD:GN_034); MIC in CAMBH media using NBS plates, by Resazurin F(560/590)";CHEMBL4296181;Non-molecular target assigned;N;;40;CHEMBL614425;;
GN_001F;;;CHEMBL4296783;[];Escherichia coli;"[{'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Inhibition of Bacterial Growth', 'standard_type': 'ASSAY_TEST', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Inhibition of Bacterial Growth', 'type': 'ASSAY_TEST', 'units': None, 'value': None}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'Resazurin; Fluorescence (ex560/em590)', 'standard_type': 'DETECTION_METHOD', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'Resazurin; Fluorescence (ex560/em590)', 'type': 'DETECTION_METHOD', 'units': None, 'value': None}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': 'CAMHB', 'standard_type': 'MEDIA', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': 'CAMHB', 'type': 'MEDIA', 'units': None, 'value': None}, {'active': 1, 'comments': None, 'relation': None, 'standard_relation': None, 'standard_text_value': '384well; NBS; CORNING #3640 ', 'standard_type': 'PLATE_TYPE', 'standard_type_fixed': 0, 'standard_units': None, 'standard_value': None, 'text_value': '384well; NBS; CORNING #3640 ', 'type': 'PLATE_TYPE', 'units': None, 'value': None}, {'active': 1, 'comments': None, 'relation': '=', 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_type_fixed': 0, 'standard_units': 'hr', 'standard_value': '18.0', 'text_value': None, 'type': 'TIME', 'units': 'hr', 'value': '18.0'}]";ATCC 25922;;562.0;In vitro;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;"Antibacterial activity against Escherichia coli ATCC 25922 (CO-ADD:GN_001); MIC in CAMBH media using NBS plates, by Resazurin F(560/590)";CHEMBL4296181;Non-molecular target assigned;N;;40;CHEMBL354;;
1_ELL;;Caco-2;CHEMBL4303805;[];Homo sapiens;[];;;9606.0;In vitro;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307519;Target assigned is non-molecular;1;Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging;CHEMBL4303101;Non-molecular target assigned;N;;52;CHEMBL4303835;;
1_HEI;;HRCE;CHEMBL4303810;[];Homo sapiens;[];;;9606.0;In vitro;;F;Functional;BAO_0000218;organism-based format;CHEMBL4303839;Target assigned is non-molecular;1;Antiviral activity against SARS-CoV-2 (USA-WA1/2020 strain) measured by imaging in HRCE cells at MOI 0.4 after 96 hrs (reported as hit score from 0-1 for on-disease vs off-disease activity: scores >0.6 considered hits);CHEMBL4303122;Non-molecular target assigned;N;;52;CHEMBL4303835;;
1_TOU;;Vero C1008;CHEMBL4303819;[];Chlorocebus sabaeus;[];;;60711.0;In vitro;;F;Functional;BAO_0000218;organism-based format;CHEMBL4295411;Target assigned is non-molecular;1;Inhibition of cell viability relative to arbidol control (inhibition index > 1 indicates higher activity) measured by fluorescence (OD590nm) in Vero E6 cells infected with SARS-CoV-2 (strain BavPat1) at MOI 0.002 after 72hrs;CHEMBL4303097;Non-molecular target assigned;N;;52;CHEMBL4303835;;
1158671;;MV4-11;CHEMBL4315143;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3308063;Target assigned is non-molecular;1;Induction of apoptosis in human MV4-11 cells harboring FLT3 ITD mutant assessed as increase in caspase 3/7 activity incubated for 24 hrs by caspase glo 3/7 assay;CHEMBL4311995;Non-molecular target assigned;N;;1;CHEMBL613835;;
1117967;;;CHEMBL4348164;[];Mus musculus;[];Swiss;;10090.0;;;T;Toxicity;BAO_0000218;organism-based format;;Default value - Target unknown or has yet to be assigned;0;Mutagenicity in Swiss albino mouse assessed as frequency of micronucleated reticulocytes per 2000 cells at 50 mg/kg, ip by acridine orange staining-based micronucleus test;CHEMBL4346679;Default value - Target has yet to be curated;U;;1;CHEMBL612558;;
1117994;;;CHEMBL4348178;[];Mus musculus;[];Swiss;;10090.0;;;A;ADME;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Mutagenic index, ratio of cyclophosphamide effect to hydroxyethylcellulose effect for Swiss albino mouse assessed as frequency of micronucleated reticulocytes per 2000 cells at 50 mg/kg, ip;CHEMBL4346679;Non-molecular target assigned;N;;1;CHEMBL375;;
847858;;COLO 320;CHEMBL4427840;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307577;Target assigned is non-molecular;1;Cytotoxicity against human COLO320 cells assessed as cell growth inhibition at 156 uM by MTT assay relative to control;CHEMBL4425183;Non-molecular target assigned;N;;1;CHEMBL614257;;
845901;;;CHEMBL4478999;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000219;cell-based format;;Direct single protein target assigned;9;Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NADPH measured after 24 hrs in absence of compound, CYP3A4 and NADPH by cell titer-glo luminescence assay relative to BSO alone;CHEMBL4477225;Direct protein target assigned;D;;1;CHEMBL3397;;
845714;;;CHEMBL4479000;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000219;cell-based format;;Direct single protein target assigned;9;Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NADPH measured after 24 hrs in absence of compound, CYP3A4 and NADPH by cell titer-glo luminescence assay relative to BSO alone;CHEMBL4477225;Direct protein target assigned;D;;1;CHEMBL340;;
845813;;;CHEMBL4479083;[];Homo sapiens;[];;;9606.0;;;A;ADME;BAO_0000219;cell-based format;;Direct single protein target assigned;9;Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NADPH measured after 24 hrs in absence of compound, CYP3A4 and NADPH by cell titer-glo luminescence assay relative to BSO alone;CHEMBL4477225;Direct protein target assigned;D;;1;CHEMBL289;;
1_KUZ;;;CHEMBL4495582;[];Severe acute respiratory syndrome coronavirus 2;[];;;2697049.0;In vitro;;F;Functional;BAO_0000019;assay format;;Direct single protein target assigned;9;SARS-CoV-2 3CL-Pro protease inhibition percentage at 20M  by FRET kind of response from peptide substrate;CHEMBL4495564;Direct protein target assigned;D;;52;CHEMBL4523582;;
1_LEY;;Vero C1008;CHEMBL4513082;[];Chlorocebus sabaeus;[];;;60711.0;In vitro;;F;Functional;BAO_0000218;organism-based format;CHEMBL4295411;Target assigned is non-molecular;1;Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging;CHEMBL4495565;Non-molecular target assigned;N;;52;CHEMBL4303835;;
1197842;;;CHEMBL4605725;[{'assay_class_id': 265, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'GENITO URINARY SYSTEM AND SEX HORMONES', 'l2': 'Assessment of Renal Function', 'l3': 'Urinalysis', 'source': 'Hock_2016'}];Mus musculus;[];NZBWF1/J;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Protective activity in NZBWF1/J mouse SLE model assessed as reduction in proteinuria at 5 mg/kg, ip administered daily for 12 weeks measured weekly from week 28-40;CHEMBL4602710;Non-molecular target assigned;N;;1;CHEMBL375;;
1197845;;;CHEMBL4605726;[];Mus musculus;[];NZBWF1/J;;10090.0;;;F;Functional;BAO_0000218;organism-based format;;Target assigned is non-molecular;1;Protective activity in NZBWF1/J mouse SLE model assessed as increase in animal survival rate at 5 mg/kg, po administered daily for 12 weeks measured at week 40;CHEMBL4602710;Non-molecular target assigned;N;;1;CHEMBL375;;
1207243;;SK-HEP1;CHEMBL4611289;[];Mus musculus;[];;;10090.0;;;T;Toxicity;BAO_0000218;organism-based format;CHEMBL3307741;Default value - Target unknown or has yet to be assigned;0;Toxicity in NOD/SCID mouse xenografted with human SKHEP1 cells assessed as animal death at 50 mg/kg, po administered on day 4 to day 30 post-tumor cell inoculation;CHEMBL4610036;Default value - Target has yet to be curated;U;;1;CHEMBL612558;;
1207244;;SK-HEP1;CHEMBL4611290;[];Mus musculus;[];;;10090.0;;;T;Toxicity;BAO_0000218;organism-based format;CHEMBL3307741;Default value - Target unknown or has yet to be assigned;0;Toxicity in NOD/SCID mouse xenografted with human SKHEP1 cells assessed as effect on behavior phenotypes at 50 mg/kg, po administered on day 4 to day 30 post-tumor cell inoculation;CHEMBL4610036;Default value - Target has yet to be curated;U;;1;CHEMBL612558;;
1207247;;SK-HEP1;CHEMBL4611293;[{'assay_class_id': 32, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ALIMENTARY TRACT AND METABOLISM', 'l2': 'Genetically Diabetic Animals', 'l3': 'Spontaneously Diabetic Mice: KK Mouse, KK-AY Mouse, NOD Mouse, Obese Hyperglycemic Mice, Diabetic db/db Mice, Diabetes Obesity Syndrome in CBA/Ca Mice, Wellesley Mouse', 'source': 'Vogel_2008'}, {'assay_class_id': 114, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'Spontaneous Autoimmune Diseases In Animals', 'source': 'Vogel_2008'}, {'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}, {'assay_class_id': 119, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Xenograft Oncology Models', 'l3': 'Xenograft Models of Anti-Tumor Assays', 'source': 'phenotype'}];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307741;Target assigned is non-molecular;1;Antitumor activity against human SKHEP1 cells xenografted in NOD/SCID mouse assessed as tumor weight at 50 mg/kg, po administered on day 4 to day 30 post-tumor cell inoculation (Rvb = 151 +/- 66 mg);CHEMBL4610036;Non-molecular target assigned;N;;1;CHEMBL614912;;
1207336;;SK-HEP1;CHEMBL4611296;[{'assay_class_id': 32, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ALIMENTARY TRACT AND METABOLISM', 'l2': 'Genetically Diabetic Animals', 'l3': 'Spontaneously Diabetic Mice: KK Mouse, KK-AY Mouse, NOD Mouse, Obese Hyperglycemic Mice, Diabetic db/db Mice, Diabetes Obesity Syndrome in CBA/Ca Mice, Wellesley Mouse', 'source': 'Vogel_2008'}, {'assay_class_id': 114, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Methods for Testing Immunological Factors', 'l3': 'Spontaneous Autoimmune Diseases In Animals', 'source': 'Vogel_2008'}, {'assay_class_id': 115, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Neoplasm Oncology Models', 'l3': 'Neoplasms', 'source': 'phenotype'}, {'assay_class_id': 119, 'bao_id': None, 'class_type': 'In vivo efficacy', 'l1': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS', 'l2': 'Xenograft Oncology Models', 'l3': 'Xenograft Models of Anti-Tumor Assays', 'source': 'phenotype'}];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307741;Target assigned is non-molecular;1;Antitumor activity against human SKHEP1 cells xenografted in NOD/SCID mouse assessed as inhibition of tumor growth at 50 mg/kg, po administered on day 4 to day 30 post-tumor cell inoculation;CHEMBL4610036;Non-molecular target assigned;N;;1;CHEMBL614912;;
1207338;;SK-HEP1;CHEMBL4611298;[];Mus musculus;[];;;10090.0;;;T;Toxicity;BAO_0000218;organism-based format;CHEMBL3307741;Default value - Target unknown or has yet to be assigned;0;Toxicity in NOD/SCID mouse xenografted with human SKHEP1 cells assessed as animal weight at 50 mg/kg, po administered on day 4 to day 30 post-tumor cell inoculation;CHEMBL4610036;Default value - Target has yet to be curated;U;;1;CHEMBL612558;;
CARE_1_ELL;;Vero C1008;CHEMBL4651403;[];Chlorocebus sabaeus;[];;;60711.0;In vitro;;F;Functional;BAO_0000218;organism-based format;CHEMBL4295411;Target assigned is non-molecular;1;Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging;CHEMBL4651402;Non-molecular target assigned;N;;57;CHEMBL4303835;;
1272988;;B16-F10;CHEMBL4685089;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307762;Default value - Target unknown or has yet to be assigned;0;Antitumor activity against human B16-F10 cells xenografted in C57BL/6 mouse assessed as tumor weight at 60 mg/kg, ip administered for 20 days and measured on day 20 (Rvb = 0.93 +/- 0.78 g);CHEMBL4680192;Default value - Target has yet to be curated;U;;1;CHEMBL612545;;
1272992;;B16-F10;CHEMBL4685092;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307762;Default value - Target unknown or has yet to be assigned;0;Antitumor activity against human B16-F10 cells xenografted in C57BL/6 mouse assessed as T/C ratio at 60 mg/kg, ip administered for 20 days and measured on day 20;CHEMBL4680192;Default value - Target has yet to be curated;U;;1;CHEMBL612545;;
1272998;;B16-F10;CHEMBL4685095;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307762;Default value - Target unknown or has yet to be assigned;0;Antitumor activity against human B16-F10 cells xenografted in C57BL/6 mouse assessed as tumor growth inhibition at 60 mg/kg, ip administered for 20 days and measured on day 20;CHEMBL4680192;Default value - Target has yet to be curated;U;;1;CHEMBL612545;;
1273006;;;CHEMBL4685098;[];Mus musculus;[];C57BL/6;;10090.0;;;T;Toxicity;BAO_0000218;organism-based format;;Default value - Target unknown or has yet to be assigned;0;Toxicity in C57BL/6 mouse xenografted with human B16-F10 cells assessed as body weight at 60 mg/kg, ip administered and measured on day 1 (Rvb = 18.4 +/- 0.3 g);CHEMBL4680192;Default value - Target has yet to be curated;U;;1;CHEMBL612558;;
1273009;;;CHEMBL4685101;[];Mus musculus;[];C57BL/6;;10090.0;;;T;Toxicity;BAO_0000218;organism-based format;;Default value - Target unknown or has yet to be assigned;0;Toxicity in C57BL/6 mouse xenografted with human B16-F10 cells assessed as body weight at 60 mg/kg, ip administered for 20 days and measured on day 20 (Rvb = 21.1 +/- 1.51 g);CHEMBL4680192;Default value - Target has yet to be curated;U;;1;CHEMBL612558;;
1293575;;Lewis lung carcinoma cell line;CHEMBL4713491;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307859;Default value - Target unknown or has yet to be assigned;0;Antitumor activity against human Lewis lung cancer cells xenografted in BALB/c mouse assessed as tumor weight at 20 mg/kg, ig administered every day for 10 days (Rvb = 1.68 +/- 0.78 g);CHEMBL4706663;Default value - Target has yet to be curated;U;;1;CHEMBL612545;;
1293587;;Lewis lung carcinoma cell line;CHEMBL4713495;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307859;Default value - Target unknown or has yet to be assigned;0;Antitumor activity against human Lewis lung cancer cells xenografted in BALB/c mouse assessed as tumor growth inhibition at 20 mg/kg, ig administered every day for 10 days relative to control;CHEMBL4706663;Default value - Target has yet to be curated;U;;1;CHEMBL612545;;
1293718;;Lewis lung carcinoma cell line;CHEMBL4713499;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000218;organism-based format;CHEMBL3307859;Default value - Target unknown or has yet to be assigned;0;Antitumor activity against human Lewis lung cancer cells xenografted in BALB/c mouse assessed as lung weight at 20 mg/kg, ig administered every day for 10 days measured post last dose (Rvb = 0.13 +/- 0.03 g);CHEMBL4706663;Default value - Target has yet to be curated;U;;1;CHEMBL612545;;
1293722;;;CHEMBL4713503;[];Mus musculus;[];BALB/c;;10090.0;;;T;Toxicity;BAO_0000218;organism-based format;;Default value - Target unknown or has yet to be assigned;0;Toxicity in human Lewis lung cancer cells xenografted BALB/c mouse assessed as net weight at 20 mg/kg, ig administered every day for 10 days (Rvb = 1.16 +/- 1.55 g);CHEMBL4706663;Default value - Target has yet to be curated;U;;1;CHEMBL612558;;
1293726;;;CHEMBL4713507;[];Mus musculus;[];BALB/c;;10090.0;;;T;Toxicity;BAO_0000218;organism-based format;;Default value - Target unknown or has yet to be assigned;0;Toxicity in human Lewis lung cancer cells xenografted BALB/c mouse assessed as survival rate at 20 mg/kg, ig administered every day for 10 days (Rvb = 100%);CHEMBL4706663;Default value - Target has yet to be curated;U;;1;CHEMBL612558;;
1293730;;H22;CHEMBL4713511;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000218;organism-based format;;Default value - Target unknown or has yet to be assigned;0;Antitumor activity against human H22 cells xenografted in KM mouse assessed as tumor weight at 20 mg/kg, ig administered every day for 10 days (Rvb = 0.55 +/- 0.57 g);CHEMBL4706663;Default value - Target has yet to be curated;U;;1;CHEMBL612545;;
1293734;;H22;CHEMBL4713515;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000218;organism-based format;;Default value - Target unknown or has yet to be assigned;0;Antitumor activity against human H22 cells xenografted in KM mouse assessed as tumor growth inhibition at 20 mg/kg, ig administered every day for 10 days relative to control;CHEMBL4706663;Default value - Target has yet to be curated;U;;1;CHEMBL612545;;
1293738;;H22;CHEMBL4713519;[];Homo sapiens;[];;;9606.0;;Liver;F;Functional;BAO_0000218;organism-based format;;Default value - Target unknown or has yet to be assigned;0;Antitumor activity against human H22 cells xenografted in KM mouse assessed as liver weight at 20 mg/kg, ig administered every day for 10 days measured post last dose (Rvb = 1.57 +/- 0.3 g);CHEMBL4706663;Default value - Target has yet to be curated;U;;1;CHEMBL612545;;
1293742;;;CHEMBL4713523;[];Mus musculus;[];KM;;10090.0;;;T;Toxicity;BAO_0000218;organism-based format;;Default value - Target unknown or has yet to be assigned;0;Toxicity in human H22 cells xenografted KM mouse assessed as net weight at 20 mg/kg, ig administered every day for 10 days (Rvb = 9.45 +/- 4 g);CHEMBL4706663;Default value - Target has yet to be curated;U;;1;CHEMBL612558;;
1293746;;;CHEMBL4713527;[];Mus musculus;[];KM;;10090.0;;;T;Toxicity;BAO_0000218;organism-based format;;Default value - Target unknown or has yet to be assigned;0;Toxicity in human H22 cells xenografted KM mouse assessed as survival rate at 20 mg/kg, ig administered every day for 10 days relative to control;CHEMBL4706663;Default value - Target has yet to be curated;U;;1;CHEMBL612558;;
1299527;;MDA-MB-231;CHEMBL4734029;[];Homo sapiens;[];;;9606.0;;;F;Functional;BAO_0000219;cell-based format;CHEMBL3307960;Target assigned is non-molecular;1;Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs;CHEMBL4732084;Non-molecular target assigned;N;;1;CHEMBL400;;
